Form 10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001193125-18-326712.txt : 20181114 0001193125-18-326712.hdr.sgml : 20181114 20181114160911 ACCESSION NUMBER: 0001193125-18-326712 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181114 DATE AS OF CHANGE: 20181114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUNLINK HEALTH SYSTEMS INC CENTRAL INDEX KEY: 0000096793 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 310621189 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12607 FILM NUMBER: 181183758 BUSINESS ADDRESS: STREET 1: 900 CIRCLE 75 PARKWAY STREET 2: SUITE 1120 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 7709337000 MAIL ADDRESS: STREET 1: 900 CIRCLE 75 PARKWAY STREET 2: SUITE 1120 CITY: ATLANTA STATE: GA ZIP: 30339 FORMER COMPANY: FORMER CONFORMED NAME: KRUG INTERNATIONAL CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: TECHNOLOGY INC DATE OF NAME CHANGE: 19860803 FORMER COMPANY: FORMER CONFORMED NAME: COMANCO INDUSTRIES INC DATE OF NAME CHANGE: 19710719 10-Q 1 d643339d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 1-12607

SUNLINK HEALTH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Ohio

31-0621189

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

900 Circle 75 Parkway, Suite 1120, Atlanta, Georgia 30339

(Address of principal executive offices)

(Zip Code)

(770) 933-7000

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filings requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (of for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of Common Shares, without par value, outstanding as of November 13, 2018 was 7,346,814.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)


	September 30,
	2018			June 30,
	(unaudited)			2018
ASSETS
Current Assets:
Cash and cash equivalents	$	3,393		$	3,456
Receivables - net		4,606			4,823
Inventory		1,905			1,894
Prepaid expense and other assets		2,687			2,937

Total current assets		12,591			13,110
Property, plant and equipment, at cost		30,441			29,995
Less accumulated depreciation		19,967			19,589

Property, plant and equipment - net		10,474			10,406
Noncurrent Assets:
Intangible assets - net		1,441			1,470
Income tax receivable		305			305
Other noncurrent assets		902			885

Total noncurrent assets		2,648			2,660

TOTAL ASSETS	$	25,713		$	26,176

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,432		$	1,239
Current maturities of long-term debt, net of debt issuance costs		260			255
Accrued payroll and related taxes		2,154			1,959
Due to third party payors		542			290
Other accrued expenses		1,010			1,108

Total current liabilities		5,398			4,851
Long-Term Liabilities
Long-term debt, net of debt issuance costs		2,737			2,803
Noncurrent liability for professional liability risks		941			996
Other noncurrent liabilities		330			340

Total long-term liabilities		4,008			4,139
Commitment and Contingencies
Shareholders’ Equity
Preferred Shares, authorized and unissued, 2,000 shares		0			0
Common Shares, without par value:
Issued and outstanding, 7,347 shares at September 30, 2018 and at June 30, 2018		3,673			3,673
Additional paid-in capital		10,948			10,947
Retained earnings		1,863			2,743
Accumulated other comprehensive loss		(177	)		(177	)

Total Shareholders’ Equity		16,307			17,186

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	25,713		$	26,176

See notes to condensed consolidated financial statements.

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE EARNINGS (LOSS)

(In thousands, except per share amounts)

(unaudited)


	Three Months Ended
	September 30,
	2018			2017
Net revenues	$	12,052			13,243
Costs and Expenses
Cost of goods sold		3,917			4,458
Salaries, wages and benefits		5,947			5,764
Supplies		410			425
Purchased services		707			687
Other operating expenses		1,274			1,442
Rent and lease expense		137			154
EHR incentive payments		0			(17	)
Depreciation and amortization		418			429

Operating Loss		(758	)		(99	)
Other Income (Expense):
Gains on sale of assets		2			2
Interest expense, net		(61	)		(127	)

Loss from Continuing Operations before income taxes		(817	)		(224	)
Income Tax expense		0			0

Loss from Continuing Operations		(817	)		(224	)
Loss from Discontinued Operations, net of tax		(63	)		(53	)

Net Loss		(880	)		(277	)
Other comprehensive income		0			0

Comprehensive Loss	$	(880	)	$	(277	)

Loss Per Share:
Continuing Operations:
Basic	$	(0.11	)	$	(0.02	)

Diluted	$	(0.11	)	$	(0.02	)

Discontinued Operations:
Basic	$	(0.01	)	$	(0.01	)

Diluted	$	(0.01	)	$	(0.01	)

Net Loss:
Basic	$	(0.12	)	$	(0.03	)

Diluted	$	(0.12	)	$	(0.03	)

Weighted-Average Common Shares Outstanding:
Basic		7,347			9,163

Diluted		7,347			9,163

See notes to condensed consolidated financial statements.

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)


	Three Months Ended
	September 30,
	2018			2017
Net Cash Provided by Operating Activities	$	458		$	233
Cash Flows Provided by (Used in) Investing Activities:
Expenditures for property, plant and equipment - continuing operations		(456	)		(684	)
Proceeds from sale of other assets		2			2

Net Cash Used in Investing Activities		(454	)		(682	)

Cash Flows Used in Financing Activities:
Payments on long-term debt		(67	)		(136	)

Net Cash Used in Financing Activities		(67	)		(136	)

Net decrease in Cash and Cash Equivalents		(63	)		(585	)
Cash and Cash Equivalents Beginning of Period		3,456			10,494

Cash and Cash Equivalents End of Period	$	3,393		$	9,909

Supplemental Disclosure of Cash Flow Information:
Cash Paid for:
Interest	$	55		$	111

Income taxes	$	0		$	0

See notes to condensed consolidated financial statements.

SUNLINK HEALTH SYSTEMS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE MONTHS ENDED SEPTEMBER 30, 2018

(all dollar amounts in thousands except per share amounts)

(unaudited)

Note 1. –Basis of Presentation and Adoption of Recently Issued Accounting Standards

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements as of September 30, 2018 and for the three month periods ended September 30, 2018 and 2017 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2018 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2018, filed with the SEC on September 25, 2018. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and month period ended September 30, 2018 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

Adoption of Recently Issued Accounting Standards

ASC 606, “Revenue from Contracts with Customers”

Effective July 1, 2018, the Company adopted the provisions of Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers” (“ASC 606”), which supersedes most existing revenue recognition guidance, including industry-specific healthcare guidance, by applying the full retrospective method for all periods presented. ASC 606 provides for a single comprehensive principles-based standard for the recognition of revenue across all industries through the application of the following five-step process:

Step 1: Identify the contract(s) with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

The adoption of the provisions of ASC 606 had no material impact on the Company’s current or historical financial position, results of operations or cash flows. Additionally, management does not anticipate that the provisions of ASC 606 will have an impact on the amount or timing of when the Company recognizes revenue prospectively. However, in accordance with ASC 606, the Company now recognizes the majority of its previously reported provision for doubtful accounts, primarily related to its self-pay patient population, as a direct reduction to revenues as an implicit pricing concession, instead of separately as a discrete deduction to arrive at revenue, and the related presentation of the allowance for doubtful accounts has been eliminated for all periods presented. The Company’s revenue recognition and accounts receivable policies are more fully described in Note 5.

Note 2. – Business Operations

Business Operations

SunLink Health Systems, Inc., through subsidiaries, owns businesses which provide healthcare products and services in certain markets in the southeastern United States. Unless the context indicates otherwise, all references to “SunLink,” “we,” “our,” “ours,” “us” and the “Company” refer to SunLink Health Systems, Inc. and our consolidated subsidiaries. References to our specific operations refer to operations conducted through our subsidiaries and references to “we,” “our,” “ours,” and “us” in such context refer to the operations of our subsidiaries. Our business is composed of two business segments, the Healthcare Services segment and the Pharmacy segment. Our Healthcare Services segment subsidiaries own and operate an 84- bed community hospital and a 66- bed nursing home in Mississippi, a 100- bed nursing home in Georgia, an IT service company based in Georgia, and healthcare facilities, which are leased to third parties. Our Pharmacy segment subsidiary operates a pharmacy business in Louisiana with four service lines.

The business strategy of SunLink is to focus its efforts on expanding the services and improving the operations and profitability of its existing Healthcare Services and Pharmacy business while seeking to sell certain of its subsidiaries’ underperforming assets. The Company is investing in upgrades and improvements to certain of its Healthcare Services and Pharmacy businesses.

The Company has used a portion of the cash proceeds from dispositions of assets to pay down debt and certain other liabilities, to repurchase common shares in tender offers completed in February and December 2017, and to make improvements to its Healthcare Services businesses.

The Company may also use existing cash, as well as any net proceeds from future dispositions, if any, to prepay debts, return capital to shareholders including through potential public or private purchases of shares, improve its existing businesses, make selective acquisitions of Healthcare Services and Pharmacy businesses and for other general corporate purposes. There is no assurance that any further dispositions will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis.

The Company considers the disposition of business segments, facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments, competition from existing and potential competitors, capital improvement needs, the prevailing reimbursement environment under various Federal and state programs (e.g., Medicare and Medicaid) and private payors, and other corporate objectives. The Company believes certain facilities in its Healthcare Services segment as well as its Pharmacy segment continue to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of assets in its Healthcare Services and its Pharmacy business lines.

On October 11, 2018, the Company sold a vacant medical office building and approximately two adjacent acres of undeveloped land. After expenses, the Company received net proceeds from the sale of approximately $935 which will be retained for working capital and general corporate purposes. The pre-tax gain on the sale of property is estimated to be approximately $452 and will be reported in the Company’s fiscal quarter ended December 31, 2018.

Note 3. – Discontinued Operations

All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation.

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended
	September 30,
	2018			2017
Net Revenues:
Sold Hospitals	$	(6	)	$	(12	)

	$	(6	)	$	(12	)

Earnings (Loss) before income taxes:
Sold Hospitals	$	(38	)	$	(17	)
Life sciences and engineering		(25	)		(36	)

Earnings (Loss) before income taxes		(63	)		(53	)
Income tax expense		0			0

Earnings (Loss) from discontinued operations	$	(63	)	$	(53	)

Sold Hospitals – Subsidiaries of the Company sold substantially all of the assets of four hospitals (“Sold Hospitals”) during the period July 2, 2012 to August 31, 2016. The earnings (loss) before income taxes of the Sold Hospitals results primarily from retained professional liability claims expenses.

Life Sciences and Engineering Segment—SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three months ended September 30, 2018 and 2017.

The components of pension expense for the three months ended September 31, 2018 and 2017, respectively, were as follows:


	Three Months Ended
	September 30,
	2018			2017
Interest Cost	$	14		$	14
Expected return on assets		(9	)		(9	)
Amortization of prior service cost		20			31

Net pension expense	$	25		$	36

SunLink contributed $25 to the plan in the three months ended September 30, 2018 and expects to contribute an additional $75 during the last three fiscal quarter of the fiscal year ending June 30, 2019.

Note 4. – Shareholders’ Equity

Stock-Based Compensation – For the three months ended September 30, 2018 and 2017, the Company recognized $1 and $5, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were no share options granted under the 2011 Director Stock Option Plan during the three months ended September 30, 2018 and 2017, respectively, and the Company does not have any option plans with authorized shares available for grants.

Note 5. – Revenue Recognition and Accounts Receivables

Revenue Recognition

Effective July 1, 2018, the Company adopted the provisions of Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers” which supersedes most existing revenue recognition guidance, including industry-specific healthcare guidance, by applying the full retrospective method for all periods presented. ASC 606 provides for a single comprehensive principles-based standard for the recognition of revenue across all industries through the application of the following five-step process:

Step 1: Identify the contract(s) with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

The adoption of the provisions of ASC 606 had no material impact on the Company’s current or historical financial position, results of operations or cash flows. Additionally, management does not anticipate that the provisions of ASC 606 will have an impact on the amount or timing of when the Company recognizes revenue prospectively. However, in accordance with ASC 606 the Company now recognizes the majority of its previously reported provision for doubtful accounts, primarily related to its self-pay patient population, as a direct reduction to revenues as an implicit pricing concession, instead of separately as a discrete deduction to arrive at revenue, and the related presentation of the allowance for doubtful accounts has been eliminated for all periods presented.

Disaggregation of Revenue

The Company disaggregates revenue from contracts with its patients by reportable operating segments and payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A reconciliation of disaggregated revenue to segment revenue is disclosed in Note 12, Financial Information by Segment.

The Company’s service specific revenue recognition policies are as follows:

Healthcare Services

The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed.

Pharmacy

The Company’s revenue is derived primarily from providing pharmacy services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. Revenue is recognized when control of the promised goods or services are transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Each prescription claim represents a separate performance obligation of the Company, separate and distinct from other prescription claims under customer arrangements. Significant portions of the revenue from sales of pharmaceutical and medical products are reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs. The Company monitors its revenues and receivables from these reimbursement sources, as well as other third-party insurance payors, and reduces revenue at the revenue recognition date, to properly account for the variable consideration due to anticipated differences between billed and reimbursed amounts. Accordingly, the total net revenues and receivables reported in the Company’s financial statements are recorded at the amount expected to be ultimately received from these payors.

Medicare Revenue

Net healthcare services revenue is recorded under the Medicare prospective payment system based on an episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if patient care was unusually costly; (b) a low utilization payment adjustment if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or the Company received a patient from another provider before completing the episode; (d) a payment adjustment based upon the level of therapy services required; (e) the number of episodes of care provided to a patient, regardless of whether the same provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.

The Company makes adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Revenue is also adjusted for estimates for variable consideration. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered.

In addition to revenue recognized on completed services, the Company also recognizes a portion of revenue associated with services in progress. Services in progress are days of care that begin during the reporting period but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of services in progress at the end of the reporting period, expected Medicare revenue per episode and its estimate of the average percentage complete based on services performed.

Non-Medicare Revenue

The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for service-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.

Revenue is recorded on an accrual basis based upon the date of service at amounts equal to its established or estimated per-visit rates, and adjusted for estimates for variable consideration, as applicable.

Impact of New Revenue Guidance on Financial Statement Line Items

The following tables summarize the impacts of adopting ASC 606 on the Company’s condensed consolidated statements of operations and comprehensive earnings (loss). There was no impact to the condensed consolidated balance sheet as of June 30, 2018 or condensed consolidated statements of cash flows for the year ended June 30, 2018 and for the year ended June 30, 2017, respectively. The majority of what was previously presented as bad debt expense of the Pharmacy Segment under operating expenses has been incorporated as an implicit price concession factored into the calculation of net revenues. Subsequent material events that alter the payor’s ability to pay are recorded as bad debt expense.

There is no material change, related to the adoption of ASC 606, for the presentation of the Company’s Fiscal 2018 revenues or prior years. Historically, the Company only presented total revenue for all revenue services in “Operating Revenues”. What was previously presented as provision for bad debts of Pharmacy segment under operating expenses has been incorporated as an implicit price concession factored into the calculation of net revenues, as shown in the “Adjustments” line in the table below. The Condensed Consolidated Statement of Operations and Comprehensive Earnings (Loss) for the three months ended September 30, 2017 has been restated to reflect the adoption of ASC 606. Subsequent material events that alter the payor’s ability to pay are recorded as bad debt expense.

Prior period results reflect reclassifications, for comparative purposes, related to the adoption of ASC 606, for the presentation of the Company’s revenues. Historically, the Company only presented total revenue for all revenue services. This reclassification had no effect on the reported results of operations.

Revenues for the fiscal quarter ended September 30, 2017 and the fiscal years ended June 30, 2018 and June 30, 2017 are summarized in the following tables:


	Fiscal Quarter Ended			Fiscal Years Ended June 30,
	September 30, 2017			2018			2017
Total Net Revenues	$	13,363		$	52,872		$	53,288
Adjustment for bad debts of Pharmacy segment		(120	)		(703	)		(438	)

Net Revenues	$	13,243		$	52,169		$	52,850


Total Cost of goods sold	$	4,458		$	18,529		$	19,917
Adjustment for bad debts of Pharmacy segment		0			0			0

Cost of goods sold	$	4,458		$	18,529		$	19,917

Total Expenses	$	13,462		$	54,866		$	57,798
Adjustment for bad debts of Pharmacy segment		(120	)		(703	)		(438	)

Total Expenses	$	13,342		$	54,163		$	57,360

Practical Expedients and Exemptions

The Company’s contracts with its patients have an original duration of one year or less, therefore, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.

Revenues by payor were as follows for the three months ended September 30, 2018 and 2017:


	Three Months Ended September 30,
	2018		2017
Medicare	$	4,520	$	5,349
Medicaid		4,274		3,794
Retail and Institutional Pharmacy		1,633		1,686
Managed Care & Other Insurance		1,122		1,891
Self-pay		229		103
Rent		88		88
Other		186		332

Total Net Revenues	$	12,052	$	13,243

Summary information for accounts receivable is as follows:


	September 30, 2018			June 30, 2018
Accounts receivable (net of contractual allowances)	$	5,057		$	5,352
Less allowance for concession adjustments		(451	)		(529	)

Patient accounts receivable - net	$	4,606		$	4,823

The following is a summary of the activity in the allowance for concession adjustments for the Healthcare Services Segment and the Pharmacy Segment for the three months ended September 30, 2018 and 2017:


Three Months Ended September 30, 2018	Healthcare Services			Pharmacy			Total
Balance at July 1, 2018	$	253		$	276		$	529
Additions recognized as a reduction to revenues:
Continuing Operations		34			103			137
Discontinued Operations		(6	)		0			(6	)
Accounts written off, net of recoveries		(96	)		(113	)		(209	)

Balance at September 30, 2018	$	185		$	266		$	451


Three Months Ended September 30, 2017	Healthcare Services			Pharmacy			Total
Balance at July 1, 2017	$	328		$	224		$	552
Additions recognized as a reduction to revenues:
Continuing Operations		70			120			190
Discontinued Operations		12			0			12
Accounts written off, net of recoveries		(102	)		(152	)		(254	)

Balance at September 30, 2017	$	308		$	192		$	500

Note 6. – Intangible Assets

Intangibles consist of the following, net of amortization:


	September 30, 2018			June 30, 2018
Pharmacy Segment Intangibles
Trade Name (non-amortizing)		1,180			1,180
Customer Relationships		1,089			1,089
Medicare License		623			623

		2,892			2,892
Accumulated Amortization		(1,451	)		(1,422	)

Net Intangibles	$	1,441		$	1,470

Amortization expense was $29 and $29 for the three months ended September 30, 2018 and 2017, respectively.

Note 7. –Long-Term Debt

Long-term debt consisted of the following:


	September 30, 2018			June 30, 2018
Trace RDA Loan	$	3,210		$	3,277
Less unamortized debt issuance costs		(213	)		(219	)
Less current maturities		(260	)		(255	)

Long-term Debt	$	2,737		$	2,803

Trace RDA Loan—Southern Health Corporation of Houston, Inc. (“Trace”) a wholly owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement (“Trace RDA Loan”) with a bank, dated as of July 5, 2012. The Trace RDA Loan has a term of 15 years with level monthly payments of principal and interest until repaid. On December 26, 2017, the Fifth Amendment to Loan Agreement, Modification of Note and Waiver (“Modification”) was entered into by Trace and the bank. Under the Modification, Trace made a $3,548 prepayment on the Trace RDA Loan. The monthly principal and interest payments on the RDA Loan were reduced, the interest rate was reduced to the prime rate (as published in the Wall Street Journal) plus 1% with a floor of 5.5%, (6.25% at September 30, 2018) and certain loan covenants were modified. Management was not aware of any violations with the amended financial covenants at September 30, 2018. The Trace RDA Loan is collateralized by real estate and equipment of Trace in Houston, MS, is guaranteed by the Company, and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program.

The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require Trace to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge ratio, and funded debt to EBITDA, all as defined in the Trace RDA Loan. The ability of Trace to continue to make the required debt service payments under the Trace RDA Loan depends on, among other things, its ability to generate sufficient cash, including from operating activities and asset sales. If Trace is unable to generate sufficient cash to meet debt service payments on the Trace RDA Loan, including in the event the lender were to declare an event of default and accelerate the maturity of the indebtedness, such failure could have material adverse effects on the Company. The Trace RDA Loan is guaranteed by the Company and one subsidiary.

Note 8. – Income Taxes

Income tax expense of $0 ($0 federal expense and state tax expense) and income tax expense of $0 ($0 federal expense and $0 state tax expense) was recorded for continuing operations for the three months ended September 30, 2018 and 2017, respectively.

In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates.

The Tax Cut and Jobs Act (“TCJA”) was enacted on December 22, 2017. Under ASC 740, the impact of changes in tax law must be recorded in the financial statements in the reporting period that included the date of enactment. In addition, in conjunction with the TCJA, on December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), which provides guidance on accounting for the tax effects of the TCJA. SAB 118 allows for recording certain effects of the TCJA as “provisional” during a one-year measurement period, which for the Company will end in the second quarter of fiscal 2019.

At September 30, 2018, consistent with the above process, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $8,610 against the deferred tax asset so that there is no net long-term deferred income tax asset or liability at September 30, 2018. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans.

The principal negative evidence that led us to determine at September 30, 2018 that all the deferred tax assets should have full valuation allowances was the three-year cumulative pre-tax loss from continuing operations as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Services Segment businesses operate.

For Federal income tax purposes, at September 30, 2018, the Company had approximately $16,100 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire primarily in fiscal 2023 through fiscal 2038; however with the enactment of the Tax Cut and Jobs Act (“TCJA”) on December 22, 2017, federal net operating loss carryforwards generated in taxable years beginning after December 31, 2017 now have no expiration date.

Note 9. – Commitments and Contingencies

Contractual obligations, commitments and contingencies related to outstanding debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at September 30, 2018 were as follows:


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	260	$	557	$	179
2 years		301		417		178
3 years		321		229		158
4 years		341		63		137
5+ years		1,987		5		325

	$	3,210	$	1,271	$	977

Note 10. – Related Party Transactions

A director of the Company is a member of a law firm which provides services to SunLink. The Company expensed an aggregate of $76 and $65 for legal services to this law firm in the three months ended September 30, 2018 and 2017, respectively. Included in the Company’s condensed consolidated balance sheets at September 30, 2018 and June 30, 2018 is $65 and $10, respectively, of amounts payable to this law firm.

Note 11. – Subsequent Events

Note 12. – Financial Information by Segment

Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Services and Pharmacy.

We evaluate performance of our operating segments based on revenue and operating profit (loss). At the beginning of the current fiscal year, the Company modified the approach to certain assets, and expense allocations to calculate segment assets, operating profit and depreciation and amortization. All prior year amounts have been changed to consistently apply the changed allocation method used in the current year. Segment information as of September 30, 2018 and 2017 and for the three months then ended is as follows:


	Healthcare Services			Pharmacy			Corporate and Other			Total
As of and for the three months ended September 30, 2018,
Net revenues from external customers	$	5,536		$	6,516		$	0		$	12,052
Operating profit (loss)		(247	)		(57	)		(454	)		(758	)
Depreciation and amortization		162			256			0			418
Assets		13,451			8,067			4,195			25,713
Expenditures for property, plant and equipment		187			269			0			456
As of and for the three months ended September 30, 2017
Net revenues from external customers	$	5,654		$	7,589		$	0		$	13,243
Operating profit (loss)		(57	)		423			(465	)		(99	)
Depreciation and amortization		158			270			1			429
Assets		14,576			9,614			11,212			35,402
Expenditures for property, plant and equipment		476			208			0			684

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

(Dollars in thousands, except per share and admissions data)

Forward-Looking Statements

This Quarterly Report and the documents that are incorporated by reference in this Quarterly Report contain certain forward-looking statements within the meaning of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and may be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue.” Throughout item 2, SunLink Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as “SunLink”, “we”, “our”, “ours”, “us” or the “Company.” This drafting style is not meant to indicate that SunLink Health Systems, Inc. or any particular subsidiary of SunLink Health Systems, Inc. owns or operates any asset, business, or property. Trace, Parkside Ellijay, pharmacy operations and businesses described in this filing are owned and operated by distinct and indirect subsidiaries of SunLink Health System, Inc. These forward-looking statements are based on current plans and expectations and are subject to a number of risks, uncertainties and other factors which could significantly affect current plans and expectations and our future financial condition and results. These factors, which could cause actual results, performance and achievements to differ materially from those anticipated, include, but are not limited to:

General Business Conditions

•

general economic and business conditions in the U.S., both nationwide and in the states in which we operate;

•

increases in uninsured and/or underinsured patients due to unemployment or other conditions, higher deductibles and

co-insurance, or other terms of health insurance coverage resulting in higher bad debt amounts;

•

the competitive nature of the U.S. community hospital, nursing home, and pharmacy businesses;

•

demographic changes in areas where we operate;

•

the availability of cash or borrowings to fund working capital, renovations, replacements, expansions, and capital improvements at existing healthcare and pharmacy facilities and for acquisitions and replacement of such facilities;

•

changes in accounting principles generally accepted in the U.S.; and

•

fluctuations in the market value of equity securities including SunLink common shares.

Operational Factors

•

the ability or inability to operate profitably in one or more segments of the healthcare business;

•

the availability of, and our ability to attract and retain, sufficient qualified staff physicians, management, nurses, pharmacists, and staff personnel for our operations;

•

timeliness and amount of reimbursement payments received under government programs;

•

changes in interest rates under lending agreements and other indebtedness;

•

the ability or inability to refinance or pay principal on existing indebtedness and existing or potential defaults under existing indebtedness;

•

restrictions imposed by existing or future lending agreements or other indebtedness;

•

the cost and availability of insurance coverage including professional liability (e.g., medical malpractice) and general, fiduciary and other liability insurance;

•

the efforts of insurers, healthcare providers, and others to contain healthcare costs;

•

the impact on hospital services of the treatment of patients in lower acuity healthcare settings, whether with drug therapy or in alternative healthcare settings, such as surgery centers or urgent care centers;

•

changes in medical and other technology;

•

changes in estimates of self-insurance claims and reserves;

•

changes in prices of materials and services utilized in our Healthcare Facilities and Pharmacy segments;

•

changes in wages as a result of inflation or competition for physician, nursing, pharmacy, management and staff positions;

•

changes in the amount and risk of collectability of accounts receivable, including deductibles and co-pay amounts;

•

the functionality of or costs with respect to our information systems for our Healthcare Services and Pharmacy segments and our corporate office, including both software and hardware;

•

the availability of and competition from alternative drugs or treatments to those provided by our Pharmacy segment; and

•

the restrictions, processes, and conditions relating to our Pharmacy segment imposed by pharmacy benefit providers, drug manufacturers, and distributors.

Liabilities, Claims, Obligations and Other Matters

•

claims under leases, guarantees, disposition agreements, and other obligations relating to asset sales or discontinued operations, including claims from sold or leased facilities and services, retained liabilities or retained subsidiaries;

•

potential adverse consequences of known and unknown government investigations;

•

claims for product and environmental liabilities from continuing and discontinued operations;

•

professional, general, and other claims which may be asserted against us; and

•

natural disasters and weather-related events such as earthquakes, hurricanes, flooding, snow, ice and wind damage, and population evacuations affecting areas in which we operate.

Regulation and Governmental Activity

•

existing and proposed governmental budgetary constraints;

•

Federal and state insurance exchanges and their rules relating to reimbursement terms;

•

the decision by states in which we operate our remaining hospital (Mississippi) and two remaining nursing homes (Georgia and Mississippi) to not expand Medicaid;

•

the regulatory environment for our businesses, including state certificate of need laws and regulations, pharmacy licensing laws and regulations, rules and judicial cases relating thereto;

•

changes in the levels and terms of government (including Medicare, Medicaid and other programs) and private reimbursement for SunLink’s healthcare services including the payment arrangements and terms of managed care agreements; EHR reimbursement and indigent care reimbursements (Medicare Upper Payment Limit “UPL” and Disproportionate Share Hospital “DSH” adjustments);

•

changes in or failure to comply with Federal, state or local laws and regulations and enforcement interpretations of such laws and regulations affecting our Healthcare Services and Pharmacy Segments; and

•

the possible enactment of additional Federal healthcare reform laws or reform laws in states where our subsidiaries operate hospital and pharmacy facilities (including Medicaid waivers, bundled payments, accountable care and similar organizations, competitive bidding and other reforms).

Dispositions, Acquisition and Renovation Related Matters

•

the ability to dispose of underperforming facilities and business segments;

•

the availability of cash and the terms of capital to fund acquisitions, improvements, renovations or replacement facilities; and

•

competition in the market for acquisitions of hospitals, nursing homes, pharmacy facilities, and healthcare businesses.

The foregoing are significant factors we think could cause our actual results to differ materially from expected results. However, there could be additional factors besides those listed herein that also could affect SunLink in an adverse manner.

You should read this Quarterly Report completely and with the understanding that actual future results may be materially different from what we expect. You are cautioned not to unduly rely on forward-looking statements when evaluating the information presented in this Quarterly Report or our other disclosures because current plans, anticipated actions, and future financial conditions and results may differ from those expressed in any forward-looking statements made by or on behalf of SunLink.

We have not undertaken any obligation to publicly update or revise any forward-looking statements. All of our forward-looking statements speak only as of the date of the document in which they are made or, if a date is specified, as of such date. We disclaim any obligation or undertaking to provide any updates or revisions to any forward-looking statement to reflect any change in our expectations or any changes in events, conditions, circumstances or information on which the forward-looking statement is based, except as required by applicable law. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing factors and the other risk factors set forth elsewhere in this report and in our Annual Report on Form 10-K.

Business Strategy: Operations, Dispositions and Acquisitions

The business strategy of SunLink is to focus its efforts on improving the operations and expanding the services and profitability of its existing Healthcare Services and Pharmacy businesses. The Company is investing in upgrades and improvements to certain of its Healthcare Services and Pharmacy businesses, while seeking to sell certain of its subsidiaries’ underperforming assets.

The Company has used a portion of the cash proceeds from recent dispositions of assets to pay down debt and certain other liabilities, and to repurchase common shares in tender offers completed in February and December 2017 and to make improvements to its Healthcare Services businesses. The Company may also use existing cash, as well as any net proceeds from future dispositions, if any, to prepay debts, return capital to shareholders including through potential public or private purchases of shares, improve its existing businesses, make selective acquisitions of Healthcare Services and Pharmacy businesses and for other general corporate purposes. There is no assurance that any further dispositions will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis. The Company considers the disposition of business segments, facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments, competition from existing and potential competitors, capital improvement needs, the prevailing reimbursement environment under various Federal and state programs (e.g., Medicare and Medicaid) and private payors, and other corporate objectives. The Company believes certain facilities in its Healthcare Services segment as well as its Pharmacy segment continue to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of its Pharmacy business lines.

On January 11, 2018, Carmichael’s Cashway Pharmacy, Inc., a wholly owned subsidiary of the Company, sold the assets of a retail pharmacy operation it operates for $410. A pre-tax gain on the sale of the assets of $183 was included in the results for the fiscal year ended June 30, 2018. On October 11, 2018, the Company sold a vacant medical office building and approximately two adjacent acres of undeveloped land. After expenses, the Company received net proceeds from the sale of approximately $935 which will be retained for working capital and general corporate purposes. The pre-tax gain on the sale of property is estimated to be approximately $450 and will be reported in the Company’s fiscal quarter ending December 31, 2018.

A subsidiary of the Company has received an indication of interest to purchase one of the Company’s nursing homes for approximately $7,300 and, on August 29, 2018, entered into a non-binding letter of intent (“LOI”) and exclusivity agreement with a potential buyer. The non-binding LOI provides that any transaction will be subject to various terms and conditions to be negotiated, including reaching agreement on a contract, satisfactory due diligence and other matters. Accordingly there can be no assurance that a transaction will be completed on any terms or at any specific price.

Critical Accounting Estimates

The preparation of financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect reported amounts and related disclosures. We consider an accounting estimate to be critical if:

•

it requires assumptions to be made that were uncertain at the time the estimate was made; and

•

changes in the estimate or different estimates that could have been made could have a material impact on our consolidated results of operations or financial condition.

Our critical accounting estimates are more fully described in our 2017 Annual Report on Form 10-K and continue to include the following areas:

•

Receivables – net and provision for doubtful accounts;

•

Revenue recognition / Net Patient Service Revenues;

•

Goodwill, intangible assets and accounting for business combinations;

•

Professional and general liability claims; and

•

Accounting for income taxes

Financial Summary

The results of continuing operations shown in the financial summary below are for our two business segments, Healthcare Services and Pharmacy.


	Three Months Ended
	September 30,
	2018			2017			% Change
Net Revenues - Healthcare Services	$	5,536		$	5,654			-2.1	%
Net Revenues - Pharmacy		6,516			7,589			-14.1	%

Total Net Revenues		12,052			13,243			-9.0	%
Costs and expenses		(12,810	)		(13,342	)		-4.0	%

Operating profit (loss)		(758	)		(99	)		665.7	%
Interest expense - net		(61	)		(127	)		-52.0	%
Gain (Loss) on sale of assets		2			2			NA

Earnings (Loss) from continuing operations before income taxes	$	(817	)	$	(224	)		264.7	%

Healthcare Facilities Segment:
Hospital and Nursing Home Admissions		151			166			-9.0	%
Hospital and Nursing Patient Days		14,838			14,745			0.6	%

Results of Operations

Healthcare Services Segment Net Revenues

The following table sets forth the percentage of net patient revenues from major payors for the Healthcare Services segment for the periods indicated:


	Three Months Ended
	September 30,
	2018			2017
Source:
Medicare		37.1	%		43.2	%
Medicaid		48.0	%		40.2	%
Managed Care Insurance & Other		10.6	%		13.4	%
Self-pay		4.3	%		3.2	%

		100.0	%		100.0	%

The Healthcare Services segment in the current year is composed of two nursing homes, one hospital, a subsidiary which provides information technology (“IT”) services to outside customers and SunLink subsidiaries, two leased medical office buildings, and unimproved land at three locations. Healthcare Services net revenues decreased $118, or 2%, for the three months ended September 30, 2018 compared to the prior year period. The decrease in net revenues this year resulted from decreased hospital and IT services net revenues which were only partially offset by increased nursing home net revenues. Hospital patient days decreased 7 % while nursing home resident days increased 2% this year compared to the prior year. There were no prior years’ Medicare cost report settlements for the three months ended September 30, 2018 and 2017.

Pharmacy Segment Net Revenues

Pharmacy segment net revenues for the three months ended September 30, 2018 decreased $1,073, or 14%, from the three months ended September 30, 2017. The decrease was a result of a 14% decrease in Retail Pharmacy net revenues, a 13% decrease in Institutional Pharmacy net revenues and a 19% decrease in Durable Medical Equipment (“DME”) net revenues. The decrease in Retail Pharmacy net revenues is primarily due to the sale of a retail pharmacy operation in early January 2018. On a same store comparison, Retail Pharmacy net revenues increased 3%. Average net revenue per Pharmacy script decreased 3% this year compared to last year. The Institutional Pharmacy decrease was due primarily to the loss of one large institutional customer and a significant reduction of products sold to another institutional customer due to the change in a federally funded reimbursement program. DME net revenues decreased this year compared to the prior year due to $391 of DME revenues last year from the 21^st Century Cures Act which did not recur in the current quarter and due to the elimination of certain unprofitable DME products this year.

Healthcare Services Segment Cost and Expenses

Costs and expenses for our Healthcare Services Segment, including depreciation and amortization, were $5,783 and $5,711 for the three months ended September 30, 2018 and 2017, respectively.


	Cost and Expenses as a % of Net Revenues
	Three Months Ended
	September 30,
	2018			2017
Salaries, wages and benefits		72.2	%		67.6	%
Supplies		6.8	%		7.0	%
Purchased services		8.0	%		6.7	%
Other operating expenses		13.5	%		16.2	%
Rent and lease expense		1.0	%		1.0	%
Depreciation and amortization expense		2.9	%		2.8	%

Salaries, wages and benefits increased as a percent of net revenue for the three months ended September 30, 2018 compared to last year due to increased contract labor and average salaries paid due to local labor shortages and related local labor market competition. Purchased services increased this year primarily due to the addition of a contracted new service line at a hospital.

Pharmacy Segment Cost and Expenses

Cost and expenses for our Pharmacy segment, including depreciation and amortization, were $6,573 and $7,166 for the three months ended September 30, 2018 and 2017, respectively.


	Cost and Expenses as a % of Net Revenues
	Three Months Ended
	September 30,
	2018			2017
Cost of goods sold		60.1	%		58.8	%
Salaries, wages and benefits		26.6	%		22.8	%
Supplies		0.5	%		0.4	%
Purchased services		3.9	%		3.9	%
Other operating expenses		4.6	%		4.1	%
Rent and lease expense		1.3	%		1.0	%
Depreciation and amortization expense		3.9	%		3.6	%

Cost of goods sold as a percent of net revenues increased in the three month period ended September 30, 2018 as compared to the comparable period of the prior year due to changes in sales product mix and increases in the cost of certain drugs. Salaries, wages and benefits(‘SWB”) and other operating expenses increased as a percent of net revenues in the three month period ended September 30, 2018 as compared to the comparable period of the prior year due to the lower sales in this year’s first fiscal quarter. Actual SWB and other operating expenses decreased from the prior year due to the January 2018 sale of a retail pharmacy location.

Operating Profit and Loss

The Company reported an operating loss of $758 for the three months ended September 30, 2018 compared to an operating loss of $99 for the three months ended September 30, 2017. The operating loss for the three months ended September 30, 2018 compared to the operating loss for the prior year’s three month period was a result of decreased operating profit of both the Healthcare Facilities and Pharmacy segments due to their lower net revenues and the higher SWB cost of the Healthcare Facilities segment.

Interest Expense

Interest expense was $61 and $127 for the three months ended September 30, 2018 and 2017, respectively. The decrease in interest expense resulted from lower debt outstanding in the current fiscal year, primarily because debt was reduced $3,926 last fiscal year with no additional debt undertaken.

Income Taxes

Loss from Continuing Operations after Income Taxes

The loss from continuing operations after income tax was $817 for the three months ended September 30, 2018 as compared to a loss from continuing operations after income tax of $224 for the three months ended September 30, 2017. The increased loss from continuing operations for the three months period ended September 30, 2018 as compared to the loss from continuing operations for the three month period last year resulted from the lower net revenues this year.

Net Loss

The net loss for the three months ended September 30, 2018 was $880 (or a loss of $0.12 per fully diluted share) as compared to a net loss of $277 (or a loss of $0.03 per fully diluted share) for the three months ended September 30, 2017.

Adjusted earnings before income taxes, interest, depreciation and amortization

Earnings before income taxes, interest, depreciation and amortization (“EBITDA”) represent the sum of income before income taxes, interest, depreciation and amortization. We understand that certain industry analysts and investors generally consider EBITDA to be one measure of the liquidity of a company, and it is presented to assist analysts and investors in analyzing the ability of a company to generate cash, service debt and meet capital requirements. We believe increased EBITDA is an indicator of improved ability to service debt and to satisfy capital requirements. EBITDA, however, is not a measure of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income as a measure of operating performance or to cash liquidity. Because EBITDA is not a measure determined in accordance with accounting principles generally accepted in the United States of America and is thus susceptible to varying calculations, EBITDA, as presented, may not be comparable to other similarly titled measures of other corporations. Where we adjust EBITDA for non-cash charges, we refer to such measurement as “Adjusted EBITDA”, which we report on a Company wide basis. Non-cash adjustments in Adjusted EBITDA are not intended to be identified or characterized in any respect as “non-recurring, infrequent or unusual,” if we believe such charge is reasonably likely to recur within two years, or if there was a similar charge (or gain) within the prior two years. Where we report Adjusted EBITDA, we typically also report Healthcare Services segment Adjusted EBITDA and Pharmacy segment Adjusted EBITDA which is the EBITDA for the applicable segments without any allocation of corporate overhead, which we report as a separate line item, without gains on sales of businesses and without any allocation of the non-cash adjustments, which we also report as a separate line item in Adjusted EBITDA. Net cash used in operations for the three and nine months ended September 30, 2018 and 2017, respectively, is shown below.


	Three Months Ended
	September 30,
	2018			2017
Healthcare Services Adjusted EBITDA	$	(85	)	$	101
Pharmacy Adjusted EBITDA		199			693
Corporate overhead costs		(454	)		(465	)
Taxes and interest expense		(61	)		(127	)
Other non-cash expenses and net change in operating assets and liabilities		859			31

Net cash provided by operations	$	458		$	233

Liquidity and Capital Resources

Overview

Our primary source of liquidity is unrestricted cash on hand of $3,393 at September 30, 2018. Currently, the Company’s ability to raise capital (debt or equity) in the public or private markets on what it considers acceptable terms is uncertain. We nevertheless periodically seek options to obtain financing for the liquidity needs of the Company or individual subsidiaries. The Company and its subsidiaries currently are funding working capital needs primarily from cash on hand and from the sale of assets. See “Subsidiary Loans” below.

Subject to the risks and uncertainties discussed herein, we believe we have adequate financing and liquidity to support our current level of operations through the next twelve months.

Subsidiary Loans

Contractual Obligations, Commitments and Contingencies


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	260	$	557	$	179
2 years		301		417		178
3 years		321		229		158
4 years		341		63		137
5+ years		1,987		5		325

	$	3,210	$	1,271	$	977

At September 30, 2018, we had outstanding long-term debt of $3,210 under the Trace RDA Loan.

Discontinued Operations

Sold Hospitals – Subsidiaries of the Company sold substantially all of the assets of four hospitals (“Sold Hospitals”) during the period July 2, 2012 to August 31, 2016. The earnings (loss) before income taxes of the Sold Hospitals result primarily from retained professional liability claims expenses.

Related Party Transactions

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We have not entered into any transactions using derivative financial instruments or derivative commodity instruments and believe that our exposure to market risk associated with other financial instruments (such as investments and borrowings) and interest rate risk is not material.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 and Rule 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this report, we carried out an evaluation of the effectiveness of the design and operation of our Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) and the changes in our disclosure controls and procedures during the quarter. Under the direction of our principal executive officer and principal financial officer, we evaluated our disclosure controls and procedures and internal control over financial reporting and concluded that our disclosure controls and procedures were effective as of September 30, 2018.

Disclosure controls and procedures and other procedures are designed to ensure that information required to be disclosed in our reports or submitted under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Based on an evaluation of the effectiveness of disclosure controls and procedures performed in connection with the preparation of this Form 10-Q, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of September 30, 2018.

Changes in Internal Control Over Financial Reporting

There were no changes during the quarter ended September 30, 2018 in our internal control over financial reporting that materially affected, or is likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

Items required under Part II not specifically shown below are not applicable.

ITEM 1A.

RISK FACTORS

Risk Factors Relating to an Investment in SunLink

Information regarding risk factors appears in “MD&A – Forward-Looking Statements,” in Part I – Item 2 of this Form 10-Q and in “MD&A -Risks Factors Relating to an Investment in SunLink” in Part I – Item 1A of the Company’s Annual Rep ort on Form 10-K for the year ended June 30, 2018. While we believe there have been no material changes from the risk factors previously disclosed in such Annual Report except as set forth herein, you should carefully consider, in addition to the other information set forth in this report, the risk factors discussed in our Annual Report which could materially affect our business, financial condition or future results. Such risk factors are expressly incorporated herein by reference. The risks described in our Annual Report are not the only risks facing our Company. In addition to risks and uncertainties inherent in forward-looking statements contained in this Report on Form 10-Q, additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. Whenever we refer to “SunLink,” “Company”, “we,” “our,” or “us” in this Item 1A, we mean SunLink Health Systems, Inc. and its subsidiaries, unless the context suggests otherwise.

ITEM 6.

EXHIBITS

Exhibits:



31.1		Chief Executive Officer’s Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

31.2		Chief Financial Officer’s Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

32.1		Chief Executive Officer’s Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Chief Financial Officer’s Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following materials from the Company’s quarterly report on Form 10-Q for the three months ended September 30, 2018, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of September 30, 2018 (unaudited) and June 30, 2017, (ii) Condensed Consolidated Statements of Operations for the three months ended September 30, 2018 and 2017 (unaudited), (iii) Condensed Consolidated Statements of Cash Flows for the three months ended September 30, 2018 and 2017 (unaudited), and (iv) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, SunLink Health Systems, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


SunLink Health Systems, Inc.

By:		/s/ Mark J. Stockslager
		Mark J. Stockslager
		Chief Financial Officer

Dated: November 14, 2018

EX-31.1 2 d643339dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION

I, Robert M. Thornton, Jr., the Chief Executive Officer of SunLink Health Systems, Inc. (the “registrant”), certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended September 30, 2018 (the “report”);

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of September 30, 2018 (the “Evaluation Date”), based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 3 d643339dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION

I, Mark J. Stockslager, the Chief Financial Officer of SunLink Health Systems, Inc. (the “registrant”), certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended September 30, 2018 (the “report”);

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32.1 4 d643339dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

SUNLINK HEALTH SYSTEMS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of SunLink Health Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2018, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), I, Robert M. Thornton, Jr., Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


By:		/s/ Robert M. Thornton, Jr.
		Robert M. Thornton, Jr.
		Chief Executive Officer

November 14, 2018

EX-32.2 5 d643339dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

SUNLINK HEALTH SYSTEMS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of SunLink Health Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2018, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), I, Mark J. Stockslager, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

EX-101.INS 6 ssy-20180930.xml XBRL INSTANCE DOCUMENT 7346814 0.055

500000

35402000

9909000

11212000

14576000

9614000

308000

192000

542000

12591000

451000

19967000

10948000

1432000

5057000

-177000

25713000

3393000

7347000

3673000

8610000

2154000

305000

1441000

1905000

5398000

25713000

4008000

260000

2737000

2648000

16100000

902000

1010000

330000

10474000

2000000

2687000

30441000

4606000

1863000

16307000

213000

941000

4195000

13451000

8067000

0.0625

3210000

9975000

341000

301000

260000

3210000

321000

1987000

63000

417000

557000

1271000

229000

5000

137000

178000

179000

977000

158000

325000

1089000

623000

75000

1180000

65000

185000

1451000

1441000

2892000

266000

552000

10494000

328000

224000

290000

13110000

529000

19589000

10947000

1239000

5352000

-177000

26176000

3456000

7347000

3673000

1959000

305000

1470000

1894000

4851000

26176000

4139000

255000

2803000

2660000

885000

1108000

340000

10406000

2000000

2937000

29995000

4823000

2743000

17186000

219000

996000

3277000

1089000

623000

1180000

10000

253000

1422000

1470000

2892000

276000

935000

0.01

3548000

57360000

52850000

19917000

57798000

53288000

-438000

19917000

54163000

52169000

18529000

54866000

52872000

-703000

18529000

5000

254000

29000

-585000

-277000

-53000

429000

-0.03

2000

-224000

-0.02

-0.01

-224000

-0.02

-0.01

127000

111000

5764000

-682000

-136000

233000

-277000

13342000

-99000

154000

1442000

684000

2000

136000

13243000

425000

9163000

684000 17000

4458000

13462000

13363000

-120000

1000

-465000

158000

-57000

476000

5654000

270000

423000

208000

7589000

-53000

-12000

-36000

-17000

-12000 103000 88000 332000 5349000 3794000 1891000 1686000

14000

9000

31000

36000

4458000

687000

65000

190000

70000

120000

12000

102000

152000

1000

209000

false

29000

<div> Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of September 30, 2018 and for the three month periods ended September 30, 2018 and 2017 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2018 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2018, filed with the SEC on September 25, 2018. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and month period ended September 30, 2018 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. </div>

<div> Note 9. – Commitments and Contingencies Contractual obligations, commitments and contingencies related to outstanding debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at September 30, 2018 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> Payments due in: </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Operating Leases</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Interest on Outstanding Debt</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 1 year </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">260</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">557</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">179</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> 2 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">301</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">417</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">178</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 3 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">321</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">229</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">158</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> 4 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">341</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 5+ years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,987</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">325</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,210</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,271</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">977</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-63000

-880000

<div> Contractual obligations, commitments and contingencies related to outstanding debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at September 30, 2018 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> Payments due in: </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Operating Leases</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Interest on Outstanding Debt</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 1 year </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">260</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">557</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">179</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> 2 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">301</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">417</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">178</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 3 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">321</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">229</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">158</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> 4 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">341</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 5+ years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,987</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">325</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,210</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,271</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">977</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

--06-30

-63000

<div> Note 3. – Discontinued Operations All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation.   Results for all of the businesses included in discontinued operations are presented in the following table:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net Revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(12</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(12</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Earnings (Loss) before income taxes: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(38</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(17</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Life sciences and engineering </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(25</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(36</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Earnings (Loss) before income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(63</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(53</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Income tax expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Earnings (Loss) from discontinued operations </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(63</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(53</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Sold Hospitals – Subsidiaries of the Company sold substantially all of the assets of four hospitals (“Sold Hospitals”) during the period July 2, 2012 to August 31, 2016. The earnings (loss) before income taxes of the Sold Hospitals results primarily from retained professional liability claims expenses. Life Sciences and Engineering Segment—SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three months ended September 30, 2018 and 2017. The components of pension expense for the three months ended September 31, 2018 and 2017, respectively, were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Interest Cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expected return on assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Amortization of prior service cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net pension expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">25</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> SunLink contributed $25 to the plan in the three months ended September 30, 2018 and expects to contribute an additional $75 during the last three fiscal quarter of the fiscal year ending June 30, 2019. </div>

Q1 2019 10-Q

418000

-0.12

0000096793 SUNLINK HEALTH SYSTEMS INC true 2018-09-30

-0.12

false Non-accelerated Filer

2000

-817000

-0.11

-0.01

-817000

-0.11

-0.01

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Note 8. – Income Taxes <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Income tax expense of $0 ($0 federal expense and state tax expense) and income tax expense of $0 ($0 federal expense and $0 state tax expense) was recorded for continuing operations for the three months ended September 30, 2018 and 2017, respectively. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Tax Cut and Jobs Act (“TCJA”) was enacted on December 22, 2017. Under ASC 740, the impact of changes in tax law must be recorded in the financial statements in the reporting period that included the date of enactment. In addition, in conjunction with the TCJA, on December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), which provides guidance on accounting for the tax effects of the TCJA. SAB 118 allows for recording certain effects of the TCJA as “provisional” during a one-year measurement period, which for the Company will end in the second quarter of fiscal 2019. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> At September 30, 2018, consistent with the above process, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $8,610 against the deferred tax asset so that there is no net long-term deferred income tax asset or liability at September 30, 2018. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The principal negative evidence that led us to determine at September 30, 2018 that all the deferred tax assets should have full valuation allowances was the three-year cumulative pre-tax loss from continuing operations as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Services Segment businesses operate. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> For Federal income tax purposes, at September 30, 2018, the Company had approximately $16,100 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire primarily in fiscal 2023 through fiscal 2038; however with the enactment of the Tax Cut and Jobs Act (“TCJA”) on December 22, 2017, federal net operating loss carryforwards generated in taxable years beginning after December 31, 2017 now have no expiration date. </div>

61000

<div> Note 6. – Intangible Assets Intangibles consist of the following, net of amortization:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Pharmacy Segment Intangibles </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Trade Name (non-amortizing) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,180</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,180</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Customer Relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Medicare License </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">623</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">623</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,892</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,892</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accumulated Amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,451</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,422</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net Intangibles </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,441</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,470</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Amortization expense was $29 and $29 for the three months ended September 30, 2018 and 2017, respectively. </div>

55000

5947000

<div> Note 7. –Long-Term Debt Long-term debt consisted of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Trace RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,210</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,277</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Less unamortized debt issuance costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(213</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(219</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Less current maturities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(260</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(255</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Long-term Debt </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,737</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,803</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Trace RDA Loan—Southern Health Corporation of Houston, Inc. (“Trace”) a wholly owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement (“Trace RDA Loan”) with a bank, dated as of July 5, 2012. The Trace RDA Loan has a term of 15 years with level monthly payments of principal and interest until repaid. On December 26, 2017, the Fifth Amendment to Loan Agreement, Modification of Note and Waiver (“Modification”) was entered into by Trace and the bank. Under the Modification, Trace made a $3,548 prepayment on the Trace RDA Loan. The monthly principal and interest payments on the RDA Loan were reduced, the interest rate was reduced to the prime rate (as published in the Wall Street Journal) plus 1% with a floor of 5.5%, (6.25% at September 30, 2018) and certain loan covenants were modified. Management was not aware of any violations with the amended financial covenants at September 30, 2018. The Trace RDA Loan is collateralized by real estate and equipment of Trace in Houston, MS, is guaranteed by the Company, and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require Trace to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge ratio, and funded debt to EBITDA, all as defined in the Trace RDA Loan. The ability of Trace to continue to make the required debt service payments under the Trace RDA Loan depends on, among other things, its ability to generate sufficient cash, including from operating activities and asset sales. If Trace is unable to generate sufficient cash to meet debt service payments on the Trace RDA Loan, including in the event the lender were to declare an event of default and accelerate the maturity of the indebtedness, such failure could have material adverse effects on the Company. The Trace RDA Loan is guaranteed by the Company and one subsidiary. </div>

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Note 2. – Business Operations <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Business Operations <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> SunLink Health Systems, Inc., through subsidiaries, owns businesses which provide healthcare products and services in certain markets in the southeastern United States. Unless the context indicates otherwise, all references to “SunLink,” “we,” “our,” “ours,” “us” and the “Company” refer to SunLink Health Systems, Inc. and our consolidated subsidiaries. References to our specific operations refer to operations conducted through our subsidiaries and references to “we,” “our,” “ours,” and “us” in such context refer to the operations of our subsidiaries. Our business is composed of two business segments, the Healthcare Services segment and the Pharmacy segment. Our Healthcare Services segment subsidiaries own and operate an 84- bed community hospital and a 66- bed nursing home in Mississippi, a 100- bed nursing home in Georgia, an IT service company based in Georgia, and healthcare facilities, which are leased to third parties. Our Pharmacy segment subsidiary operates a pharmacy business in Louisiana with four service lines. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The business strategy of SunLink is to focus its efforts on expanding the services and improving the operations and profitability of its existing Healthcare Services and Pharmacy business while seeking to sell certain of its subsidiaries’ underperforming assets. The Company is investing in upgrades and improvements to certain of its Healthcare Services and Pharmacy businesses. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company has used a portion of the cash proceeds from dispositions of assets to pay down debt and certain other liabilities, to repurchase common shares in tender offers completed in February and December 2017, and to make improvements to its Healthcare Services businesses. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company may also use existing cash, as well as any net proceeds from future dispositions, if any, to prepay debts, return capital to shareholders including through potential public or private purchases of shares, improve its existing businesses, make selective acquisitions of Healthcare Services and Pharmacy businesses and for other general corporate purposes. There is no assurance that any further dispositions will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company considers the disposition of business segments, facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments, competition from existing and potential competitors, capital improvement needs, the prevailing reimbursement environment under various Federal and state programs (e.g., Medicare and Medicaid) and private payors, and other corporate objectives. The Company believes certain facilities in its Healthcare Services segment as well as its Pharmacy segment continue to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of assets in its Healthcare Services and its Pharmacy business lines. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On October 11, 2018, the Company sold a vacant medical office building and approximately two adjacent acres of undeveloped land. After expenses, the Company received net proceeds from the sale of approximately $935 which will be retained for working capital and general corporate purposes. The pre-tax gain on the sale of property is estimated to be approximately $452 and will be reported in the Company’s fiscal quarter ended December 31, 2018. </div>

<div> Adoption of Recently Issued Accounting Standards ASC 606, “Revenue from Contracts with Customers” Effective July 1, 2018, the Company adopted the provisions of Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers” (“ASC 606”), which supersedes most existing revenue recognition guidance, including industry-specific healthcare guidance, by applying the full retrospective method for all periods presented. ASC 606 provides for a single comprehensive principles-based standard for the recognition of revenue across all industries through the application of the following five-step process: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The adoption of the provisions of ASC 606 had no material impact on the Company’s current or historical financial position, results of operations or cash flows. Additionally, management does not anticipate that the provisions of ASC 606 will have an impact on the amount or timing of when the Company recognizes revenue prospectively. However, in accordance with ASC 606, the Company now recognizes the majority of its previously reported provision for doubtful accounts, primarily related to its self-pay patient population, as a direct reduction to revenues as an implicit pricing concession, instead of separately as a discrete deduction to arrive at revenue, and the related presentation of the allowance for doubtful accounts has been eliminated for all periods presented. The Company’s revenue recognition and accounts receivable policies are more fully described in Note 5. </div>

-454000

-67000

458000

-880000

<div> Note 1. –Basis of Presentation and Adoption of Recently Issued Accounting Standards Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of September 30, 2018 and for the three month periods ended September 30, 2018 and 2017 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2018 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2018, filed with the SEC on September 25, 2018. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and month period ended September 30, 2018 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. Adoption of Recently Issued Accounting Standards ASC 606, “Revenue from Contracts with Customers” Effective July 1, 2018, the Company adopted the provisions of Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers” (“ASC 606”), which supersedes most existing revenue recognition guidance, including industry-specific healthcare guidance, by applying the full retrospective method for all periods presented. ASC 606 provides for a single comprehensive principles-based standard for the recognition of revenue across all industries through the application of the following five-step process: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The adoption of the provisions of ASC 606 had no material impact on the Company’s current or historical financial position, results of operations or cash flows. Additionally, management does not anticipate that the provisions of ASC 606 will have an impact on the amount or timing of when the Company recognizes revenue prospectively. However, in accordance with ASC 606, the Company now recognizes the majority of its previously reported provision for doubtful accounts, primarily related to its self-pay patient population, as a direct reduction to revenues as an implicit pricing concession, instead of separately as a discrete deduction to arrive at revenue, and the related presentation of the allowance for doubtful accounts has been eliminated for all periods presented. The Company’s revenue recognition and accounts receivable policies are more fully described in Note 5. </div>

-758000

137000

1274000

456000

2000

<div> Note 10. – Related Party Transactions A director of the Company is a member of a law firm which provides services to SunLink. The Company expensed an aggregate of $76 and $65 for legal services to this law firm in the three months ended September 30, 2018 and 2017, respectively. Included in the Company’s condensed consolidated balance sheets at September 30, 2018 and June 30, 2018 is $65 and $10, respectively, of amounts payable to this law firm. </div>

67000

12052000

<div> Summary information for accounts receivable is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts receivable (net of contractual allowances) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,057</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,352</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Less allowance for concession adjustments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(451</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(529</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Patient accounts receivable - net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,606</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,823</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Revenues by payor were as follows for the three months ended September 30, 2018 and 2017:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Medicare </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,520</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,349</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Medicaid </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,274</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,794</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Retail and Institutional Pharmacy </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,633</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,686</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Managed Care & Other Insurance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,122</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,891</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Self-pay </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">229</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">103</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Rent </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">88</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">88</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">186</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">332</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,052</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,243</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Results for all of the businesses included in discontinued operations are presented in the following table:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net Revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(12</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(12</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Earnings (Loss) before income taxes: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(38</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(17</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Life sciences and engineering </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(25</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(36</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Earnings (Loss) before income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(63</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(53</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Income tax expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Earnings (Loss) from discontinued operations </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(63</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(53</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Note 12. – Financial Information by Segment Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Services and Pharmacy.   We evaluate performance of our operating segments based on revenue and operating profit (loss). At the beginning of the current fiscal year, the Company modified the approach to certain assets, and expense allocations to calculate segment assets, operating profit and depreciation and amortization. All prior year amounts have been changed to consistently apply the changed allocation method used in the current year. Segment information as of September 30, 2018 and 2017 and for the three months then ended is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Services</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Corporate and Other</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top" colspan="4"> As of and for the three months ended September 30, 2018, </td> <td valign="top">   </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,536</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,516</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,052</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(247</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(57</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(454</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(758</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">162</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">256</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">418</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,451</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,067</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,195</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25,713</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">187</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">269</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">456</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top" colspan="4"> As of and for the three months ended September 30, 2017 </td> <td valign="top">   </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,654</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,589</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,243</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(57</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">423</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(465</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(99</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">158</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">270</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">429</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,576</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,614</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,212</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35,402</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">476</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">208</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">684</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

<div> We evaluate performance of our operating segments based on revenue and operating profit (loss). At the beginning of the current fiscal year, the Company modified the approach to certain assets, and expense allocations to calculate segment assets, operating profit and depreciation and amortization. All prior year amounts have been changed to consistently apply the changed allocation method used in the current year. Segment information as of September 30, 2018 and 2017 and for the three months then ended is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Services</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Corporate and Other</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top" colspan="4"> As of and for the three months ended September 30, 2018, </td> <td valign="top">   </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,536</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,516</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,052</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(247</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(57</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(454</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(758</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">162</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">256</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">418</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,451</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,067</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,195</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25,713</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">187</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">269</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">456</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top" colspan="4"> As of and for the three months ended September 30, 2017 </td> <td valign="top">   </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,654</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,589</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,243</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(57</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">423</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(465</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(99</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">158</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">270</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">429</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,576</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,614</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,212</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35,402</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">476</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">208</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">684</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

410000

SSY

<div> Note 11. – Subsequent Events On October 11, 2018, the Company sold a vacant medical office building and approximately two adjacent acres of undeveloped land. After expenses, the Company received net proceeds from the sale of approximately $935 which will be retained for working capital and general corporate purposes. The pre-tax gain on the sale of property is estimated to be approximately $452 and will be reported in the Company’s fiscal quarter ended December 31, 2018. </div>

<div> Note 4. – Shareholders’ Equity Stock-Based Compensation – For the three months ended September 30, 2018 and 2017, the Company recognized $1 and $5, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were no share options granted under the 2011 Director Stock Option Plan during the three months ended September 30, 2018 and 2017, respectively, and the Company does not have any option plans with authorized shares available for grants. </div>

7347000

456000 0 2023 through fiscal 2038 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Note 5. – Revenue Recognition and Accounts Receivables <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Revenue Recognition <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Effective July 1, 2018, the Company adopted the provisions of Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers” which supersedes most existing revenue recognition guidance, including industry-specific healthcare guidance, by applying the full retrospective method for all periods presented. ASC 606 provides for a single comprehensive principles-based standard for the recognition of revenue across all industries through the application of the following five-step process: <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Step 1: Identify the contract(s) with a customer. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Step 2: Identify the performance obligations in the contract. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Step 3: Determine the transaction price. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Step 4: Allocate the transaction price to the performance obligations in the contract. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The adoption of the provisions of ASC 606 had no material impact on the Company’s current or historical financial position, results of operations or cash flows. Additionally, management does not anticipate that the provisions of ASC 606 will have an impact on the amount or timing of when the Company recognizes revenue prospectively. However, in accordance with ASC 606 the Company now recognizes the majority of its previously reported provision for doubtful accounts, primarily related to its self-pay patient population, as a direct reduction to revenues as an implicit pricing concession, instead of separately as a discrete deduction to arrive at revenue, and the related presentation of the allowance for doubtful accounts has been eliminated for all periods presented. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Disaggregation of Revenue <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company disaggregates revenue from contracts with its patients by reportable operating segments and payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A reconciliation of disaggregated revenue to segment revenue is disclosed in Note 12, Financial Information by Segment. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company’s service specific revenue recognition policies are as follows: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Healthcare Services <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Pharmacy <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company’s revenue is derived primarily from providing pharmacy services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. Revenue is recognized when control of the promised goods or services are transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Each prescription claim represents a separate performance obligation of the Company, separate and distinct from other prescription claims under customer arrangements. Significant portions of the revenue from sales of pharmaceutical and medical products are reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs. The Company monitors its revenues and receivables from these reimbursement sources, as well as other third-party insurance payors, and reduces revenue at the revenue recognition date, to properly account for the variable consideration due to anticipated differences between billed and reimbursed amounts. Accordingly, the total net revenues and receivables reported in the Company’s financial statements are recorded at the amount expected to be ultimately received from these payors. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Medicare Revenue <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Net healthcare services revenue is recorded under the Medicare prospective payment system based on an episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if patient care was unusually costly; (b) a low utilization payment adjustment if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or the Company received a patient from another provider before completing the episode; (d) a payment adjustment based upon the level of therapy services required; (e) the number of episodes of care provided to a patient, regardless of whether the same provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company makes adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Revenue is also adjusted for estimates for variable consideration. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In addition to revenue recognized on completed services, the Company also recognizes a portion of revenue associated with services in progress. Services in progress are days of care that begin during the reporting period but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of services in progress at the end of the reporting period, expected Medicare revenue per episode and its estimate of the average percentage complete based on services performed. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Non-Medicare Revenue <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for service-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Revenue is recorded on an accrual basis based upon the date of service at amounts equal to its established or estimated per-visit rates, and adjusted for estimates for variable consideration, as applicable. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Impact of New Revenue Guidance on Financial Statement Line Items <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The following tables summarize the impacts of adopting ASC 606 on the Company’s condensed consolidated statements of operations and comprehensive earnings (loss). There was no impact to the condensed consolidated balance sheet as of June 30, 2018 or condensed consolidated statements of cash flows for the year ended June 30, 2018 and for the year ended June 30, 2017, respectively. The majority of what was previously presented as bad debt expense of the Pharmacy Segment under operating expenses has been incorporated as an implicit price concession factored into the calculation of net revenues. Subsequent material events that alter the payor’s ability to pay are recorded as bad debt expense. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> There is no material change, related to the adoption of ASC 606, for the presentation of the Company’s Fiscal 2018 revenues or prior years. Historically, the Company only presented total revenue for all revenue services in “Operating Revenues”. What was previously presented as provision for bad debts of Pharmacy segment under operating expenses has been incorporated as an implicit price concession factored into the calculation of net revenues, as shown in the “Adjustments” line in the table below. The Condensed Consolidated Statement of Operations and Comprehensive Earnings (Loss) for the three months ended September 30, 2017 has been restated to reflect the adoption of ASC 606. Subsequent material events that alter the payor’s ability to pay are recorded as bad debt expense. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Prior period results reflect reclassifications, for comparative purposes, related to the adoption of ASC 606, for the presentation of the Company’s revenues. Historically, the Company only presented total revenue for all revenue services. This reclassification had no effect on the reported results of operations. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Revenues for the fiscal quarter ended September 30, 2017 and the fiscal years ended June 30, 2018 and June 30, 2017 are summarized in the following tables: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Fiscal Quarter Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Fiscal Years Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,363</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">52,872</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,288</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Adjustment for bad debts of Pharmacy segment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(120</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(703</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(438</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,243</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">52,169</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">52,850</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total Cost of goods sold </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,458</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,529</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,917</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Adjustment for bad debts of Pharmacy segment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cost of goods sold </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,458</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,529</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,917</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total Expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,462</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54,866</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">57,798</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Adjustment for bad debts of Pharmacy segment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(120</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(703</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(438</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total Expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,342</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54,163</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">57,360</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Practical Expedients and Exemptions <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company’s contracts with its patients have an original duration of one year or less, therefore, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Revenues by payor were as follows for the three months ended September 30, 2018 and 2017: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Medicare </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,520</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,349</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Medicaid </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,274</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,794</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Retail and Institutional Pharmacy </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,633</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,686</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Managed Care & Other Insurance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,122</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,891</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Self-pay </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">229</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">103</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Rent </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">88</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">88</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">186</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">332</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,052</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,243</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Summary information for accounts receivable is as follows: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts receivable (net of contractual allowances) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,057</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,352</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Less allowance for concession adjustments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(451</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(529</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Patient accounts receivable - net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,606</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,823</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The following is a summary of the activity in the allowance for concession adjustments for the Healthcare Services Segment and the Pharmacy Segment for the three months ended September 30, 2018 and 2017: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom">Three Months Ended September 30, 2018</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Services</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">253</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">276</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">529</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">34</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">103</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(96</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(113</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(209</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Balance at September 30, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">185</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">266</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">451</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom">Three Months Ended September 30, 2017</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Services</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">328</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">224</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">552</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">120</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">190</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(102</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(152</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(254</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Balance at September 30, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">308</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">192</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">500</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> The following is a summary of the activity in the allowance for concession adjustments for the Healthcare Services Segment and the Pharmacy Segment for the three months ended September 30, 2018 and 2017:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">Three Months Ended September 30, 2018</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Services</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">253</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">276</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">529</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">34</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">103</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(96</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(113</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(209</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at September 30, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">185</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">266</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">451</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">Three Months Ended September 30, 2017</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Services</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">328</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">224</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">552</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">120</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">190</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(102</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(152</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(254</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at September 30, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">308</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">192</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">500</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> The components of pension expense for the three months ended September 31, 2018 and 2017, respectively, were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Interest Cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expected return on assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Amortization of prior service cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net pension expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">25</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Intangibles consist of the following, net of amortization:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Pharmacy Segment Intangibles </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Trade Name (non-amortizing) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,180</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,180</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Customer Relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Medicare License </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">623</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">623</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,892</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,892</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accumulated Amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,451</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,422</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net Intangibles </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,441</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,470</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Long-term debt consisted of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Trace RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,210</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,277</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Less unamortized debt issuance costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(213</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(219</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Less current maturities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(260</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(255</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Long-term Debt </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,737</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,803</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Revenues for the fiscal quarter ended September 30, 2017 and the fiscal years ended June 30, 2018 and June 30, 2017 are summarized in the following tables:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fiscal Quarter Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Fiscal Years Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,363</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">52,872</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,288</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Adjustment for bad debts of Pharmacy segment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(120</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(703</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(438</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,243</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">52,169</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">52,850</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total Cost of goods sold </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,458</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,529</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,917</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Adjustment for bad debts of Pharmacy segment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cost of goods sold </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,458</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,529</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,917</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total Expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,462</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54,866</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">57,798</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Adjustment for bad debts of Pharmacy segment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(120</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(703</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(438</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total Expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,342</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54,163</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">57,360</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-454000

162000

-247000

187000

5536000

256000

-57000

269000

6516000

P15Y

Prime rate plus 1% with a floor of 5.5%.

2012-07-05

-63000

-6000

-25000

-38000

-6000 229000 88000 186000 4520000 4274000 1122000 1633000

14000

9000

20000

25000

3917000

707000

76000

84 100 66

137000

34000

103000

-6000

96000

113000

452000

0000096793 ssy:MedicalOfficeBuildingAndUndevelopedLandMemberus-gaap:ScenarioForecastMember 2018-10-01 2018-12-31 0000096793 ssy:PharmacySegmentMember 2018-07-01 2018-09-30 0000096793 ssy:HealthcareServicesSegmentMember 2018-07-01 2018-09-30 0000096793 stpr:LAssy:PharmacySegmentMember 2018-07-01 2018-09-30 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2018-07-01 2018-09-30 0000096793 ssy:HealthcareServicesSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2018-07-01 2018-09-30 0000096793 us-gaap:SegmentDiscontinuedOperationsMember 2018-07-01 2018-09-30 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentContinuingOperationsMember 2018-07-01 2018-09-30 0000096793 ssy:HealthcareServicesSegmentMemberus-gaap:SegmentContinuingOperationsMember 2018-07-01 2018-09-30 0000096793 us-gaap:SegmentContinuingOperationsMember 2018-07-01 2018-09-30 0000096793 stpr:MSssy:NursingHomeMemberssy:HealthcareServicesSegmentMember 2018-07-01 2018-09-30 0000096793 stpr:GAssy:NursingHomeMemberssy:HealthcareServicesSegmentMember 2018-07-01 2018-09-30 0000096793 ssy:CommunityHospitalMemberssy:HealthcareServicesSegmentMember 2018-07-01 2018-09-30 0000096793 us-gaap:ManagementMember 2018-07-01 2018-09-30 0000096793 us-gaap:ServiceMember 2018-07-01 2018-09-30 0000096793 us-gaap:ProductMember 2018-07-01 2018-09-30 0000096793 ssy:TwoThousandElevenDirectorStockOptionPlanMember 2018-07-01 2018-09-30 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2018-07-01 2018-09-30 0000096793 ssy:RetailAndInstitutionalPharmacyMember 2018-07-01 2018-09-30 0000096793 ssy:ManagedCareAndOtherInsurersMember 2018-07-01 2018-09-30 0000096793 ssy:MedicaidMember 2018-07-01 2018-09-30 0000096793 ssy:MedicareMember 2018-07-01 2018-09-30 0000096793 ssy:OtherMember 2018-07-01 2018-09-30 0000096793 ssy:RentMember 2018-07-01 2018-09-30 0000096793 us-gaap:SelfPayMember 2018-07-01 2018-09-30 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:SoldHospitalsMember 2018-07-01 2018-09-30 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:LifeSciencesAndEngineeringSegmentMember 2018-07-01 2018-09-30 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2018-07-01 2018-09-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:MortgagesMember 2018-07-01 2018-09-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2018-07-01 2018-09-30 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2018-07-01 2018-09-30 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareServicesSegmentMember 2018-07-01 2018-09-30 0000096793 us-gaap:CorporateNonSegmentMember 2018-07-01 2018-09-30 0000096793 us-gaap:AccountingStandardsUpdate201409Member 2018-07-01 2018-09-30 0000096793 2018-07-01 2018-09-30 0000096793 ssy:PharmacySegmentMember 2017-07-01 2017-09-30 0000096793 ssy:HealthcareServicesSegmentMember 2017-07-01 2017-09-30 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2017-07-01 2017-09-30 0000096793 ssy:HealthcareServicesSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2017-07-01 2017-09-30 0000096793 us-gaap:SegmentDiscontinuedOperationsMember 2017-07-01 2017-09-30 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentContinuingOperationsMember 2017-07-01 2017-09-30 0000096793 ssy:HealthcareServicesSegmentMemberus-gaap:SegmentContinuingOperationsMember 2017-07-01 2017-09-30 0000096793 us-gaap:SegmentContinuingOperationsMember 2017-07-01 2017-09-30 0000096793 us-gaap:ManagementMember 2017-07-01 2017-09-30 0000096793 us-gaap:ServiceMember 2017-07-01 2017-09-30 0000096793 us-gaap:ProductMember 2017-07-01 2017-09-30 0000096793 ssy:TwoThousandElevenDirectorStockOptionPlanMember 2017-07-01 2017-09-30 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2017-07-01 2017-09-30 0000096793 ssy:RetailAndInstitutionalPharmacyMember 2017-07-01 2017-09-30 0000096793 ssy:ManagedCareAndOtherInsurersMember 2017-07-01 2017-09-30 0000096793 ssy:MedicaidMember 2017-07-01 2017-09-30 0000096793 ssy:MedicareMember 2017-07-01 2017-09-30 0000096793 ssy:OtherMember 2017-07-01 2017-09-30 0000096793 ssy:RentMember 2017-07-01 2017-09-30 0000096793 us-gaap:SelfPayMember 2017-07-01 2017-09-30 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:SoldHospitalsMember 2017-07-01 2017-09-30 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:LifeSciencesAndEngineeringSegmentMember 2017-07-01 2017-09-30 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2017-07-01 2017-09-30 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2017-07-01 2017-09-30 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareServicesSegmentMember 2017-07-01 2017-09-30 0000096793 us-gaap:CorporateNonSegmentMember 2017-07-01 2017-09-30 0000096793 us-gaap:AccountingStandardsUpdate201409Memberus-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2017-07-01 2017-09-30 0000096793 us-gaap:AccountingStandardsUpdate201409Memberus-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-07-01 2017-09-30 0000096793 2017-07-01 2017-09-30 0000096793 us-gaap:ProductMember 2017-07-01 2018-06-30 0000096793 us-gaap:AccountingStandardsUpdate201409Memberus-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2017-07-01 2018-06-30 0000096793 us-gaap:AccountingStandardsUpdate201409Memberus-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-07-01 2018-06-30 0000096793 2017-07-01 2018-06-30 0000096793 us-gaap:ProductMember 2016-07-01 2017-06-30 0000096793 us-gaap:AccountingStandardsUpdate201409Memberus-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2016-07-01 2017-06-30 0000096793 us-gaap:AccountingStandardsUpdate201409Memberus-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2016-07-01 2017-06-30 0000096793 2016-07-01 2017-06-30 0000096793 2012-07-03 2016-08-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2017-12-26 2017-12-26 0000096793 ssy:MedicalOfficeBuildingAndUndevelopedLandMemberus-gaap:SubsequentEventMember 2018-10-11 2018-10-11 0000096793 ssy:PharmacySegmentMember 2018-06-30 0000096793 ssy:SpecialtyPharmacySegmentMember 2018-06-30 0000096793 ssy:HealthcareServicesSegmentMember 2018-06-30 0000096793 us-gaap:ManagementMember 2018-06-30 0000096793 us-gaap:TradeNamesMemberssy:SpecialtyPharmacySegmentMember 2018-06-30 0000096793 ssy:MedicareLicenseMemberssy:SpecialtyPharmacySegmentMember 2018-06-30 0000096793 us-gaap:CustomerRelationshipsMemberssy:SpecialtyPharmacySegmentMember 2018-06-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2018-06-30 0000096793 2018-06-30 0000096793 ssy:PharmacySegmentMember 2017-06-30 0000096793 ssy:HealthcareServicesSegmentMember 2017-06-30 0000096793 2017-06-30 0000096793 ssy:PharmacySegmentMember 2018-09-30 0000096793 ssy:SpecialtyPharmacySegmentMember 2018-09-30 0000096793 ssy:HealthcareServicesSegmentMember 2018-09-30 0000096793 us-gaap:ManagementMember 2018-09-30 0000096793 us-gaap:TradeNamesMemberssy:SpecialtyPharmacySegmentMember 2018-09-30 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2018-09-30 0000096793 ssy:MedicareLicenseMemberssy:SpecialtyPharmacySegmentMember 2018-09-30 0000096793 us-gaap:CustomerRelationshipsMemberssy:SpecialtyPharmacySegmentMember 2018-09-30 0000096793 ssy:InterestOnOutstandingDebtMember 2018-09-30 0000096793 ssy:OperatingLeasesMember 2018-09-30 0000096793 us-gaap:LongTermDebtMember 2018-09-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:MortgagesMember 2018-09-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2018-09-30 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2018-09-30 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareServicesSegmentMember 2018-09-30 0000096793 us-gaap:CorporateNonSegmentMember 2018-09-30 0000096793 2018-09-30 0000096793 ssy:PharmacySegmentMember 2017-09-30 0000096793 ssy:HealthcareServicesSegmentMember 2017-09-30 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2017-09-30 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareServicesSegmentMember 2017-09-30 0000096793 us-gaap:CorporateNonSegmentMember 2017-09-30 0000096793 2017-09-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2017-12-26 0000096793 2018-11-13 shares pure iso4217:USD iso4217:USD shares utr:acre ssy:Hospital ssy:Segment ssy:Bed ssy:Services

EX-101.SCH 7 ssy-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Basis of Presentation and Adoption of Recently Issued Accounting Standards link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Business Operations link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Discontinued Operations link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Shareholders' Equity link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Revenue Recognition and Accounts Receivables link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Long-Term Debt link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Financial Information by Segment link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Basis of Presentation and Adoption of Recently Issued Accounting Standards (Policies) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Discontinued Operations (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Revenue Recognition and Accounts Receivables (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Long-Term Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Financial Information by Segment (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Business Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Discontinued Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Discontinued Operations - Components of Pension Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Shareholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Revenue Recognition and Accounts Receivables - Summary of Revenue by Payor (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Revenue Recognition and Accounts Receivables - Summary Information for Receivable (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Revenue Recognition and Accounts Receivables - Summary of Allowance for Concession Adjustments (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Intangible Assets - Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Financial Information by Segment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Financial Information by Segment - Segment Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 ssy-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 ssy-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 ssy-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Standards Update 2014-09 [Member] Accounting Standards Update 2014-09 [Member] Accounts Payable, Current Accounts payable Accounts Payable, Related Parties Amount payable to law firms Accounts Receivable, Gross, Current Accounts receivable (net of contractual allowances) Accrued Liabilities, Current Due to third party payors Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Additional Paid in Capital, Common Stock Additional paid-in capital Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Allocated Share-based Compensation Expense Share-based compensation, amount recognized Allowance for Doubtful Accounts Receivable, Current Ending balance Beginning balance Less allowance for concession adjustments Allowance for Doubtful Accounts Receivable, Period Increase (Decrease) Additions recognized as a reduction to revenues Allowance for Doubtful Accounts Receivable, Write-offs Accounts written off, net of recoveries Allowance for doubtful accounts. Allowance For Doubtful Accounts [Table Text Block] Summary of Allowance for Concession Adjustments Amendment Flag Amendment Flag Amortization of Intangible Assets Amortization expense Asset Purchase Agreement And Related License Agreement [Abstract] Asset Purchase Agreement And Related License Agreement [Abstract] Asset Purchase Agreement And Related License Agreement [Abstract] Assets Assets TOTAL ASSETS Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current Assets: Assets, Noncurrent [Abstract] Noncurrent Assets: Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Business And Organization [Line Items] Business And Organization [Line Items] Business And Organization [Line Items] Business And Organization [Table] Business And Organization [Table] Business And Organization [Table] Calculated under Revenue Guidance in Effect before Topic 606 [Member] Calculated under Revenue Guidance in Effect before Topic 606 [Member] Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and Cash Equivalents End of Period Cash and Cash Equivalents Beginning of Period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net decrease in Cash and Cash Equivalents Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment, Contingency And Related Party Transactions [Abstract] Commitment, Contingency And Related Party Transactions [Abstract] Commitment, Contingency And Related Party Transactions [Abstract] Commitments and Contingencies Commitment and Contingencies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock, No Par Value Common shares, without par value Common Stock, Shares, Issued Common shares, issued Common Stock, Shares, Outstanding Common shares, outstanding Common Stock, Value, Issued Common Shares, without par value: Issued and outstanding, 7,347 shares at September 30, 2018 and at June 30, 2018 Community hospital. Community Hospital [Member] Community Hospital [Member] Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive Loss Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Contractual Obligation Contractual obligations, commitments and contingencies Contractual Obligation, Due after Fifth Year Payments due in 5+ years Contractual Obligation, Due in Fourth Year Payments due in 4 years Contractual Obligation, Due in Second Year Payments due in 2 years Contractual Obligation, Due in Third Year Payments due in 3 years Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Schedule of Contractual Obligations, Commitments and Contingencies Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year Payments due in 1 year Corporate, Non-Segment [Member] Corporate and Other [Member] Cost of Goods and Services Sold Cost of goods sold Costs and Expenses [Abstract] Costs and Expenses Current Federal Tax Expense (Benefit) Federal tax expense (benefit) Current Fiscal Year End Date Current Fiscal Year End Date Current State and Local Tax Expense (Benefit) State tax expense (benefit) Customer Relationships [Member] Customer Relationships [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Basis Spread on Variable Rate Debt instrument interest rate, basis spread Debt Instrument, Description of Variable Rate Basis Debt instrument description Debt Instrument, Face Amount Loan agreement amount Debt Instrument Floor Interest Rate Debt Instrument Floor Interest Rate Debt instrument, interest rate floor Debt Instrument, Interest Rate, Effective Percentage Effective interest rate Debt Instrument, Issuance Date Date of loan agreement Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument, Term Debt instrument maturity period Deferred Tax Assets, Net, Noncurrent Net long-term deferred income tax asset or liability Deferred Tax Assets, Valuation Allowance Deferred income tax valuation allowance Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Amortization of prior service cost Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year Expected contribution to pension plan during the remaining fiscal year Defined Benefit Plan, Expected Return (Loss) on Plan Assets Expected return on assets Defined Benefit Plan, Interest Cost Interest Cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Net pension expense Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Adjustment for Bad Debts of Pharmacy Segment [Member] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Discontinued operation income loss from discontinued operation before income tax. Discontinued Operation Income Loss From Discontinued Operation Before Income Tax [Abstract] Earnings (Loss) before income taxes: Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax Earnings (Loss) before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax Loss from Discontinued Operations, net of tax Earnings (Loss) from discontinued operations Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations, Disposed of by Sale [Member] Discontinued Operations, Disposed of by Sale [Member] Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period Income tax expense Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Disposal group including discontinued operation revenue net of expenses. Disposal Group Including Discontinued Operation Revenue Net Of Expenses Net revenues Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations Disposal Group Name [Domain] Disposal Group Name [Domain] Document and entity information Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings (loss) per share continuing operations. Earnings Loss Per Share Continuing Operations [Abstract] Continuing Operations: Earnings (loss) per share discontinued operations. Earnings Loss Per Share Discontinued Operations [Abstract] Discontinued Operations: Earnings Per Share [Abstract] Net Loss: Earnings Per Share, Basic Basic Earnings Per Share, Diluted Diluted Employee-related Liabilities, Current Accrued payroll and related taxes Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Emerging Growth Company Entity Emerging Growth Company Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Entity Small Business Entity Small Business Extinguishment of Debt [Axis] Extinguishment of Debt [Axis] Extinguishment of Debt, Type [Domain] Extinguishment of Debt, Type [Domain] Federal Home Loan Banks [Abstract] Federal Home Loan Banks [Abstract] Revenue from Financial and Health Care Services Financial And Healthcare Services Revenue Revenues before provision for doubtful accounts Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] GEORGIA Georgia [Member] Gain (Loss) on Disposition of Assets for Financial Service Operations Gains on sale of assets Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Amount of increase (decrease) in Electronic Health Records of health care organizations. Electronic Health Records ("EHR") payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the "HITECH Act") which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 ("ARRA"). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals ("CAH") participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015. Health Care Organization, Medicare and Medicaid Electronic Health Records Incentives, Gain (Loss) EHR incentive payments Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Domain] Health Care Organization, Revenue Sources [Domain] Health Care Organizations [Abstract] Health Care Organizations [Abstract] Healthcare services segment. Healthcare Services Segment [Member] Healthcare Services Segment [Member] Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Loss from Continuing Operations before income taxes Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Loss from Continuing Operations Income (Loss) from Continuing Operations, Per Basic Share Basic Income (Loss) from Continuing Operations, Per Diluted Share Diluted Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Basic Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Diluted Income Statement [Abstract] Income Statement [Abstract] Disposal Group Name [Axis] Disposal Group Name [Axis] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Taxes Paid, Net Income taxes Income Taxes Receivable, Noncurrent Income tax receivable Income Tax Expense (Benefit) Income Tax expense Income tax expense (benefit) Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Intangible Assets Disclosure [Text Block] Intangible Assets Intangible Assets, Gross (Excluding Goodwill) Finite and Indefinite-Lived Intangible Assets, Gross Intangible Assets, Net (Excluding Goodwill) Intangible assets - net Total Intangible Liability Disclosure [Abstract] Intangible Liability Disclosure [Abstract] Intangible Liability Disclosure [Abstract] Interest Expense Interest expense, net Interest on outstanding debt. Interest On Outstanding Debt [Member] Interest on Outstanding Debt [Member] Interest Paid, Excluding Capitalized Interest, Operating Activities Interest Inventory, Net Inventory LOUISIANA Louisiana [Member] Labor and Related Expense Salaries, wages and benefits Liabilities and Equity TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: Liabilities, Noncurrent Total long-term liabilities Liabilities, Noncurrent [Abstract] Long-Term Liabilities Life sciences and engineering segment. Life Sciences And Engineering Segment [Member] Life Sciences and Engineering [Member] Loans Payable RDA Loan Long-term Debt, Current Maturities Current maturities of long-term debt, net of debt issuance costs Less current maturities Long-term Debt [Member] Long-Term Debt [Member] Long-term Debt, Excluding Current Maturities Long-term debt, net of debt issuance costs Long-term Debt Long-term Debt [Text Block] Long-Term Debt Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Long term obligations. Long Term Obligations [Text Block] Summary of Long-Term Debt Managed care and other insurers. Managed Care And Other Insurers [Member] Managed Care & Other Insurance [Member] Management [Member] Management [Member] Medicaid. Medicaid [Member] Medicaid [Member] Medical office building and undeveloped land. Medical Office Building And Undeveloped Land [Member] Medical Office Building And Undeveloped Land [Member] Medicare license. Medicare License [Member] Medicare License [Member] Medicare. Medicare [Member] Medicare [Member] Mortgages [Member] Mortgages [Member] MISSISSIPPI Mississippi [Member] Nature of Operations [Text Block] Business Operations Net Cash Provided by (Used in) Financing Activities Net Cash Used in Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows Used in Financing Activities: Net Cash Provided by (Used in) Investing Activities Net Cash Used in Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flows Provided by (Used in) Investing Activities: Net Cash Provided by (Used in) Operating Activities Net Cash Provided by Operating Activities Net Income (Loss) Attributable to Parent Net Loss Net Operating Loss Carry Forwards Expire Period Net Operating Loss Carry Forwards Expire Period Net operating loss carryforward expiration year Net revenue. Net Revenue [Abstract] Net Revenues: New Accounting Pronouncements, Policy [Policy Text Block] Adoption of Recently Issued Accounting Standards Nonoperating Income (Expense) [Abstract] Other Income (Expense): Number of bed in nursing home owned and operated by subsidiary. Number Of Bed In Nursing Home Owned And Operated By Subsidiary Number of bed in nursing home owned and operated by subsidiary Number of hospitals sold. Number Of Hospitals Sold Number of Hospitals Sold Number of licensed-bed owned and operated by subsidiary. Number Of Licensed Bed Owned And Operated By Subsidiary Number of licensed-bed owned and operated by a subsidiary Number of Reportable Segments Number of segments EX-101.PRE 11 ssy-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Nov. 13, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Trading Symbol	SSY
Entity Registrant Name	SUNLINK HEALTH SYSTEMS INC
Entity Central Index Key	0000096793
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		7,346,814

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2018	Jun. 30, 2018
Current Assets:
Cash and cash equivalents	$ 3,393	$ 3,456
Receivables - net	4,606	4,823
Inventory	1,905	1,894
Prepaid expense and other assets	2,687	2,937
Total current assets	12,591	13,110
Property, plant and equipment, at cost	30,441	29,995
Less accumulated depreciation	19,967	19,589
Property, plant and equipment - net	10,474	10,406
Noncurrent Assets:
Intangible assets - net	1,441	1,470
Income tax receivable	305	305
Other noncurrent assets	902	885
Total noncurrent assets	2,648	2,660
TOTAL ASSETS	25,713	26,176
Current liabilities:
Accounts payable	1,432	1,239
Current maturities of long-term debt, net of debt issuance costs	260	255
Accrued payroll and related taxes	2,154	1,959
Due to third party payors	542	290
Other accrued expenses	1,010	1,108
Total current liabilities	5,398	4,851
Long-Term Liabilities
Long-term debt, net of debt issuance costs	2,737	2,803
Noncurrent liability for professional liability risks	941	996
Other noncurrent liabilities	330	340
Total long-term liabilities	4,008	4,139
Commitment and Contingencies
Shareholders' Equity
Preferred Shares, authorized and unissued, 2,000 shares	0	0
Common Shares, without par value: Issued and outstanding, 7,347 shares at September 30, 2018 and at June 30, 2018	3,673	3,673
Additional paid-in capital	10,948	10,947
Retained earnings	1,863	2,743
Accumulated other comprehensive loss	(177)	(177)
Total Shareholders' Equity	16,307	17,186
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 25,713	$ 26,176

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Jun. 30, 2018
Statement of Financial Position [Abstract]
Preferred shares, authorized	2,000,000	2,000,000
Preferred shares, unissued	2,000,000	2,000,000
Common shares, without par value
Common shares, issued	7,347,000	7,347,000
Common shares, outstanding	7,347,000	7,347,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Net Revenues	$ 12,052	$ 13,243
Costs and Expenses
Salaries, wages and benefits	5,947	5,764
Supplies	410	425
Other operating expenses	1,274	1,442
Rent and lease expense	137	154
EHR incentive payments	0	(17)
Depreciation and amortization	418	429
Operating Loss	(758)	(99)
Other Income (Expense):
Gains on sale of assets	2	2
Interest expense, net	(61)	(127)
Loss from Continuing Operations before income taxes	(817)	(224)
Income Tax expense	0	0
Loss from Continuing Operations	(817)	(224)
Loss from Discontinued Operations, net of tax	(63)	(53)
Net Loss	(880)	(277)
Other comprehensive income	0	0
Comprehensive Loss	$ (880)	$ (277)
Continuing Operations:
Basic	$ (0.11)	$ (0.02)
Diluted	(0.11)	(0.02)
Discontinued Operations:
Basic	(0.01)	(0.01)
Diluted	(0.01)	(0.01)
Net Loss:
Basic	(0.12)	(0.03)
Diluted	$ (0.12)	$ (0.03)
Weighted-Average Common Shares Outstanding:
Basic	7,347	9,163
Diluted	7,347	9,163
Product [Member]
Costs and Expenses
Cost of goods sold	$ 3,917	$ 4,458
Service [Member]
Costs and Expenses
Cost of goods sold	$ 707	$ 687

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Statement of Cash Flows [Abstract]
Net Cash Provided by Operating Activities	$ 458	$ 233
Cash Flows Provided by (Used in) Investing Activities:
Expenditures for property, plant and equipment - continuing operations	(456)	(684)
Proceeds from sale of other assets	2	2
Net Cash Used in Investing Activities	(454)	(682)
Cash Flows Used in Financing Activities:
Payments on long-term debt	(67)	(136)
Net Cash Used in Financing Activities	(67)	(136)
Net decrease in Cash and Cash Equivalents	(63)	(585)
Cash and Cash Equivalents Beginning of Period	3,456	10,494
Cash and Cash Equivalents End of Period	3,393	9,909
Cash Paid for:
Interest	55	111
Income taxes	$ 0	$ 0

XML 17 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Adoption of Recently Issued Accounting Standards	3 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Adoption of Recently Issued Accounting Standards	Note 1. –Basis of Presentation and Adoption of Recently Issued Accounting Standards Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of September 30, 2018 and for the three month periods ended September 30, 2018 and 2017 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2018 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2018, filed with the SEC on September 25, 2018. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and month period ended September 30, 2018 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. Adoption of Recently Issued Accounting Standards ASC 606, “Revenue from Contracts with Customers” Effective July 1, 2018, the Company adopted the provisions of Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers” (“ASC 606”), which supersedes most existing revenue recognition guidance, including industry-specific healthcare guidance, by applying the full retrospective method for all periods presented. ASC 606 provides for a single comprehensive principles-based standard for the recognition of revenue across all industries through the application of the following five-step process: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The adoption of the provisions of ASC 606 had no material impact on the Company’s current or historical financial position, results of operations or cash flows. Additionally, management does not anticipate that the provisions of ASC 606 will have an impact on the amount or timing of when the Company recognizes revenue prospectively. However, in accordance with ASC 606, the Company now recognizes the majority of its previously reported provision for doubtful accounts, primarily related to its self-pay patient population, as a direct reduction to revenues as an implicit pricing concession, instead of separately as a discrete deduction to arrive at revenue, and the related presentation of the allowance for doubtful accounts has been eliminated for all periods presented. The Company’s revenue recognition and accounts receivable policies are more fully described in Note 5.

XML 18 R7.htm IDEA: XBRL DOCUMENT

Business Operations	3 Months Ended
Business Operations	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Operations	Note 2. – Business Operations Business Operations SunLink Health Systems, Inc., through subsidiaries, owns businesses which provide healthcare products and services in certain markets in the southeastern United States. Unless the context indicates otherwise, all references to “SunLink,” “we,” “our,” “ours,” “us” and the “Company” refer to SunLink Health Systems, Inc. and our consolidated subsidiaries. References to our specific operations refer to operations conducted through our subsidiaries and references to “we,” “our,” “ours,” and “us” in such context refer to the operations of our subsidiaries. Our business is composed of two business segments, the Healthcare Services segment and the Pharmacy segment. Our Healthcare Services segment subsidiaries own and operate an 84- bed community hospital and a 66- bed nursing home in Mississippi, a 100- bed nursing home in Georgia, an IT service company based in Georgia, and healthcare facilities, which are leased to third parties. Our Pharmacy segment subsidiary operates a pharmacy business in Louisiana with four service lines. The business strategy of SunLink is to focus its efforts on expanding the services and improving the operations and profitability of its existing Healthcare Services and Pharmacy business while seeking to sell certain of its subsidiaries’ underperforming assets. The Company is investing in upgrades and improvements to certain of its Healthcare Services and Pharmacy businesses. The Company has used a portion of the cash proceeds from dispositions of assets to pay down debt and certain other liabilities, to repurchase common shares in tender offers completed in February and December 2017, and to make improvements to its Healthcare Services businesses. The Company may also use existing cash, as well as any net proceeds from future dispositions, if any, to prepay debts, return capital to shareholders including through potential public or private purchases of shares, improve its existing businesses, make selective acquisitions of Healthcare Services and Pharmacy businesses and for other general corporate purposes. There is no assurance that any further dispositions will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis. The Company considers the disposition of business segments, facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments, competition from existing and potential competitors, capital improvement needs, the prevailing reimbursement environment under various Federal and state programs (e.g., Medicare and Medicaid) and private payors, and other corporate objectives. The Company believes certain facilities in its Healthcare Services segment as well as its Pharmacy segment continue to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of assets in its Healthcare Services and its Pharmacy business lines. On October 11, 2018, the Company sold a vacant medical office building and approximately two adjacent acres of undeveloped land. After expenses, the Company received net proceeds from the sale of approximately $935 which will be retained for working capital and general corporate purposes. The pre-tax gain on the sale of property is estimated to be approximately $452 and will be reported in the Company’s fiscal quarter ended December 31, 2018.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Discontinued Operations

3 Months Ended

Sep. 30, 2018

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

Note 3. – Discontinued Operations

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended
	September 30,
	2018			2017
Net Revenues:
Sold Hospitals	$	(6	)	$	(12	)

	$	(6	)	$	(12	)

Earnings (Loss) before income taxes:
Sold Hospitals	$	(38	)	$	(17	)
Life sciences and engineering		(25	)		(36	)

Earnings (Loss) before income taxes		(63	)		(53	)
Income tax expense		0			0

Earnings (Loss) from discontinued operations	$	(63	)	$	(53	)

The components of pension expense for the three months ended September 31, 2018 and 2017, respectively, were as follows:


	Three Months Ended
	September 30,
	2018			2017
Interest Cost	$	14		$	14
Expected return on assets		(9	)		(9	)
Amortization of prior service cost		20			31

Net pension expense	$	25		$	36

XML 20 R9.htm IDEA: XBRL DOCUMENT

Shareholders' Equity	3 Months Ended
Shareholders' Equity	Sep. 30, 2018
Federal Home Loan Banks [Abstract]
Shareholders' Equity	Note 4. – Shareholders’ Equity *Stock-Based Compensation* – For the three months ended September 30, 2018 and 2017, the Company recognized $1 and $5, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were no share options granted under the 2011 Director Stock Option Plan during the three months ended September 30, 2018 and 2017, respectively, and the Company does not have any option plans with authorized shares available for grants.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables

3 Months Ended

Sep. 30, 2018

Receivables [Abstract]

Revenue Recognition and Accounts Receivables

Note 5. – Revenue Recognition and Accounts Receivables

Revenue Recognition

Step 1: Identify the contract(s) with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

The adoption of the provisions of ASC 606 had no material impact on the Company’s current or historical financial position, results of operations or cash flows. Additionally, management does not anticipate that the provisions of ASC 606 will have an impact on the amount or timing of when the Company recognizes revenue prospectively. However, in accordance with ASC 606 the Company now recognizes the majority of its previously reported provision for doubtful accounts, primarily related to its self-pay patient population, as a direct reduction to revenues as an implicit pricing concession, instead of separately as a discrete deduction to arrive at revenue, and the related presentation of the allowance for doubtful accounts has been eliminated for all periods presented.

Disaggregation of Revenue

The Company’s service specific revenue recognition policies are as follows:

Healthcare Services

Pharmacy

Medicare Revenue

Non-Medicare Revenue

Impact of New Revenue Guidance on Financial Statement Line Items

Revenues for the fiscal quarter ended September 30, 2017 and the fiscal years ended June 30, 2018 and June 30, 2017 are summarized in the following tables:


	Fiscal Quarter Ended			Fiscal Years Ended June 30,
	September 30, 2017			2018			2017
Total Net Revenues	$	13,363		$	52,872		$	53,288
Adjustment for bad debts of Pharmacy segment		(120	)		(703	)		(438	)

Net Revenues	$	13,243		$	52,169		$	52,850

Total Cost of goods sold	$	4,458		$	18,529		$	19,917
Adjustment for bad debts of Pharmacy segment		0			0			0

Cost of goods sold	$	4,458		$	18,529		$	19,917

Total Expenses	$	13,462		$	54,866		$	57,798
Adjustment for bad debts of Pharmacy segment		(120	)		(703	)		(438	)

Total Expenses	$	13,342		$	54,163		$	57,360

Practical Expedients and Exemptions

Revenues by payor were as follows for the three months ended September 30, 2018 and 2017:


	Three Months Ended September 30,
	2018		2017
Medicare	$	4,520	$	5,349
Medicaid		4,274		3,794
Retail and Institutional Pharmacy		1,633		1,686
Managed Care & Other Insurance		1,122		1,891
Self-pay		229		103
Rent		88		88
Other		186		332

Total Net Revenues	$	12,052	$	13,243

Summary information for accounts receivable is as follows:


	September 30, 2018			June 30, 2018
Accounts receivable (net of contractual allowances)	$	5,057		$	5,352
Less allowance for concession adjustments		(451	)		(529	)

Patient accounts receivable - net	$	4,606		$	4,823


Three Months Ended September 30, 2018	Healthcare Services			Pharmacy			Total
Balance at July 1, 2018	$	253		$	276		$	529
Additions recognized as a reduction to revenues:
Continuing Operations		34			103			137
Discontinued Operations		(6	)		0			(6	)
Accounts written off, net of recoveries		(96	)		(113	)		(209	)

Balance at September 30, 2018	$	185		$	266		$	451


Three Months Ended September 30, 2017	Healthcare Services			Pharmacy			Total
Balance at July 1, 2017	$	328		$	224		$	552
Additions recognized as a reduction to revenues:
Continuing Operations		70			120			190
Discontinued Operations		12			0			12
Accounts written off, net of recoveries		(102	)		(152	)		(254	)

Balance at September 30, 2017	$	308		$	192		$	500

XML 22 R11.htm IDEA: XBRL DOCUMENT

Intangible Assets

3 Months Ended

Sep. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 6. – Intangible Assets

Intangibles consist of the following, net of amortization:


	September 30, 2018			June 30, 2018
Pharmacy Segment Intangibles
Trade Name (non-amortizing)		1,180			1,180
Customer Relationships		1,089			1,089
Medicare License		623			623

		2,892			2,892
Accumulated Amortization		(1,451	)		(1,422	)

Net Intangibles	$	1,441		$	1,470

Amortization expense was $29 and $29 for the three months ended September 30, 2018 and 2017, respectively.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Long-Term Debt

3 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Long-Term Debt

Note 7. –Long-Term Debt

Long-term debt consisted of the following:


	September 30, 2018			June 30, 2018
Trace RDA Loan	$	3,210		$	3,277
Less unamortized debt issuance costs		(213	)		(219	)
Less current maturities		(260	)		(255	)

Long-term Debt	$	2,737		$	2,803

XML 24 R13.htm IDEA: XBRL DOCUMENT

Income Taxes	3 Months Ended
Income Taxes	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 8. – Income Taxes Income tax expense of $0 ($0 federal expense and state tax expense) and income tax expense of $0 ($0 federal expense and $0 state tax expense) was recorded for continuing operations for the three months ended September 30, 2018 and 2017, respectively. In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates. The Tax Cut and Jobs Act (“TCJA”) was enacted on December 22, 2017. Under ASC 740, the impact of changes in tax law must be recorded in the financial statements in the reporting period that included the date of enactment. In addition, in conjunction with the TCJA, on December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), which provides guidance on accounting for the tax effects of the TCJA. SAB 118 allows for recording certain effects of the TCJA as “provisional” during a one-year measurement period, which for the Company will end in the second quarter of fiscal 2019. At September 30, 2018, consistent with the above process, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $8,610 against the deferred tax asset so that there is no net long-term deferred income tax asset or liability at September 30, 2018. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans. The principal negative evidence that led us to determine at September 30, 2018 that all the deferred tax assets should have full valuation allowances was the three-year cumulative pre-tax loss from continuing operations as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Services Segment businesses operate. For Federal income tax purposes, at September 30, 2018, the Company had approximately $16,100 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire primarily in fiscal 2023 through fiscal 2038; however with the enactment of the Tax Cut and Jobs Act (“TCJA”) on December 22, 2017, federal net operating loss carryforwards generated in taxable years beginning after December 31, 2017 now have no expiration date.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Sep. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 9. – Commitments and Contingencies


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	260	$	557	$	179
2 years		301		417		178
3 years		321		229		158
4 years		341		63		137
5+ years		1,987		5		325

	$	3,210	$	1,271	$	977

XML 26 R15.htm IDEA: XBRL DOCUMENT

Related Party Transactions	3 Months Ended
Related Party Transactions	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Note 10. – Related Party Transactions A director of the Company is a member of a law firm which provides services to SunLink. The Company expensed an aggregate of $76 and $65 for legal services to this law firm in the three months ended September 30, 2018 and 2017, respectively. Included in the Company’s condensed consolidated balance sheets at September 30, 2018 and June 30, 2018 is $65 and $10, respectively, of amounts payable to this law firm.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events	3 Months Ended
Subsequent Events	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 11. – Subsequent Events On October 11, 2018, the Company sold a vacant medical office building and approximately two adjacent acres of undeveloped land. After expenses, the Company received net proceeds from the sale of approximately $935 which will be retained for working capital and general corporate purposes. The pre-tax gain on the sale of property is estimated to be approximately $452 and will be reported in the Company’s fiscal quarter ended December 31, 2018.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Financial Information by Segment

3 Months Ended

Sep. 30, 2018

Segment Reporting [Abstract]

Financial Information by Segment

Note 12. – Financial Information by Segment


	Healthcare Services			Pharmacy			Corporate and Other			Total
As of and for the three months ended September 30, 2018,
Net revenues from external customers	$	5,536		$	6,516		$	0		$	12,052
Operating profit (loss)		(247	)		(57	)		(454	)		(758	)
Depreciation and amortization		162			256			0			418
Assets		13,451			8,067			4,195			25,713
Expenditures for property, plant and equipment		187			269			0			456
As of and for the three months ended September 30, 2017
Net revenues from external customers	$	5,654		$	7,589		$	0		$	13,243
Operating profit (loss)		(57	)		423			(465	)		(99	)
Depreciation and amortization		158			270			1			429
Assets		14,576			9,614			11,212			35,402
Expenditures for property, plant and equipment		476			208			0			684

XML 29 R18.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Adoption of Recently Issued Accounting Standards (Policies)	3 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of September 30, 2018 and for the three month periods ended September 30, 2018 and 2017 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2018 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2018, filed with the SEC on September 25, 2018. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and month period ended September 30, 2018 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.
Adoption of Recently Issued Accounting Standards	Adoption of Recently Issued Accounting Standards ASC 606, “Revenue from Contracts with Customers” Effective July 1, 2018, the Company adopted the provisions of Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers” (“ASC 606”), which supersedes most existing revenue recognition guidance, including industry-specific healthcare guidance, by applying the full retrospective method for all periods presented. ASC 606 provides for a single comprehensive principles-based standard for the recognition of revenue across all industries through the application of the following five-step process: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The adoption of the provisions of ASC 606 had no material impact on the Company’s current or historical financial position, results of operations or cash flows. Additionally, management does not anticipate that the provisions of ASC 606 will have an impact on the amount or timing of when the Company recognizes revenue prospectively. However, in accordance with ASC 606, the Company now recognizes the majority of its previously reported provision for doubtful accounts, primarily related to its self-pay patient population, as a direct reduction to revenues as an implicit pricing concession, instead of separately as a discrete deduction to arrive at revenue, and the related presentation of the allowance for doubtful accounts has been eliminated for all periods presented. The Company’s revenue recognition and accounts receivable policies are more fully described in Note 5.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Tables)

3 Months Ended

Sep. 30, 2018

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended
	September 30,
	2018			2017
Net Revenues:
Sold Hospitals	$	(6	)	$	(12	)

	$	(6	)	$	(12	)

Earnings (Loss) before income taxes:
Sold Hospitals	$	(38	)	$	(17	)
Life sciences and engineering		(25	)		(36	)

Earnings (Loss) before income taxes		(63	)		(53	)
Income tax expense		0			0

Earnings (Loss) from discontinued operations	$	(63	)	$	(53	)

Components of Pension Expense

The components of pension expense for the three months ended September 31, 2018 and 2017, respectively, were as follows:


	Three Months Ended
	September 30,
	2018			2017
Interest Cost	$	14		$	14
Expected return on assets		(9	)		(9	)
Amortization of prior service cost		20			31

Net pension expense	$	25		$	36

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

XML 31 R20.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables (Tables)

3 Months Ended

Sep. 30, 2018

Summary of Revenues

Revenues by payor were as follows for the three months ended September 30, 2018 and 2017:


	Three Months Ended September 30,
	2018		2017
Medicare	$	4,520	$	5,349
Medicaid		4,274		3,794
Retail and Institutional Pharmacy		1,633		1,686
Managed Care & Other Insurance		1,122		1,891
Self-pay		229		103
Rent		88		88
Other		186		332

Total Net Revenues	$	12,052	$	13,243

Summary Information for Accounts Receivable

Summary information for accounts receivable is as follows:


	September 30, 2018			June 30, 2018
Accounts receivable (net of contractual allowances)	$	5,057		$	5,352
Less allowance for concession adjustments		(451	)		(529	)

Patient accounts receivable - net	$	4,606		$	4,823

Summary of Allowance for Concession Adjustments


Three Months Ended September 30, 2018	Healthcare Services			Pharmacy			Total
Balance at July 1, 2018	$	253		$	276		$	529
Additions recognized as a reduction to revenues:
Continuing Operations		34			103			137
Discontinued Operations		(6	)		0			(6	)
Accounts written off, net of recoveries		(96	)		(113	)		(209	)

Balance at September 30, 2018	$	185		$	266		$	451


Three Months Ended September 30, 2017	Healthcare Services			Pharmacy			Total
Balance at July 1, 2017	$	328		$	224		$	552
Additions recognized as a reduction to revenues:
Continuing Operations		70			120			190
Discontinued Operations		12			0			12
Accounts written off, net of recoveries		(102	)		(152	)		(254	)

Balance at September 30, 2017	$	308		$	192		$	500

Accounting Standards Update 2014-09 [Member]

Summary of Revenues

Revenues for the fiscal quarter ended September 30, 2017 and the fiscal years ended June 30, 2018 and June 30, 2017 are summarized in the following tables:


	Fiscal Quarter Ended			Fiscal Years Ended June 30,
	September 30, 2017			2018			2017
Total Net Revenues	$	13,363		$	52,872		$	53,288
Adjustment for bad debts of Pharmacy segment		(120	)		(703	)		(438	)

Net Revenues	$	13,243		$	52,169		$	52,850

Total Cost of goods sold	$	4,458		$	18,529		$	19,917
Adjustment for bad debts of Pharmacy segment		0			0			0

Cost of goods sold	$	4,458		$	18,529		$	19,917

Total Expenses	$	13,462		$	54,866		$	57,798
Adjustment for bad debts of Pharmacy segment		(120	)		(703	)		(438	)

Total Expenses	$	13,342		$	54,163		$	57,360

XML 32 R21.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

3 Months Ended

Sep. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Intangibles consist of the following, net of amortization:


	September 30, 2018			June 30, 2018
Pharmacy Segment Intangibles
Trade Name (non-amortizing)		1,180			1,180
Customer Relationships		1,089			1,089
Medicare License		623			623

		2,892			2,892
Accumulated Amortization		(1,451	)		(1,422	)

Net Intangibles	$	1,441		$	1,470

XML 33 R22.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Tables)

3 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Summary of Long-Term Debt

Long-term debt consisted of the following:


	September 30, 2018			June 30, 2018
Trace RDA Loan	$	3,210		$	3,277
Less unamortized debt issuance costs		(213	)		(219	)
Less current maturities		(260	)		(255	)

Long-term Debt	$	2,737		$	2,803

XML 34 R23.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

3 Months Ended

Sep. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of Contractual Obligations, Commitments and Contingencies


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	260	$	557	$	179
2 years		301		417		178
3 years		321		229		158
4 years		341		63		137
5+ years		1,987		5		325

	$	3,210	$	1,271	$	977

XML 35 R24.htm IDEA: XBRL DOCUMENT

Financial Information by Segment (Tables)

3 Months Ended

Sep. 30, 2018

Segment Reporting [Abstract]

Segment Information


	Healthcare Services			Pharmacy			Corporate and Other			Total
As of and for the three months ended September 30, 2018,
Net revenues from external customers	$	5,536		$	6,516		$	0		$	12,052
Operating profit (loss)		(247	)		(57	)		(454	)		(758	)
Depreciation and amortization		162			256			0			418
Assets		13,451			8,067			4,195			25,713
Expenditures for property, plant and equipment		187			269			0			456
As of and for the three months ended September 30, 2017
Net revenues from external customers	$	5,654		$	7,589		$	0		$	13,243
Operating profit (loss)		(57	)		423			(465	)		(99	)
Depreciation and amortization		158			270			1			429
Assets		14,576			9,614			11,212			35,402
Expenditures for property, plant and equipment		476			208			0			684

XML 36 R25.htm IDEA: XBRL DOCUMENT

Business Operations - Additional Information (Detail) $ in Thousands		3 Months Ended
	Oct. 11, 2018 USD ($) a	Dec. 31, 2018 USD ($)	Sep. 30, 2018 Segment Bed Services
Business And Organization [Line Items]
Number of segments \| Segment			2
Medical Office Building And Undeveloped Land [Member] \| Scenario, Forecast [Member]
Business And Organization [Line Items]
Earnings (Loss) before income taxes \| $		$ 452
Medical Office Building And Undeveloped Land [Member] \| Subsequent Event [Member]
Business And Organization [Line Items]
Proceeds from sale \| $	$ 935
Undeveloped land sold \| a	2
Healthcare Services Segment [Member] \| Community Hospital [Member]
Business And Organization [Line Items]
Number of licensed-bed owned and operated by a subsidiary			84
Healthcare Services Segment [Member] \| Nursing Home [Member] \| Mississippi [Member]
Business And Organization [Line Items]
Number of bed in nursing home owned and operated by subsidiary			66
Healthcare Services Segment [Member] \| Nursing Home [Member] \| Georgia [Member]
Business And Organization [Line Items]
Number of bed in nursing home owned and operated by subsidiary			100
Pharmacy Segment [Member] \| Louisiana [Member]
Business And Organization [Line Items]
Number of material service lines \| Services			4

XML 37 R26.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Schedule of Discontinued Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Earnings (Loss) before income taxes:
Income tax expense	$ 0	$ 0
Earnings (Loss) from discontinued operations	(63)	(53)
Discontinued Operations, Disposed of by Sale [Member]
Net Revenues:
Net revenues	(6)	(12)
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes	(63)	(53)
Discontinued Operations, Disposed of by Sale [Member] \| Sold Hospitals [Member]
Net Revenues:
Net revenues	(6)	(12)
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes	(38)	(17)
Discontinued Operations, Disposed of by Sale [Member] \| Life Sciences and Engineering [Member]
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes	$ (25)	$ (36)

XML 38 R27.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Additional Information (Detail) $ in Thousands	3 Months Ended	50 Months Ended
	Sep. 30, 2018 USD ($)	Aug. 31, 2016 Hospital
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of Hospitals Sold \| Hospital		4
Life Sciences and Engineering [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contribution to pension plan	$ 25
Expected contribution to pension plan during the remaining fiscal year	$ 75

XML 39 R28.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Components of Pension Expense (Detail) - Life Sciences and Engineering [Member] - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Defined Benefit Plan Disclosure [Line Items]
Interest Cost	$ 14	$ 14
Expected return on assets	(9)	(9)
Amortization of prior service cost	20	31
Net pension expense	$ 25	$ 36

XML 40 R29.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, amount recognized	$ 1	$ 5
2011 Director Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	0	0

XML 41 R30.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenues	$ 12,052	$ 13,243	$ 52,169	$ 52,850
Total Expenses		13,342	54,163	57,360
Accounting Standards Update 2014-09 [Member] \| Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenues		13,363	52,872	53,288
Cost of goods sold		4,458	18,529	19,917
Total Expenses		13,462	54,866	57,798
Accounting Standards Update 2014-09 [Member] \| Adjustment for Bad Debts of Pharmacy Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenues		(120)	(703)	(438)
Cost of goods sold		0	0	0
Total Expenses		(120)	(703)	(438)
Product [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Cost of goods sold	$ 3,917	$ 4,458	$ 18,529	$ 19,917

XML 42 R31.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables - Summary of Revenue by Payor (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net Revenues	$ 12,052	$ 13,243	$ 52,169	$ 52,850
Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenues before provision for doubtful accounts	4,520	5,349
Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenues before provision for doubtful accounts	4,274	3,794
Retail and Institutional Pharmacy [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenues before provision for doubtful accounts	1,633	1,686
Managed Care & Other Insurance [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenues before provision for doubtful accounts	1,122	1,891
Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenues before provision for doubtful accounts	229	103
Rent [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenues before provision for doubtful accounts	88	88
Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenues before provision for doubtful accounts	$ 186	$ 332

XML 43 R32.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables - Summary Information for Receivable (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2017
Receivables [Abstract]
Accounts receivable (net of contractual allowances)	$ 5,057	$ 5,352
Less allowance for concession adjustments	(451)	(529)	$ (500)	$ (552)
Patient accounts receivable - net	$ 4,606	$ 4,823

XML 44 R33.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables - Summary of Allowance for Concession Adjustments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Beginning balance	$ 529	$ 552
Accounts written off, net of recoveries	(209)	(254)
Ending balance	451	500
Continuing Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	137	190
Discontinued Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	(6)	12
Healthcare Services Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Beginning balance	253	328
Accounts written off, net of recoveries	(96)	(102)
Ending balance	185	308
Healthcare Services Segment [Member] \| Continuing Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	34	70
Healthcare Services Segment [Member] \| Discontinued Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	(6)	12
Pharmacy Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Beginning balance	276	224
Accounts written off, net of recoveries	(113)	(152)
Ending balance	266	192
Pharmacy Segment [Member] \| Continuing Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	103	120
Pharmacy Segment [Member] \| Discontinued Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	$ 0	$ 0

XML 45 R34.htm IDEA: XBRL DOCUMENT

Intangible Assets - Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Jun. 30, 2018
Indefinite-lived Intangible Assets [Line Items]
Total	$ 1,441	$ 1,470
Specialty Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite and Indefinite-Lived Intangible Assets, Gross	2,892	2,892
Accumulated Amortization	(1,451)	(1,422)
Total	1,441	1,470
Trade Name [Member] \| Specialty Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets	1,180	1,180
Customer Relationships [Member] \| Specialty Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	1,089	1,089
Medicare License [Member] \| Specialty Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 623	$ 623

XML 46 R35.htm IDEA: XBRL DOCUMENT

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 29	$ 29

XML 47 R36.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Summary of Long-Term Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Jun. 30, 2018
Debt Instrument [Line Items]
Less unamortized debt issuance costs	$ (213)	$ (219)
Less current maturities	(260)	(255)
Long-term Debt	2,737	2,803
Trace RDA Loan [Member]
Debt Instrument [Line Items]
RDA Loan	$ 3,210	$ 3,277

XML 48 R37.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended
	Dec. 26, 2017	Sep. 30, 2018	Sep. 30, 2017
Debt Instrument [Line Items]
Prepayment of loan		$ 67	$ 136
Trace RDA Loan [Member]
Debt Instrument [Line Items]
Debt instrument maturity period		15 years
Prepayment of loan	$ 3,548
Debt instrument description		Prime rate plus 1% with a floor of 5.5%.
Debt instrument interest rate, basis spread	1.00%
Debt instrument, interest rate floor	5.50%
Effective interest rate		6.25%
Trace RDA Loan [Member] \| Mortgages [Member]
Debt Instrument [Line Items]
Loan agreement amount		$ 9,975
Date of loan agreement		Jul. 05, 2012

XML 49 R38.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 0	$ 0
Federal tax expense (benefit)	0	0
State tax expense (benefit)	0	$ 0
Deferred income tax valuation allowance	8,610,000
Net long-term deferred income tax asset or liability	0
Net operating loss carry-forward	$ 16,100,000
Net operating loss carryforward expiration year	2023 through fiscal 2038

XML 50 R39.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) $ in Thousands	Sep. 30, 2018 USD ($)
Long-Term Debt [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	$ 260
Payments due in 2 years	301
Payments due in 3 years	321
Payments due in 4 years	341
Payments due in 5+ years	1,987
Contractual obligations, commitments and contingencies	3,210
Operating Leases [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	557
Payments due in 2 years	417
Payments due in 3 years	229
Payments due in 4 years	63
Payments due in 5+ years	5
Contractual obligations, commitments and contingencies	1,271
Interest on Outstanding Debt [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	179
Payments due in 2 years	178
Payments due in 3 years	158
Payments due in 4 years	137
Payments due in 5+ years	325
Contractual obligations, commitments and contingencies	$ 977

XML 51 R40.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Detail) - Management [Member] - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018
Related Party Transaction [Line Items]
Legal services to these law firms	$ 76	$ 65
Amount payable to law firms	$ 65		$ 10

XML 52 R41.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail) - Medical Office Building And Undeveloped Land [Member] $ in Thousands		3 Months Ended
	Oct. 11, 2018 USD ($) a	Dec. 31, 2018 USD ($)
Scenario, Forecast [Member]
Subsequent Event [Line Items]
Earnings (Loss) before income taxes		$ 452
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from sale	$ 935
Undeveloped land to sale \| a	2

XML 53 R42.htm IDEA: XBRL DOCUMENT

Financial Information by Segment - Additional Information (Detail)	3 Months Ended
	Sep. 30, 2018 Segment
Segment Reporting [Abstract]
Number of segments	2

XML 54 R43.htm IDEA: XBRL DOCUMENT

Financial Information by Segment - Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Segment Reporting Information [Line Items]
Net revenues from external customers	$ 12,052	$ 13,243	$ 52,169	$ 52,850
Operating profit (loss)	(758)	(99)
Depreciation and amortization	418	429
Assets	25,713	35,402	$ 26,176
Expenditures for property, plant and equipment	456	684
Operating Segments [Member] \| Healthcare Services Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	5,536	5,654
Operating profit (loss)	(247)	(57)
Depreciation and amortization	162	158
Assets	13,451	14,576
Expenditures for property, plant and equipment	187	476
Operating Segments [Member] \| Pharmacy Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	6,516	7,589
Operating profit (loss)	(57)	423
Depreciation and amortization	256	270
Assets	8,067	9,614
Expenditures for property, plant and equipment	269	208
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	0	0
Operating profit (loss)	(454)	(465)
Depreciation and amortization	0	1
Assets	4,195	11,212
Expenditures for property, plant and equipment	$ 0	$ 0

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( %N!;DT?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ 6X%N32?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " !;@6Y-(J%&ULS9+!:L,P#(9?9?B>R&Y+&2;U96.G%@8K;.QF9+4UBQ-C:R1]^R59 MFS*V!]C1TN]/GT 51HUMHN?41DKL*=_UH6ZRQK@1)^:H 3*>*-A<#HEF:![: M%"P/SW2$:/'#'@D64JXA$%MGV<((+.),%*9RJ#&1Y39=\ YG?/Q,]01S"%13 MH(8SJ%*!,./$>.[K"FZ $<:40OXND)N)4_5/[-0!<4GVV<^IKNO*;CGEAAT4 MO.VV+].ZA6\RVP9I^)6]YG.DC;A.?ET^/.Z?A%E(=5\H5:C57JVUDEJNWD?7 M'WXWX= Z?_#_V/@J:"KX=1?F"U!+ P04 " !;@6Y-F5R<(Q & "<)P M$P 'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03 M621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( %N!;DV,[X9O?@( -T( 8 >&PO=V]R:W-H965T&UL?5;;CILP$/T5Q &M9)S=AK53_'$6RJFE+Y!/O::>_ M7+AHB=)3<8UD+R@Y6U++(AS'>=22I@NW:[MV%-LUORG6=/0H GEK6R)^[RGC MCTV(PO>%E^9:*[,0;=<]N=)O5'WOCT+/HLG*N6EI)QO>!8)>-N$./1]0;@@6 M\:.A#SD;!R:4$^>O9O+YO ECXQ%EM%+&!-&O.SU0QHPE[<>OT6@X:1KB?/QN M_:,-7@=S(I(>./O9G%6]"5=A<*87&9# M_4 4V:X%?P1B.*V>F*1 SXG>S,HLVKVSWW2T4J_>M_$ZNALS(V(_(/ ,@29$ MI&U/ A@2V&./CO\5./B(!!9(P @22T]F]!2FIR ]M?1T1L^<#? 1.2R0@0*9 M1R\< 1^Q@@5R4"#WZ*4CX"-0#"L4H$+A\Y$C,4 R"^F&8XY1"8NL0)&5+^)D MRGZ Y'/(0JJ4H$3I2Z2.! #)8 D4PP45^Q9RMZ0 3+&@LE"VR+>P);<#,,PN %%;C4D5_).'%5 ,S"_P3! M]8[\^26-G2P[C)CY^1=)FJ^0&T\T:Q8M%5?;5V50\5MG MF_IL=>K=.VR;S5_XT/B_$G%M.AF*:G_B)^U)K>\:TX31BS+# M0H_%T'"'B>+]>)F(IAO-]@]02P,$% @ 6X%N37>DY*I'! 7A4 !@ M !X;"]W;W)KCLEZ.;U[;-?+YK6O#L?PV"ZZU[HNV_^*4#7G50+)^XNOAY=]/[Y(U\M3 M^1+^"OVWTV,[/*774K:'.AR[0W- 4KV_CO1ROQ7@]Q9N;>*U($A=)-DF.%XGVFN0AB(QULA,C M.C'<"1 G%XF]J<0XY8@3092CEIU8T8GE3DBW%995 EY9XD00Y=[(3ISHQ'$G MI.$+QRI!EY-QN!%$7F>RDTQTDG$GACC)>+IH/>G#C:#2 $KVDHM>]>.Z%#,C""V/%.]I%DLKFD;D,2B:2XFX8DA2O2)G, M4"Z),A69T1 A)# ZZ0C=0,8;(,_(TXR06^5]+:JRR+@#&9; :6DH+6?-_="C M9/A$=.]%QB5P7M*<"^ L](JM0%R4YS$O,C"!$]-08@*G(3J34S.2RL5Z288F M<&H:2DT0B&@SH*N:)'.0Q6:!C$[(V"PPD54 9. !)YZAQ ,.,S!TW=I(*M0Q MRLC( \X\0YD''&?H%#4CB&QDY*%,/.3$,Y1XR%&&8"GP!-4 X$C+H,P[!.XF MIVZ U6/I9-D((O2168"1C2$GIZ'D1(&)"F@W22I0L5VJ3$[DY+24G,BA:+6G MA!!4)K<0<2.S$PV;D=$29.(A)YZEQ$.!91E=CS>2*E>1_2K*Q$-./$N)AQQE MGBV2DLA':(3>FHZR:-;>G+-*N59()N];TYJ!K/'G\LVQ?#L=N\=3T?5-/ M)UN[ING#4*3Z,B2W#^7V^E"%73_>9L-]>SGQNSSTS6D^S4RO1ZKK_P%02P,$ M% @ 6X%N32E$EQGX 0 "P8 !@ !X;"]W;W)K)4$VJQDYC,W?B:V(X& @J9U!&(:FYP!$IU((7Q=XAICUMJX[3_'OW)Y*YR.1,!1T;_ M5+DL$WMG6SD4Y$KE,^N^P9!/:%M#\C_@!E3)-8G:(V-4F+>5785D]1!%H=3D MK6^KQK1=OQ+AP;9M\ :#-QK1>'/%<4.Q&R5([3]">)L0GO'[ M4PB\[??":9_%C M'_ G>>[K>AXTN9:Z3/XD_%(UPCHSJ6ZXN8<%8Q)43.=!A2M591X'% JINUCU M>5^?^H%D[5!ZT5C_T_]02P,$% @ 6X%N34NFM($L! _!0 !@ !X M;"]W;W)KV/3\%0;,]FC)O'NW95-T_>UN7>=M=UH>@.=UGZPO]H^'8Z'-N^(5@MSOG!_&': M/\\O=7<57'O9G4I3-2=;>;79+_UG\;11N@\8%'^=S*69G7M]*J_6?N\O?MTM M_;!W9 JS;?LN\N[P;C:F*/J>.A__3)WZUS'[P/GY1^]?A^2[9%[SQFQL\?=I MUQZ7?N9[.[//WXKVF[W\8J:$8M^;LO_-O)NBD_=.NC&VMFB&7V_[UK2VG'KI MK)3YC_%XJH;C9>K_(PP'R"E 7@.ZL>\%J"E _0R(AN1'9T.J7_(V7RUJ>_'J M<;;.>;\HQ)/JBKGM&X?:#?]UV39=Z_LJ58O@O>]GDJQ'B9Q)Q%41=)U?1Y!H MA+5DX?)V@ U7I!$>0<$-CDL,H20=)->8@PY@: 2HE(X6]1-!+-'2A MYEX2'!_#^)CGDI)<1DD\@4@EI6N*,!X%YV-&^2@X_.AM>%=RZP/C47 ^ M9I2/@K,/506HW%7!B!20@I%;N2FY]8%)*3DI-23EITOM502IW53 J)4>E=JPX MB5$I.2HU1>6DR>9.PT=!(85EH0.9$B-3_NR$W7'7'#2:6XL02H>.AHC!D%(>,Z[-78<@H M#AE!;]?U))H_<91F[S% %46QXXY4F#&*,T:XP*LP%A3'@K,F& N*8P'41+-L MTY"5A(N2C#X%@MF>46GJP["]UGA;^U:U_?;,K/6ZA?-% M:\_37F-PW?!<_0=02P,$% @ 6X%N3=.P/:;/ @ H0H !@ !X;"]W M;W)K=GEG_$5<*)7>:UTU8N5?I&P7 M02 .%UH3\.OEV9NS]=+=I55 MV= ]]\2UK@G_NZ45NZ]\Y+]-/);GB]03P7K9DC/]2>53N^=J% Q9CF5-&U&R MQN/TM/(W:+%#F0XPB%\EO8O1LZ>E/#/VH@??CBL_U(QH10]2IR#J=J,[6E4Z MD^+QIT_J#S5UX/CY+?L7(UZ)>2:"[ECUNSS*R\K/?>](3^1:R4=V_TI[08GO M]>J_TQNM%%PS434.K!+FZAVN0K*ZSZ*HU.2UNY>-N=^[-QGNP^" J ^(A@!5 M^Z, W ?@]X#8B.^8&:F?B23K)6=WCW=?JR5Z4Z %5HMYT)-F[I)04 I?G,HF8@E0R@8BW8-G.JV'OC(\2$1 Z2R $2A44BA]8CMG@ H#2? MH5* 5 KWVZ(03H!"^+"&KAJ$[-,: DRM+;"#0 C/[#0T8QT(8!/9;-#_L % M\VQ E]F@"&#C.%D$L,$V&P"4Y,D,&]B1$ ;8Q#8;[!3"[D$$4,K=BIFCB&"# M0X##(=OA>M"$#RZ&C0X!3H=LIT.NBR6)KS0Y^U MB71C8,UO=?]E&H;W-%WS]H/P<]D([YE)U7:8YN#$F*2*8?B@ENFB^L5A4-&3 MU(^9>N9=T]0-)&O[AC 8NM+U/U!+ P04 " !;@6Y-6>Y&Q+ ! #2 P M& 'AL+W=O-L-/;%M0">O&K5 MN9RVWO<'QES9@A;NQO30X9_:6"T\NK9AKK<@JDC2BO$DN65:R(X668R=;)&9 MP2O9P\=>SL+!O5'/LO)M3C]14D$M!N4?S?@5YGX^4#(W_QTNH! > M*L$<'CC.I@S!.(KX#XMW&+T4:?HY8Y<@-&..$X:O,0N"H?J2@F^E./)_ MZ'R;OMNLPC>P<.1N/-QOG7QOC 4M);G"%6GQ@BZ.@]L'\B+:=UFQR MO.GG%\269US\!5!+ P04 " !;@6Y-HPC/3K ! #2 P & 'AL+W=O M=\?&7-5 M!UJX.^S!A#\-6BU\<&W+7&]!U FD%>-9]I9I(0TM\Q0[VS+'P2MIX&R)&[06 M]M<)%(X%W=%;X%&VG8\!5N:]:.$;^._]V0:/+2RUU&"<1$,L- 6]WQU/AYB? M$GY(&-W*)K&3"^)S=#[7!@^]7(2#!U1/LO9=0=]34D,C!N4?,6[(P^S MJ6(PC2+]"^)=B%[+'>@I3L+JQ0%Q[8XBAH?#3?!=M.:S8Y'OOY!;'E&9>_ M 5!+ P04 " !;@6Y-R.G!(K0! #2 P & 'AL+W=O[^?I3LNMYF[$42*9[#0XI*!V/?7 /@R;N2VF6T\;X[,.:*!I1P5Z8#C3>5 ML4IX-&W-7&=!E!&D)..;S353HM4T3Z/O9//4]%ZV&DZ6N%XI87\=09HAHUOZ MX7AJZ\8'!\O33M3P _QS=[)HL9FE;!5HUQI-+%09O=L>CDF(CP$O+0QN<2:A MDK,Q;\'X5F9T$P2!A,('!H';!>Y!RD"$,GY.G'1.&8#+\P?[EU@[UG(6#NZ- M?&U+WV3TEI(2*M%+_V2&KS#5LZ=D*OX1+B Q/"C!'(61+JZDZ)TW:F)!*4J\ MCWNKXSZ,-_O]!%L'\ G 9\!MS,/&1%'Y@_ B3ZT9B!U[WXGPQ-L#Q]X4P1E; M$>]0O$/O)=_R)&670#3%',<8OHR9(QBRSRGX6HHC_P?.U^&[586["-_]H7"_ M3I"L$B21(/EOB6LQUW\E88N>*K!UG"9'"M/K.,D+[SRP=SR^R6?X..W?A:U; M['S9V/_*& \H97.%(]3@!YL-"94/QQL\VW',1L.;;OI!;/[&^6]02P,$ M% @ 6X%N3?VJ0\:V 0 T , !@ !X;"]W;W)KMO8E_;J&!SGGW \NZ6#LLVL /'G5JG49;;SOCHRYH@$MW(WIH,6;RE@M/)JV M9JZS(,I(THKQS>:6:2%;FJ?1=[9Y:GJO9 MG2UROM;!_3Z#,D-&$OCD>9=WX MX&!YVHD:?H'_W9TM6FQ6*:6&UDG3$@M51N^3XVD7\!'P1\+@%F<2*KD8\QR, M[V5&-R$A4%#XH"!PN$#*!6$,(V729/.(0-Q>7Y3_QIKQUHNPL,^R]$U& M#Y244(E>^4)*BMYYHR<53$6+UW&7;=R' M\6:[GVCK!#X1^$S8'V(M8Z"8^1?A19Y:,Q []KX3X8F3(\?>%,$96Q'O,'F' MWFN^/Z3L&G0FR&F$\ 4DF1$,Q><(?"W"B7^B\W7Z=C7!;:1OE]'YW;K ;E5@ M%P5V_ZOP,R3AAP\QV**C&FP=9\F1PO1MG..%=Q[7>QY?Y!T^SOI/86O9.G(Q M'M\U=K\RQ@.FLKG! 6KP>\V&@LJ'XQV>[3ADH^%--_T?-G_B_!]02P,$% M @ 6X%N37J.W'FT 0 T@, !D !X;"]W;W)K&UL?5/;;IPP$/T5RQ\0LX:TZ0J0LJFJ5FJE5:JVSUX8P(K-4-LLZ=_7-H2B M!N7%]HS/.7/Q.)_0/-D.P)%GK7I;T,ZYX4/V2M>L*>D=) M#8T8E7O$Z3,L]=Q2LA3_%:Z@/#QDXF-4J&Q<235:AWI1\:EH\3SOLH_[--]D MMPMMG\ 7 E$=S$.FP/%S#\*)\KKJ;81KIZ39ZFNP+9+L"613( MWBQQ!Y/^7R3;]%2#:>,T65+AV,=)WGC7@;WG\4W^P>=I_R9,*WM++NC\R\;^ M-X@.?"K)C1^ASG^PU5#0N'!\[\]F'K/9<#@L/XBMW[C\"U!+ P04 " !; M@6Y-S386$;0! #2 P &0 'AL+W=O'B %ZG?]\!.Z[;6GD! M9IASYLPP9*.Q+ZX%\.1-2>URVGK?'QAS90M*N"O3@\:;VE@E/)JV8:ZW(*H( M4I+QW>Z&*=%I6F31=[)%9@8O.PTG2]R@E+"_CB#-F-,]?7<\=TWK@X,562\: M^ ;^>W^R:+&%I>H4:-<932S4.;W;'XYIB(\!/SH8W>I,0B5G8UZ"\53E=!<$ M@832!P:!VP7N09TZZI S ]?F=_7.L'6LY"P?W1O[L*M_F]):2"FHQ M2/]LQD>8Z[FF9"[^"UQ 8GA0@CE*(UU<23DX;]3,@E*4>)OV3L=]G&ZNDQFV M#> S@"^ VYB'38FB\@?A19%9,Q([];X7X8GW!XZ]*8,SMB+>H7B'WDNQ3WC& M+H%HCCE.,7P=LT0P9%]2\*T41_X?G&_#DTV%280G?RE,M@G238(T$J0?EK@5 MD_Z3A*UZJL V<9H<*&PO=V]R:W-H965T0-DAIUOZ[GB131NB@Q59)QKX N%K M=W9HL9FEDAJ,E]80!W5.'[;'TS[&IX!O$@:_.)-8R<7:UVA\K'*ZB8) 01DB M@\#M"H^@5"1"&3\F3CJGC,#E^9W].=6.M5R$AT>KOLLJM#F]IZ2"6O0JO-CA M TSUW%(R%?\)KJ P/"K!'*55/JVD['VP>F)!*5J\C;LT:1_&&WZ88.L /@'X M#+A/>=B8*"E_$D$4F;,#<6/O.Q&?>'ODV)LR.E,KTAV*]^B]%MO=;<:ND6B* M.8TQ?!DS1S!DGU/PM10G_@^#S@V8UC-AK!=M,/8O,W+GX!4$L#!!0 ( %N!;DU>V79= MM $ -(# 9 >&PO=V]R:W-H965T%'=W9@"--ZVQBGLT;Q56%&+X6&BR5N5(K;GV>09BKI@;XX'D77^^!@53'P#KZ _SI<+%IL M96F$ NV$T<1"6]+[P^F=Y%SKNTWR390ML'Y N@'0%'&,> M-B>*RM]QSZO"FHG8N?<##T]\.*78FSHX8ROB'8IWZ+U5A^Q8L%L@6F+."_+\E[L3DR5])V*:G M"FP7I\F1VHPZ3O+&NP[L?1K?Y'?X/.V?N>V$=N1J/+YL[']KC >4DMSA"/7X MP59#0NO#\0V>[3QFL^'-L/P@MG[CZA=02P,$% @ 6X%N36P4^#2S 0 MT@, !D !X;"]W;W)K&UL?5-A;]P@#/TKB!]0 M+ES:5:M.IL3EOG^@-CMFQ!"WN%/73^ID:CA?.F:9CM#8@J@K1B?+>[85K(CA99 M])U,D>'@E.S@9(@=M!;FQQ$4CCE-Z+OC23:M"PY69+UHX"NX;_W)>(LM+)74 MT%F)'3%0Y_0N.1S3$!\#ODL8[>I,0B5GQ)=@/%8YW05!H*!T@4'X[0+WH%0@ M\C)>9TZZI S ]?F=_5.LW==R%A;N43W+RK4YO:6D@EH,RCWA^ !S/=>4S,5_ MA@LH'QZ4^!PE*AM74@[6H9Y9O!0MWJ9==G$?IYMK/L.V 7P&\ 5P&_.P*5%4 M_E$X460&1V*FWOQ&PO=V]R:W-H965T:9M<<7!1@'\#K]^P)V'">U^@+,,.?,F6%(!S3/M@%PY%5) M;3/:.-<=&+-% TK8*^Q ^YL*C1+.FZ9FMC,@R@A2DO'-YH8IT6J:I]%W,GF* MO9.MAI,AME=*F#]'D#AD=$O?'(]MW;C@8'G:B1I^@OO5G8RWV,Q2M@JT;5$3 M U5&;[>'8Q+B8\#O%@:[.)-0R1GQ.1@/948W01!(*%Q@$'Z[P!U(&8B\C)>) MD\XI W!Y?F/_&FOWM9R%A3N43VWIFHSN*2FA$KUTCSA\@ZF>:TJFXK_#!:0/ M#TI\C@*EC2LI>NM032Q>BA*OX][JN _CS6X_P=8!? +P&;"/>=B8*"J_%T[D MJ<&!F+'WG0A/O#UPWYLB.&,KXIT7;[WWDF^3)&670#3%',<8OHR9(YAGGU/P MM11'_@^*C!UG"9+"NQU MG.2%=Q[86Q[?Y#U\G/8?PM2MMN2,SK]L['^%Z,!+V5SY$6K\!YL-"94+QR_^ M;,8Q&PV'W?2#V/R-\[]02P,$% @ 6X%N359ROV2T 0 T@, !D !X M;"]W;W)K&UL?5-A;]L@$/TKB!]0$N*M:61;:CI- MF]1*4:=MGXE]ME'!>(#C]M_WP*[GM=:^ '?<>_?N.-+!V"?7 'CRK%7K,MIX MWQT81M_)YJGIO9(M MG"QQO=;"OAQ!F2&C6_KF>)1UXX.#Y6DG:O@!_F=WLFBQF:64&EHG34LL5!F] MW1Z.28B/ ;\D#&YQ)J&2LS%/P?A>9G03!(&"P@<&@=L%[D"I0(0R_DR<=$X9 M@,OS&_O76#O6=]G&?1AO^,T$6P?P"XB?/>/POTZ0;)*D$2"Y+\EKL7\O@F?\/':7\0MI:M(V?C\65C_RMC/*"4S16.4(,?;#845#XQ^1OGKU!+ P04 " !;@6Y-G0R:NK,! #2 P &0 'AL+W=O MX4]=/ZF1J.%\Z9IF.T-B"J"M&(\26Z8%K*C119])U-D.#@E.S@98@>M MA?EQ!(5C3G?TW?$DF]8%!RNR7C3P%=RW_F2\Q1:62FKHK,2.&*AS>K<['/@5"#R,EYG3KJD#,#U^9W] M4ZS=UW(6%NY1/'X ',]UY3,Q7^&"R@?'I3X'"4J&U=2 M#M:AGEF\%"W>IEUV<1^GFS2=8=L /@/X KB->=B4*"K_*)PH,H,C,5/O>Q&> M>'?@OC=E<,96Q#LOWGKOI=A=)QF[!*(YYCC%\'7,$L$\^Y*";Z4X\K_@?!N> M;BI,(SS]3>$_\N\W"?:18/_?$K=B_E3)5CW58)HX39:4.'1QDE?>96#O>'R3 M7^'3M'\1II&=)6=T_F5C_VM$!UY*&UL;51A;]L@$/TKB!]0'!*W561;:CI5K;1)4:=MGXE] MME'!N(#C]M\/L.-Z&5\"=W[WWCO@DHU*OYD6P*(/*3J3X];:?D^(*5N0S-RH M'CKWI59:,NM"W1#3:V!5*)*"T"2Y)9+Q#A=9R!UUD:G!"M[!42,S2,GTYP&$ M&G.\P9?$*V]:ZQ.DR'K6P$^PO_JC=A%96"HNH3-<=4A#G>.'S?Z0>GP _.8P MFM4>^4Y.2KWYX*7*<>(-@8#2>@;FEC,\@A">R-EXGSGQ(ND+U_L+^U/HW?5R M8@8>E?C#*]OF^!ZC"FHV"/NJQF>8^TDQFIO_#F<0#NZ=.(U2"1-^43D8J^3, MXJQ(]C&MO OK./-?RN(%="Z@5P5D$@K.OS'+BDRK$>GI['OFKWBSI^YL2I\, M1Q&^.?/&9<_%)MUFY.R)9LQAPM U9D$0Q[Y(T)C$@?Y73N/EVZC#;2C?KM5I M$B?810EV@6#W3XN[JQ9CF#0NDD9%T@C![95(#'-W)4)6%R=!-^')&E2JH0OC MLLHN4_% P\5_P:>1^L%TPSN#3LJZYQ,NN5;*@K.2W#@OK9OB)1!06[^]4IL*J?QY0L_Q7%7U!+ P04 " !;@6Y-'_L*-,4! W! &0 'AL M+W=O7X09WKPW,S#FD](OI@.PZ%6*WA2XLW8X M$F*J#B0S=VJ WITT2DMFG:E;8@8-K Y!4A":)/=$,M[C,@^^LRYS-5K!>SAK M9$8IF?YS J&F J?XS?',V\YZ!RGS@;7P'>R/X:R=15:6FDOH#5<]TM 4^"$] MGC*/#X"?'":SV2-?R46I%V]\J0N<^(1 0&4] W/+%1Y!"$_DTOB]<.)5T@=N M]V_LGT+MKI8+,_"HQ"]>VZ[ !XQJ:-@H[+.:/L-23X;14OQ7N()P<)^)TZB4 M,.&+JM%8)1<6EXIDK_/*^[!.\TF6+6'Q +H$T#7@$'3(+!0R?V*6E;E6$])S M[P?FKS@]4M>;RCM#*\*92]XX[[5,LT-.KIYHP9QF#-UB5@1Q[*L$C4F+_P>>1^L9TRWN#+LJZYQ,NN5'*@DLEN7.Y M=&Z*5T- 8_WV@]OK^2W/AE7#,J9D_5>4?P%02P,$% @ 6X%N3=)ES4K> M 0 04 !D !X;"]W;W)K&ULC53;;IPP$/T5 MRQ\0LRR7[0J0LHFB5FJE5:JFSUX8+HJ-J6V6].]K&T+IQ@]]P9[QF7-F!H^S M2CA+I$;.J?Q] B:F'._PN^.Y:UIM':3(!MK =] _AK,T M%EE9JHY#KSK1(PEUCN]WQU-J\0[PTL&D-GMD*[D(\6J-+U6. YL0,"BU9:!F MN<(#,&:)3!J_%DZ\2MK [?Z=_N]ZMTWP21TN8/R!< L(U MX.!TR"SD,G^DFA:9%!.2<^\':G_Q[AB:WI36Z5KASDSRRGBOQ2[99^1JB1;, M:<:$6\R*((9]E0A]$J?P0WCH#]][,]R[\.B?#*.;#'V8V"\2>44B#T%R(^+# MI'Z1V"L2>P@.-R(^S">_2.(523X2I(&?(/42I/_1;P\FO;T39',%._1:C"H MM=VF9B_GJ9P-+8;EP2'KJU?\ 5!+ P04 " !;@6Y-30])3K4! #2 P M&0 'AL+W=OE XTUEK!(>35LSUUD0920IR?AF<\.4:#7-T^@[V3PU MO9>MAI,EKE=*V+]'D&;(Z)9^.)[:NO'!P?*T$S4\@__5G2Q:;%8I6P7:M483 M"U5&[[:'XR[@(^!W"X-;G$FHY&S,2S"^EQG=A(1 0N&#@L#M O<@91#"-%XG M33J'#,3E^4/](=:.M9R%@WLC_[2E;S)Z2TD)E>BE?S+#(TSU7%,R%?\#+B 1 M'C+!&(61+JZDZ)TW:E+!5)1X&_=6QWT8;ZZ3B;9.X!.!SX3;&(>-@6+FWX07 M>6K-0.S8^TZ$)]X>./:F",[8BGB'R3OT7O+MGJ?L$H0FS''$\"5F1C!4GT/P MM1!'_A^=K].3U0R32$^6T9-D76"W*K"+ KM_!+Z6N(+9?PW"%CU58.LX38X4 MIM=QDA?>>6#O>'R33_@X[3^%K5OMR-EX?-G8_\H8#YC*Y@I'J,$/-AL2*A^. M>SS;<:IZ;V2 M+9PL<;W6PKX?09DAHUOZZ7B6=>.#@^5I)VIX ?^S.UFTV*Q22@VMDZ8E%JJ, MWFT/QR3@(^"7A,$MSB14!V@7M0*@AA&G\F33J' M#,3E^5/],=:.M9R%@WNC?LO2-QF]I:2$2O3*/YOA&TSU7%,R%?\#+J 0'C+! M&(51+JZDZ)TW>E+!5+1X&W?9QGT8;_A^HJT3^$3@,^$VQF%CH)CY@_ B3ZT9 MB!U[WXGPQ-L#Q]X4P1E;$>\P>8?>2[[=)RF[!*$)7#<8]G M.X[9:'C333^(S=\X_P!02P,$% @ 6X%N3;XHP#.W 0 T@, !D !X M;"]W;W)K&UL=5/M;ML@%'T5Q .4Q'&;++(M-9VF M3=JDJ-.ZW\2^ME&!ZP&.N[M< M=V3,EBTH;F^P ^UO:C2*.V^:AMG. *\B24F6;#9W3'&A:9%%W]D4&?9."@UG M0VRO%#>_3R!QR.F6OCH>1=.ZX&!%UO$&OH/[T9V-M]BL4@D%V@K4Q$"=T_OM M\90&? 0\"1CLXDQ")1?$YV!\J7*Z"0F!A-(%!>ZW*SR E$'(I_%KTJ1SR$!< MGE_5/\7:?2T7;N$!Y4]1N3:G!THJJ'DOW2,.GV&JYY:2J?BO< 7IX2$3'Z-$ M:>-*RMXZ5).*3T7QEW$7.N[#>'.WGVCKA&0B)#/A$..P,5#,_"-WO,@,#L2, MO>]X>.+M,?&]*8,SMB+>^>2M]UZ+[7Z?L6L0FC"G$9,L,3.">?4Y1+(6XI3\ M1T_6Z;O5#'>1OEM&3]\12%<%TBB0_E/BX4V):Y@/;X*P14\5F"9.DR4E]CI. M\L([#^Q]$M_D+WR<]F_<-$);T-L#J"I" T26Z(9%SA,H^^DRES/3C!%9P, MLH.4S/P^@M!C@5/\[GCB;>>"@Y1YSUKX >YG?S+>(@M+S24HR[5"!IH"WZ:' M8Q;B8\ O#J-=G5&HY*SU2S >ZP(G01 (J%Q@8'Z[P!T($8B\C->9$R\I W!] M?F>_C[7[6L[,PIT6S[QV78'W&-70L$&X)ST^P%S/-49S\=_@ L*'!R4^1Z6% MC2NJ!NNTG%F\%,G>IIVKN(_3349GV#: S@"Z /8Q#YD21>5?F6-E;O2(S-3[ MGH4G3@_4]Z8*SMB*>.?%6^^]E.D^RFG$K=B/JLDJYY*,&V<)HLJ/:@XR2OO M,K"W\1')1_@T[=^9:;FRZ*R=?]G8_T9K!UY*&ULE5;MCILP$'P5Q ,MO)W$".H.I[237MZ]M"$U@J9(_8)O9V1WCL9V?N7B7):7*^:A9(Q=NJ53[ M['ER6]*:R"?>TD9_V7-1$Z6[XN#)5E"RLT$U\[#OQUY-JL8MMR_LGZUX+69#)%UR]JO:J7+AIJZSHWMR9.J5G[_07E#D.KWZ M;_1$F8:;2G2.+6?2/IWM42I>]RRZE)I\=.^JL>]SSW\)@P-P'X"'@&YR9@." M/B#X%X#^&Q#V >$0$-@,7B?%SLV**%+D@I\=T?W>EIA5A)Y#/?M;,V@GVW[3 MTR/UZ*E :9![)T/48UXZ#+[!A+>8)82);C$K"!,/&$_7.12+P6*Q)0AN"!*8 M( ) DL0WA"DHRH[3&0QC<5@.$4(I@B!%!E,$($$T?TB8Y @GE:0^:/?U6&2 M*Y%A-",S 9,D0!($$Z0@07J_S PDR( *\&CE9A.961#!29 /^\,'TDP,XM^[ M9M","Q&0)9RA@+V!'C '@MV! 'MD$Q-/_9'.50H[! $6R6;V 01[!#U@$@2[ M!$$V2<9BXXG8>*Y2V"<(,DHZ0P$[!3U@%01[!4%FF8C-)F*1[\_LS[!;,.26 MF=T/PU; Z'ZU>.:8P),JL#_: 5<]Z%KM>!E[5X>HN09])^)0-=+9<*7/8WMJ M[CE75-/Y3YJHU#>OH[XB]02P,$% @ M6X%N3>5TAIF4 @ M0D !D !X;"]W;W)K&UL ME5;;CILP$/T5Q/LNF$L@$4%*4E6MU$K15FV?'>($M 93VPG;OZ]M""%DB-*7 M8#MGSIR98? D#>/O(B=$6A\EK<32SJ6L%XXCLIR46+RRFE3JGP/C)99JRX^. MJ#G!>V-44L=SW9E3XJ*RT\2<;7F:L).D146VW!*GLL3\[YI0UBQM9%\.WHIC M+O6!DR8U/I(?1/ZLMUSMG)YE7Y2D$@6K+$X.2WN%%AL4:P.#^%601@S6E@YE MQ]B[WGS=+VU7*R*49%)38/4XDPVA5#,I'7\Z4KOWJ0V'ZPO[9Q.\"F:'!=DP M^KO8RWQIQ[:U)P=\HO*--5](%U!H6UWTW\B94 772I2/C%%A?JWL)"0K.Q8E MI<0?[;.HS+/I^"]FL('7&7B]@?+]R,#O#/RK06"";Y694#]AB=.$L\;B;;5J MK%\*M/!5,C-]:')G_E/1"G5Z3CT7);>T04P!Y\, C?V/LW07@P00 2!(8@N"'P1UEH,9'!5 ;CCL)XA+@1$8(B M0D!$,!+18L*!BY?92.@&P(0^+&0&"ID!0D*8( ()(J >,Y@@!@EB0$$T2D4, MI&*4"0"")MZ+.:AC_OR+A5RXOUP@E'C<8.X3985 4W5%$\V. #'S"0JPF5?( M>[ZV".Y6Y#]1W0[TL+P09JJ^"&Y\%/Q'A>&V15#?WE48:$H_'L<#@% T(09N M703T+IKX"B&X>1'4O5,I@=L70?U[EY+X[G/YXH7CE @?_RZ.8/+KB3\:.8" M867L5$E]K0Q.^]ECY>G+DNHK-A7E@3!*E MT7U5!#1+N1K.Z&)*>?U-)_4$L#!!0 ( %N!;DWH M_I?2_@$ )4% 9 >&PO=V]R:W-H965T?;0BEU)WV!_M>SCWG M7+!O.G#Q+&L Y;TPVLJ#7RO5[1&2>0V,R#O>0:O?E%PPHG0H*B0[ :2P18PB MO-GL$"--ZV>IS9U%EO)>T::%L_!DSQ@1?XY ^7#P _^6>&JJ6ID$RM*.5/ = MU(_N+'2$9I:B8=#*AK>>@/+@WP?[4V+P%O"S@4$N]I[IY,+YLPF^% =_8PP! MA5P9!J*7*YR 4D.D;?R>./U9TA0N]S?V1]N[[N5"))PX_=44JC[XB>\54)*> MJB<^?(:IG\CWIN:_PA6HAALG6B/G5-JGE_=2<3:Q:"N,O(QKT]IUF/AO9>X" M/!7@N0 '_RP(IX+PM0#;YD=GMM4'HDB6"CYX8OQ9'3%G(MB'^F/F)FF_G7VG MNY4Z>\UP$*3H:H@FS''$X 5FA3B]1^ SQBD'A2M]U^R-*#E7H)UL[O1/J?6,G ,*I3+;6._%."G& M0/%N&H)HGL397U!+ P04 " !;@6Y-HU;HDQ<" #U!0 &0 'AL+W=O M]<)D-!&!&FA6K52*T5; MM7UV8!+0VIBUG;#]^_I"6"[>O&![?.;,.<:>I&/\150 TGNCI!%[OY*RW2$D MB@HH%@^LA4;MG!BG6*HE/R/1 MN%"*^;\,".OV_MJ_!9[K]^%[N_946! 0*J1FP&JZ0 R&:2,EX[3G]H:1. M',]O[$_&N_)RQ )R1O[6I:SV_F??*^&$+T0^L^X;]'XVOM>;_P%7( JNE:@: M!2/"?+WB(B2C/8N20O&;'>O&C%W/?TMS)P1]0C DJ-KW$L(^(7Q/B(QYJ\Q8 M_8HE3A/..H_;G]5B?2?6NU =9J&#YNS,GG(K5/2:!L$J05=-U&,RBPE&F/6 M0(I]*!&X2F3!(CV8%LB7B#AR5PB=)D*3'TY,?" QS22'TO1]&A=ST& M^K7-XIGJ:;8%O=/8AO@3\W/="._(I'K+YL6=&).@%*X>U!E5J@Q MFG/;B>Q"LK9OLFCH].E_4$L#!!0 ( %N!;DWZ\):8_P$ &4% 9 M>&PO=V]R:W-H965T\,!R:#@(W4B1 M*#BNT=-\M&NCT:)\X)WLI7]WAVV&-9DX0,*B,8Z!VN< 6&'-$5L:? MGA,-)5WB>']E_^*]6R][JF$KV>_F8.HU>D3) 8[TS,RS[+Y"[V>!DM[\=[@ MLW"GQ-:H)-/^-ZG.VDC>LU@IG+Z%M1%^[7K^:UH\@?0)9$BPM3]*2/N$]#TA M\^:#,F_U,S6T+)3L$A7^K):Z.S%?I;:9E0OZWOEOUJVVT4M)R++ %T?48S8! M0T:8^8# EGTH06(E-N0NG=P6V-XC\BQ>(8V:2'U^>F,BCQ-D48+,$V0W!(^3 M+@1,[C%BTH5@XQZQB(M81$4L(B(^Q0F648+E_[CZ# KGHB[W9/XQLZ0\.3?:<( ^D'5J1$Z MV4MCWXZ_X4KK;8S;S@P.!JWS>U>A9&ULE5?;CILP$/T5Q'L7? ,2)9$VEZJ56FFU5=MG-G$2M(!3<)+MW]<& MAR7VD$U? C9GCL^,AQ,S.8OJM=YS+KVW(B_KJ;^7\C .@GJ]YT5:/X@#+]63 MK:B*5*IAM0OJ0\7331-4Y $.PR@HTJST9Y-F[JF:3<11YEG)GRJO/A9%6OV= M\URRR0I>UIDHO8IOI_XC&J]0 MH@,:Q*^,G^O>O:=3>1'B50^^;J9^J!7QG*^EIDC5Y<07/,\UD]+QQY#ZW9HZ ML']_8?_<)*^2>4EKOA#Y[VPC]U,_\;T-WZ;'7#Z+\Q=N$F*^9[+_QD\\5W"M M1*VQ%GG=_'KK8RU%85B4E")]:Z]9V5S/AO\2!@=@$X"[ +7VK0!B LA[ +T9 M0$T ?0^(;@8P$\"L%8(V]Z:8RU2FLTDESE[5]L,AU6V'QDQMUUI/-KO3/%/U MK-7L:88)F@0G360P\Q:#>Q@+L701F. .$R@%G0P,R9ACE^!ZB86+B*FE B!) MKB$K $((+)2 ]2(- ;DBH# !!0EH0T"O")A5\!83-YBR+3@.F5T1 $4P)591 M7!3#*!I9=8%0"0OAQ!B8& ,2BRS)+89=22;42FSIHAA%D978"D#%)!J0'(&2 M(T!R#!/$($%\?S#10:31@S@C0/40!&NLCPO>W*((M#Y$[FM2 ^OE^4J9E%P] Q:']9D,H M.I@W;+/(]5FW30VHOY"C^$/(ZB;D6BOLG.@>ZT2NWT$%!E! @0'4<(%A[T2N M>:)P*&_8/=%_V">"_1.Y!NIL\]R ^O]NI&\AIL N"C M 6Y%@0#;"OH'=,* M7NV:,W/MK<6QE+HPO=GN7/Z(]3'/FI^C\0(!\TM]CF^.A>_T[4? ][3:967M MO0BI#I?-$7 KA.1*??B@.F.OOCNZ0&ULE5?MCILP$'P5Q ,<>(WYB))(E]Q5K=1*IZO:_N82)T$'F(*3 M7-^^-A".X"4B?P)V9H?9P6O6\[,HWZL#Y]+ZR-*\6M@'*8N9XU2; \_BZD$4 M/%?_[$29Q5(-R[U3%26/MW50ECK@NKZ3Q4EN+^?UW$NYG(NC3).D_U!Z@EG.2_B/?_)Y:_BI50CIV/9)AG/JT3D5LEW"_N1 MS)Z!Z8 :\3OAYZIW;^E4WH1XUX-OVX7M:D4\Y1NI*6)U.?$U3U/-I'3\;4GM M[IDZL']_8?]2)Z^2>8LKOA;IGV0K#PL[M*TMW\7'5+Z*\U?>)L1LJ\W^.S_Q M5,&U$O6,C4BK^M?:'"LILI9%2K;-9#$>ME1V9,O:Z-GJS? M3OV?\K-2LZ0YX1"*6X4(KZ16L">D7@X00>2N#5!%X_#S;PNX$$-21O_ :7#0U! M4!0\.O#$1#$@_N -/V.HD+EX7@S-BQEY@3="X*,$_G1G Y0@0!0,%NJJP;!> MHAX#=^"L"6+4BW I(2HE1*2,U$.$$D33S2 N7MCN!#M:T)4?,*RK-8*B030F M9V2?(8B M=H3=80I>>,2?8HIOIDM@N"=AJ# B(W+P,B98';,1"KS\2'B'*7@!DFB**9&1 M+D T],0$$7=DY0->RX#5\LA2 [S^@$RW!/#Z YA@20OJ9QL./L+KVYAK*7@= M U;'P0@%7GO@W6$(7GN ??,,0YCYG>YM$ZTC)H@:#933Z^DR7N[K!KNR-N*8 M2YU(;[9KXA]!]X2#^169K0DR_Z2:_J9%_Z1O3@P_XG*?Y)7U)J3J1.M^<2>$ MY$J[^Z"T']0AI1ND?"?U;:#NRZ93;P92%.TIQ.F.0LO_4$L#!!0 ( %N! M;DWD[SIR"0( -L% 9 >&PO=V]R:W-H965T92M5(K15NU?2;)26PM-BZ0>/OW!4PLA]!J7PP< MSPPSQYB\9_Q55 R>&MH*XJPDK);(B0.%31$/+,.6O7FQ'A#I%KR,Q(=!W(T MI(:B)(IFJ"%U&Y:YJ>UXF;.+I'4+.QZ(2],0_F<%E/5%&(>WPDM]KJ0NH#+O MR!F^@_S1[;A:H5'E6#?0BIJU 8=3$7Z,EUNL\0;PLX9>3.:!3K)G[%4OOAR+ M,-*&@,)!:@6BABNL@5(MI&S\MIKAN*4F3N:&2%+FG/4!'XY#1_2I MBY=8?:Z#+IJO8]ZI?@I5O99)MLC150M9S&K )%/,/6+M03@BFT?(/+N';#TJ M:3IBD,HQADF\81(CD$X$XC3R"Z1>@=0(9'?=^.!T8\#,#:8U&!SAN=,0#RC% MB=]*YK62/5K!D6-EP.#)+D\9CATK'A!.G%";[,'O$XZ<[;8^T+]"86\H[ GE M^%WAAUVR631S0GE B\0]*VCR$^AK[QOAY[H5P9Y)]3^94W]B3((2C)Z58J5N MVG%!X23U=*[F?+AOAH5DG;U*T7B?EW\!4$L#!!0 ( %N!;DW#@1'A=@, M #00 9 >&PO=V]R:W-H965TJT[7,*!J(F,4M,Z?[[.3]*@_W_P\?T M**OG>B>$\EZ+O*QG_DZI_5T0U*N=*-+Z5NY%J;_9R*I(E1Y6VZ#>5R)=MT9% M'E 8QD&19J4_G[9S#]5\*@\JSTKQ4'GUH2C2ZN]"Y/(X\YG_-O&8;7>JF0CF MTWVZ%3^$^KE_J/0H.'E99X4HZTR67B4V,_^>W2WYJ#%H$;\R<:P'[UX3RI.4 MS\W@ZWKFAPTCD8N5:ERD^O$BEB+/&T^:QY_>J7]:LS$VNQ20^Y>I3'+Z(/*/*]/OIOXD7D&MXPT6NL9%ZWG][J4"M9 M]%XTE2)][9Y9V3Z/O?\W,VQ O0&=#/3:'QGPWH"_&[39##IF;:B?4I7.IY4\ M>E6W6_NT.13LCNMDKIK)-G?M=SK:6L^^S"FB:?#2..HQBPY# PP[(0+M_;0$ MH2469)D;"RQMQ'B$5^ P"-[:\^$*W.%@!!V,6@>CLRQP(PL=9MQBRA8346($ M C"#;)X1B2"1"! 9&40Z3#18Y(9"DPD"18Z3RXY% !PE@,#92D5AA,FY@E@"3.%+!0BS7$%"9.%PX M%,\N3P>#BKYG=$%">M#9$8R-A ,<^B%8>DS#J@D#A=8_&QT14*P;!G2K5E MF*U)"[0$($ZN#<;"94BY9A%AMBQO$FM[ (B%K@W"ZF5(OF8=Z4%GYV 2F6QL M$ ]=J<&5@$UL,K%+@;@6L.3RTT)8Q(1$;,JG!YU%:VSB$F#&CF@(%P-B("&N M7W=<#(BN2 @6,2$16PGA_Z\G ..J)X2+ 8&K0.QR@8L!15D*V M.FEL902 R$4&*YB0@LUZ0K8X;Q@SJQM$N6Y(A#5,0,-60>E!9V''5FYL$$M< M9' U(' UB#EVP7$UX.'EQX5C%7.@8DL_/>@LVM#<( 0B1TGAN!YP<#F(7?$X M[O-77.@YUC%'5WHK)?9]/303\A&D(Q(,>JU"5-NV+:V]E3R4JNEJ!K.GUO>> MFE[-F%_HEKAK8-_==/WT][3:9F7M/4FE.\&V7]M(J81F&-[JS=KI%OXTR,5& M-:]C_5YU?6PW4'+?]^C!Z8^"^3]02P,$% @ 6X%N37X%8AMR @ ,PD M !D !X;"]W;W)K&ULE59=;YLP%/TKB/<5;#X3 M$:0UT[1)FQ1UZO;L)$Y !BV+2FSL3,IZ[3CBD-&2B =6TTI].3%>$JFZ_.R(FE-R-$%EX6#7#9V2Y)6= M)F9LQ].$76215W3'+7$I2\+_/=*"-1L;V6\#3_DYDWK 29.:G.DO*I_K'5<] MIVT*#23TO&W([7[.77@L/W&_M4DKY+9$T&WK/B3'V6VL6/;.M(3N13R MB37?:)=08%M=]C_HE18*KI6H.0ZL$.9I'2Y"LK)C45)*\MJ^\\J\F_9+A+LP M. !W ;@/0/Z[ 5X7X$T"G%:92?4+D21-.&LLWOZMFNA%@=:>,O.@!XUWYIO* M5JC1:XK#('&NFJC#/+88/,2,$5L $?<01PGH56!0!3;QWDA%"!-X((%G"/P1 M031)H\5$!E,9#/)]-,D$ D4N+,4'I?B E 4S I @N-^,$"0( 06KB1DM)ACD MB>/5]+?> (VD1*"4:"YEX&8K)9K-\@GYP?3'@"B$"8&Q<1W+))X-@VP2"#0 MTB)9@5)6@"\()D N7+CN_;(H=J<;P W46 Z\"2 ,R/$6 M*.!M 'D?, 4N7P34;^1/3?'GZ;KQ:FK*#=18#KP9H "0$RQ0P-L!"C]@"ES& M"*KCF2G1;.\,L3?UY'U0*\89G%[Z.O&3\'->"6O/I#H(S7%U8DQ21>@^*(,R M=8/I.P4]2=V,5)NWQWC;D:SNKBA.?T]*_P-02P,$% @ 6X%N32YG06K: M 0 8 0 !D !X;"]W;W)K&UL?53;;IPP$/T5 MRQ\0[P()[8I%RFY4M5(KK5*U??;"<%%L3&VSI'_?L4T(V:"\8'M\SIF+9\A& MI9], V#)LQ2=V=/&VG['F"D:D-S _XW<)H%GOB,CDK]>0.W\H]W;B 0$!AG0+' MY0)'$,()81A_)TTZNW3$Y?Y%_8O/'7,Y6DBGY[W !@7 7"?HHE##^2XK!6"4G%0Q%\N>PMIU?QW"3IA-MG1!-A&@F MH.^/"/%$B%$OIHL1.93?>"6YYE6(]'AL7KN>F*[B[&8A3/ZVOD[S-:@]9)' MZ5W&+DYHPAP")EI@MC."H?KL(EIS<8C>T:.W#H[O$6FR[B%>32+V_'@98!RO M"R2K HD72-Y4(;VJ0L"D'M,%S.>K/#Z$A##8XF$DZ-KWL"&%&CKK2K"PSF-R M'[F'O;(?<'Q"M[_*A-G[P77==H:&PO=V]R:W-H965TAS-HEA@QNW;%]"U,R[;[(UPX#\_WP$A&[EXD@V \IX[ULN= MWR@U;!&290,=E7=\@%[/U%QT5.E0G) S_/[-A!Y!D_ M*];V/'<=%7_VP/BX\T/_9>"A/37*#* \&^@)?H!Z' Y"1VAQJ=H.>MGR MWA-0[_S[<%ND1F\%/UL8Y57?,Y4<.7\RP==JYP<&"!B4RCA0W5R@ ,:,D<;X M/7OZRY(F\;K_XO[9UJYK.5()!6>_VDHU.S_UO0IJ>F;J@8]?8*XG\;VY^&]P M :;EAD2O47(F[=$[ MJP0TD=E2/U%%\TSPT1/380W4_!/A%NO-+,V@W3L[IZN5>O221R3-T,48S9K] MI(FN-;>*PJ'X9X(TP$(1.2DBFX]O*#ZZ#;#3 %N#^ 8@6)4Q:8C5]%;S(0KQ MJA*GZ V4V(D2.U#"%- ><. . W(^W^1U&F0.@CBU6:DKTX?1^'Z7%PB0E8HZ.H"F@?Q M.Q6GMI?>D2M]E^V-JSE7H V#.[VQC7Z#EX!!K4R7Z+Z87J(I4'R8'UFTO/3Y M7U!+ P04 " !;@6Y-/W$NPE0" !C" &0 'AL+W=O3:K&+7*[MQ-%SB^*50W="4=>ZIJ(OVO* M>+=RD7O;>*G.I3(;7I&WY$Q_4/6SW0F]\D:58U731E:\<00]K=Q/Z'F+(D.P MB%\5[>3=W#&I[#E_-8NOQY7KFX@HHP=E)(@>KG1#&3-*.HX_@Z@[>AKB_?RF M_MDFKY/9$TDWG/VNCJIL:Z^@>S:8MMG^GR2+U[+8(TRKVK$1HPZQX3 M/&#B1\P&P#PBMG-$@D>(IX,<(PW 2 /+#^\=D@P6"$&!T K@AS2221H])K&8 MQF+B"60[AZ PAN/ 8!P8B".$!2)0(/IX)6)0( 8B2">5@# +)@EHDOR_W.MD M5LLPPBGLDH(NZ=PE\R>I0!@$FV2@208(3([W&L(LO%7DPZWH Q)XVHL0*%KP M66AY!$C,^AD")0L^<,.B )!8>+D(;ED4?ORH([C;$-!N63;-%L\.8I8E2V6% MNQ)%,Z/0GQY%$#0]B][=Q]M-=/9BOO7ZA>#M9(68>%W+(3X@,#?-"DCJ H"#+4X;;W MJU+'=JPJZ5F0MH<=\_BYZS#[O0%"Q[4?^F^!Y_;4"!5 53G@$WP#\7W8,;E# M (SX3\4S' M3S 5E/K>5/T7N "1<.5$:M24;:^?HWF3YA/-38@F M0C03HO0N(9X(\4P($UV\<:9+_8 %KDI&1X^97VO ZD\1/L:RF;4*ZM[I=[): M+J.7*@ZB$EU4H@FS,9AH@0EG!)+99XG();&);NB6P/86D2=NA=A91*SY\=)@ MO'(G2)P)$IT@N>I";'7!8'*-Z34FL,JXA[@RD3I-I X3B67"8-([)NXAKDQD M3A.9PT1JF]MZ,HI ML7)(%);$ZJ9=H:GE'TIR;CK/M-RKZ;D7ZJ N MHO,T?XK4^+'B&S7E]5CZF\9<$5\Q.[4]]_94R.&F1]"14@'28_ @N]W(6VG> M$#@*M&PO=V]R:W-H965T3U!/!9M6P(__) MY:]FVZI1,*KLBXK772%JK^6'M?\)EL\8ZP5]Q.^"7[O)O:=3>1/B70^^[==^ MJ'?$2[Z36H*IRX6_\++42FH??XVH/S+UPNG]3?U+G[Q*YHUU_$64?XJ]/*W] MS/?V_,#.I7P5UZ_<)!3[GLG^.[_P4H7KG2C&3I1=_^OMSIT4E5%16ZG8QW M MZOYZ-?JW9?0"- MP7(!#+@.HW_EG)MEFU8JKUPZ'WS#]CF&)ZFQV>K(_BOZ9 MVGRG9B^;"& 57+20B7D>8G 2@Q"-,8'2'R%(0K 76-Q!D!:(2(&H%XCN!!P[ M6) ""V('"RO-(2;M8^HAS22D(3$)B0E(;$&&F'@"B4*@(0D)20A(8D&2.00= MD)2$I 0DM2#I'+)P0#(2DA&0S()D,PCD64I33E>/82TC\(Y M!UT2#BO"XU4.M-& '=BY0UK4+'N;>35ROA_8N4.:U2Q[F[HT=%-J\0+G7+GF8VQ/MC5G;"=N_KR^$)03E!7O&YYPY8VPG ^/OH@&0SB.K52,4ZQ5"&OD>@YX-*0*$&!YVT0Q6WG9HG)'7F6L+,D M;0='[H@SI9C_RX&P(75]]YIX:^M&Z@3*DA[7\ OD[_[(580FE;*ET(F6=0Z' M*G5?_-TAUG@#^-/"(&9S1W=R8NQ=!]_+U/6T(2!02*V U7"!/1"BA92-CU'3 MG4IJXGQ^5?]F>E>]G+" /2-_VU(VJ?OL.B54^$SD&QM>8>PG=IVQ^1]P :+@ MVHFJ43 BS-5XW$:[V&1I^>--GN"X0 MK0I$1B"Z$5B8S"UF:S"=[6.S:/4>LHG7;<2K-N(5&_'"1ORHAMW.>XCO+6R@ MV1&BP&MS/853L',G]9^89:<7X"701W"1S_W=WE[D+QG[K/S$O&X[X9R85 ?< M',.*,0G*H?>D+#;J)9L" I74TZV:K,JQ[H 0 .@4 !D !X;"]W;W)K&UL MC53MCILP$'P5Y _ZFYZ*C2H3AB.0B@ ME2WJ&":^O\$=;7M49#:W%T7&3XJU/>R%)T]=1\6?)V!\S%& +HGG]M@HD\!% M-M C? ?U8]@+'>&%I6H[Z&7+>T] G:,/P7:7&KP%_&QAE*NY9YP<.'\QP9^9$2TM3N)Y?V#]9[]K+@4K80DB.X4$#^]L3EA$HOI+2:*B;M)[&P2.VP^N@DV3H+-^VTF M3H+D7D'HW^QX&UL=5/;;MP@$/T5Q >$7>Q-JI5M*9LJ2J566J5J^\S:8QN%BPMXG?Y]N3BN MF[HOP QGSIP9AF+2YL7V Z]2J%LB7OGAB,AMNY!,GNC!U#^IM5&,N=-TQ$[ M&&!-#)*"T-WNEDC&%:Z*Z#N;JM"C$US!V2 [2LG,KQ,(/95XC]\./Z$G_ MJ(&6C<(]Z^D)YGH.&,W%?X8K" \/2GR.6@L;5U2/UFDYLW@IDKVFG:NX3^GF M]FX.VPZ@'ZGO31V@*LU\0Q+,O*>A6BA/])SS+LFV";%-C%@FR=?[#?Q3DFP1Y M),C_4I"_*S)A#A&C(H:^2T%6/95@NCA-%M5Z5'&25]YE8.]I?),_\#3M7YCI MN++HHIU_V=C_5FL'7LCNQFOH_0=;# &M"\<[?S9IS)+A]##_(+)\X^HW4$L# M!!0 ( %N!;DV7T;40WP, +H1 9 >&PO=V]R:W-H965T1E_7*/37->>%Y]>ZDBK3^ MK,^J-/\<=%6DC6E61Z\^5RK==T%%[J'OAUZ19J6[7G9]S]5ZJ2]-GI7JN7+J M2U&DU;\;E>OKR@7WK>-K=CPU;8>W7I[3H_JFFK_.SY5I>;4^P.()DS:@0_R=J6L]NG?:J;QH_;UM_+Y?N7[+2.5JU[0I4G-Y55N5YVTF MP^/'D-2]C=D&CN_?LG_I)F\F\Y+6:JOS?[)]OLU2&]Y,U7??U-#1.2 MKC/,_@_UJG(#;YF8,78ZK[M?9W>I&UT,60R5(OW97[.RNUZ'_&]A? . 7@+ M,&/?"PB&@. ]0-P-$$. > \([P;((4!:(WC]W+MB/J9-NEY6^NI4_?-P3MO' M#A;2+->N[>Q6I_O/U+,VO:_K()!+[[5--& V/09'&)@B'BD" [QA/,/@1@,Y M&AND":9#;"DB$A8+)DD\A3PQD"#@B09LO8(N03"I5\@G$&P"T240DP215? > M$W68LB\X^M*N"(,*4 1642A*(H2)51<.%4N?GYAD)R:9B5GEW_08.1KF4R0M MT)8!)0G/)&29A(1);-5N$Y(Q!-@\& S.\(A8'A%3$:OPFX@,@C(":Q&W%!5( MX5N3>HS((F((T!"3DG(^#-$!@W)$(" MZG00DY6B(#%+AO=#H(88B)G7,_!6!M'_$!-O+(,!QF&HF)*[,AG84)# F4T%\EZ%_J^U-&"FKPJ[,APHFGF-(V]ZR)F>K26D M=A;[H5T9!I6$,&-ZR)L>,J9'E(34SM#>XVPYD#_C,\A['E+/"\3<4O-6A>+C M2D+>7)#;:ME*0NH;OEV0>Y I$=Y8D#$6HB&D^ZA/0@J;"X<*Y0P=WJ20;KBH MBNA6BI2%0F9V'L@['7).1Q3$;*,@D387B@) F/NVXJT.N]MX.&!VR_6ZW^#2RVP/0_PN*I/T9X3]^? M:OR95L>LK)T7W9BOY>Z;]J!UHPQS_[,IX$FE^ULC5X>FO8W,?=6?)O2-1I^' MDQ+O=ERS_@]02P,$% @ 6X%N303[8A4G+0 .L( !0 !X;"]S:&%R M9613=')I;F=S+GAM;.U]:7,;1[+@YZE?4>&G>8^,UZ1P$ I>QQ!798\LJ01 MJ?!.3.R'!KH ]*C1C>E#%"?FQ[\\ZNH+AZS=#<\RPA9)H+HJ*ROOS,K^H2A* M6:7Q/RKU+*O2\D_?C2\NOI-?-DE:_.F[=5ENGSQ^7"S6:A,6Y]E6I?#-,LLW M80E_YJO'Q397852LE2HWR>/18#!]O GC]+L??RCB'W\H?WR>+:J-2DL9II%\ MD99Q>2]?ISQ#G*7R3!;K,%?%#X_+'W]XC,_PB534_/9&;<_E M>!#(T6!XV?SR;?;Y7 ['W5]:>*Z[X?G;];PH\W!1_N_>)V_OMZKYY7!P]I?F M9]1G&ZDC?WFWF6M("\^6OS(XWP#VH5(Y9A MW;?AIKV[CV_?O'[[9_GJQ?6;VU?RYJ\WMR]^N9&OWS[KF>\9[" 'Z%\#K7R1 M?U;WS7'/JCQOXJ,/MV=G@^G9>-"SU,LX4;E\!L^MLKRUSMLL/0L7"P5C8$3$ MHWMFNMF$22*?5D6RY-'I_*1C%-YN\ZJ N9K;>/G*NUG5',JUT4!!U^AF>ZSBO][G:AG$DU9A^G0)%K&+ HMY8'RX7V4;),OPBW-[TT5 2A_,XB90M>6 ^X-\+E M\@QX'(\G5WRL@+>VLGM> 4(S6:[C')^"D\5GL[PUD/$:ZODUU>ZA4@\S+:+# M+=[B%M_L&?15>/!HS@!Q+T'5RFV>+8'>@;(!3O=5'A>?>K:.5D?R%DPOICI65$4@2%1JLT<,&R$-#T#WX#D M5KV2^SJ*XI*/#^7G&:B 1;B- ?MMV5R".8C$&N8I@-#%+%;FL>@%^0)H7@-I MQY\5G&9;.?(Y'X)P%AUO7E\_??WF]>WK%S?R^NUS>?/J^L.+5^_>/'_QX0:> M_,O'U[\Q/1W9%"VRV3_6T%0/%15]5+1G_$&39D<;&A9+)(3?;=&2 NP4FDU]TGBA M24J>O $B.?6,$DW@OF42[+%4?)=BUI)D(/,^*# BJBYF!-''[DV//+X!FLEC MPG&X4CQVKE*UC-LR\Z;:;I,.><5B,&-T@.W7)_L_&(F6J! ,&CVL91N^^@#( M6,!8Q"/HFDV77?7<,T%8+&RRO(S_V6F3O+.@O>G@6 9?VPXG&E&G+4W]$\@* M.'>@'[#T\/R[#0(P512<;VFV%W09*@B&7.;91@OW"F'SZ&FN0!4I1(.V9]K( MU/#>@JW3@\@]B_0/?PZ>"#\!-.\>L.H5X.DBPG[1F]Q\]^8B[BM-3B=Y3T9BDA6IB M:3 **CP3;>/M]%$6CM*R7GX!@!9*19IGC%#8Y:%9-&CP.Z'?@0+SF-;/NS?] M7@M.E%AU=V$O6%WS=ST4J45.DAR>L0XQ_?*BWR'N'2B?JE6G6DX_2[GDB1VOS?9WCY*&>*?]VAT@W=J]=!UE&WI#_@2G?^T3.Z- MR:N=/0I+H5P(\S9WOP]3B^N:9G ZF 6%_-/A>FVU.2>.1%;2@>%85)9!? M7M#8X??BQ7*I%F03_5S!.D/>1T [UV$V&2)$Z,G#9UL4F 69$]E2=,$#CT7Q M$IP#VL2)!@J U$N>$K!B/["R":P_F8!)S(1@9:[CQ5H6%9P/G#S(XTU&ME+, M&X9Z@**S M:K6F!W$CYJS0",/M9 DH!MS<$A8_*TJU!0A +8&I MRCMG(([G:$IO3RGIY8 MZ',[ 9>$3BZ4"WUVY_S$J/$$((0R$,@)V3R)5]I$!1[Q)]1/CY_(YPHU#?C5 MS)-YF!;P/4(-R%DH/?#BB;P&X&$_/>,XZ%1;7^Q??_($.1$1_$]E<7L'IR-/ M\-!@U_B0XO!S 5,52\1S*+JW><[RR^/S%F=9\EB'D4PS#-0!"8$XCH$EP;X# M O8XE,3N[/O"1L JC70/OC+&/Q?6MFWU9YW +LHJH2--6>,X',4>EZB90 T M:H,>R7T@8!M@C)(Q$V6PO31#&Z>,@3(9WV&Y8R-W,1 A2<4P=;M@&MR@$,'% MRWBC-35AU]NBR,T!%/8$MH[ADOMS^2J[@R]R9.BFH'4RTI=K:78GO6GQJTWX M=T :G"* $&/\%-:*P6)-$( M^((8Y#3[(^Z+LFI>@@2@)3'F&B"E;<#]!7%J M8Z 9SB8*E2S/P/=LZ7V=$MGA1Y&&'5D-*SL>$5V?W53IFSC])%^1(),W]\#. M&X 1S)#SP$J"HIH7<11KGSV[0V=13Z8*P=)5"RI?)&[9VV#_OF#'@7AH 78P M.+: SOP3F*Q"LU615? C!!#R5'Y,8^LX *U]3!,$W7"?^E*B.$;1!!"0_7L7 MH]\;DJQ=@FV5XF* 6:T4]$X#H]GTQW?*?&(&9E7>\5'1?+"R:@=WAW#I+SRF MPV\)&(1# R"Z4*WCDNBT>D:)C_9S$#%F5P)FP\%6#7DL:I?S/H-)\1Q(1=.! M"GK:FUU'Y#O0YO C#L,/3=7"$9QP42W6PIR=!1,1YTN8I6S"=@X>;6[I3<0% M:;\,]1R*QKO,?@?>1,N[LVCO%C'DV: MJ*$-6(&/CG9 LNORXDQ.IV=@K W.2) [Z$H>;(U1#A@_%*:KMJL\ MC!@6P=O31C@LW%CSX"T [0A_T348]!7232A15GO*E;3:UO>M11071AT6+O"& MX("$!K$.)T\9'\K'&@!1#@DOR1+@>- ,5;Y8H\^Z$/!9$V@JY##_, .3-@) M6#+D#+Q4\[P*\WM:X3E8^N1*H/<0,/FBVO^D9!-;J$FZ4-2'E0UL)TR*#%'C MZ 0Q$J '=(>G'B*&[RD49[ DR"1?5AC@D#ZR0,$N<33MG;R;>$4@58%C+:9 M$11CA9>R\"QMHWBVH-; A,"L2@7VT4)2' 7\[Q*L7HU4.AT;@V=DU&G>[3P@ ME*&BU89XN !WWCOE(VC+>H$9!$A6I=53E/42 X-(O 0_7S8G(QCT;3JGF9HZ@/PSV,P5\"J0T.-3\$^ M&[C52 Y[EJ];RI*?>=Y^$/ 8M@J1;H$21)UIM"PW5(4.O8DHHQ&\+%'>AU_D M'#WV.@6BTHN) G &#PNXJ;9P%\MPH?G+$[X8Q*/\=YEI(2(M!IBV!\@J2(B/3(S"J)]/(, MY.FFD"?J? 6&W"\*3:6Q8>CY&S^=^87IF5#@7"^ M20PV=6$%H'/L'9*V$D7'-K4Q28B2EY9[; "8?2W+]I5N@('!*1[!/8W MGC<\!L<()P+3(SP*CY.CO\A'0&4%57?4(D,N0#KG>>?8G1M0-7 >V<,/I[N"#$ M+7(6>X@5\&Z R*9P$/GXIH8S23#ZFMS>0H,]>4X$RZ9&(P&45_XT=5XH@,H M1D[D)H6-TN\NRS^QPF"R1@K;(PN1QL]0%JQ@F@/3(P<.8V5)$@36_PFTR'9O M8'+LW*:>6<5UDAA3P5, (*G ;M/Q:_PNQ>F *CIN91#A8D0EUA<] 7&/45*_@E74PJ."PJ-HW @_M?Q$ MW""_O )''HFKD(_DR51BKNAD.)*GHO%G,__=D='LFG%\J>>8P1QOXB6PPB)F M1XB2-.D*$ )8ANV 3J36W_DC"$3^2XZF-C5"T+YYC+E<^@B]-C##!2%5Z )[\ MZ+\B^-FML?.BWQBZ"J)'LXF(JMSX=TE8E'J%)9?K_@/\@I+BW@5 MN8S"+U:Z.F^*/6,PO$)Z?)/!ZD_#]-->07GA!*5?:J0-45UP)*BP]NQIR#F6 M#6*53T(_VR[0X'#=!R]&3;D@4Z3H5;/N*G3= _S$ ;]O1>%-*SH&_[ZR(J2[ MQ3')#]F1_! ')S]D*_DA#DE^R';R0QR0_) [DQ_BH.2'[$Y^B,.2'_(A^?&0 M_/@W2'[\/\M]" HDZMR' !,\7*URM;)\IZ5=+600N5'>IDD>+NKRD$"%N=#4 M$?-[;92C;/>*!TUL@3UB\H3K\DJ+BT!&<9IIMXH70X1 @83KB%%UVBVP?L9&=FJ*_;#S:K;+_DV3: M_^$:CU'@U8;XU\CF8!CH$+M_D)8[C75FM4N77MJ"7X3UZ(+V5DAK6'9%&;I6 M\8$'F?&92-90)%$/JQQ4>)YZL\%WBOXR+7$LH'!<$AF61<]-N'A]KDQNC,K( M^3P+.0>>)RK$D"T8;3"@HNIQGCX0UHM#5L)(^89H'?_"P \]:R)G+#KE2W0' M#:USC*@>0PIS$/HK[482>] 5BS/_BH6O]$VHJ!Y!LC&C.$4ZSBE 9A&+",FI M9@[5L0"D&(ZL4%;*$*A+16?5%JTNC0R &\,$&'[R=BT.V77 X3Y@9;/U $X MSY,BC8*4D*P?!VL>L#2$#>3\5FK9NN#5[X-6/MC-"0\L4BUT7EGB*=]-C%S. M5:'.E2* .92L*^S1JS'V)^L:<\:L G4T@B5A#:":]O&)3"$1G0(+&)$CADVEZPX,BE18OP6?!+3[ 4,Z)U6896M:#8-SY#UH M0E,57; @RC)11)=OI^"39GR3-Y!+]OJ$9>7WP/7RN0D6XU24LPDEIMHIBE@2 M.W%,V<@"88++=0T)SF_,4?;2WDR/T7. >L-.#,QT2^[3RCRH&J&$NQ7ZBPXI>AJ2AH1A6C"2B MK*Y'4S6/J#B(72,M-#"?L;'J-'>/TQD:;D?=PM2K+[F:90&DY:ED36,+E.9T M@ZA.D@7J6R"ON%@[46NY1)54M^@+R;%-3E8+U27-B3DHV@56%?(W"$ZDLTCT8M!+.;1[;I!P6"[4M MC4'$G'"/PTSJ4N - 1Q9I5Z)W0(H+2[I4JUO_G#QP]%VI\[J(X?4 G_")D59 M3)6>!$#7 ML_$0D%AF9DE;\L7 M=UT(,HK; 2Z:NPZ<.F\Q,[I$1K3HQ+6#0",BU%?(8"QFEO%7@SJG2 ULPG.< ML+&'5>:^H.F(12&;RP(4;1+F((C2E"XK(1K=8-$"?^GL>1W9)1=1%[*@;,6[ M-2!PF>6M:8A$ _*PYL@ZY%Q'GT/>IS%CO\>0"P7'C&%*RX!)CIQ_W]1FJ5IE M)5,VAH2*<_&AP^)AZX7Z$H!A1B32G"CB8S"LX?M[H!;A*:[EJJD73S9%>&9G M9#N(USIDN)1OU9T5;3_IH#P"TW%A1[Z)4R5>8Q$J'6 C9XNR+N';GM(O:74 78:6BCGIP7]G<*-YZ/S655&@JI9F)E+(. M$#VKS?7]=.K(I*5![2H_(O4@2+W8FC$?3,H-M&5]3O^&D!M46W@6"#]=RA+$ M#[+>(:'C5EVDU_V76DLFQ%4,H!):UVK M$7&U'V(7HVVE3@Y@H)!;5&CQ1AZ)P7V8++!E@=8"OC\#4KZ:%T#1NJ$(A^KQ MR]+P<@(?"JO&+?EXQ@+6$-9=&MH]U14*O1NR=TR9G5N)3;C K[4O&QD&4_TO MS(EM&]?=NHA;=TZBT[:^6X9V)B:;\8XXA1.&(\D&UDBVW$@6PC+=N\]\J(;.[+@ >/)EA$9W+3<"CD MG2 9([X^4R$NU78=Q&.RB\=$#X\Y&;*;D40/(\D^1D*RX,!G;7,FHZ@H;6)B MM-9\=WE!KP#*ZG^G%1I5&CVW06=$9XWZC:)#4; VJ:D.2H!8_=Q7=E4\$5I* M_46#PC4W7M,W789C9^\B7U>4PVUF_ (M+,H9!^/I&'Z9C(++V0A_&0>CRTOA MN+1?SMA:SY/A:(#U.[,!%4Q=8$V6:*\TNM K#:=7>LG)0,/5;EX (RZ"B\DE M/GL93$;XR/ JN(*M' 7<@ JUCIJ?03(-4!CXBREAYR*XG$[QEUDPN_H6:.I: M:WRAUQKRVZ913DGK)E)8L YKL9@[GD7VZ'10V]7Z:1S=9542"5XV7XO38\AXQ@/@^%H!/]>7@UA M$UQO(4<@M8:#L: ^29>7\)_@YX:74SD>CWJ$_B@83$96)HL;TD68H'$I?U*^ MIHC/BVC%12UW7T>G5437'4^>Z%Y 7D(922R[P^T5IX3.P63&:)V,!/>0- .T MX6)M43\8>G(Q&5*A[@@+2-\WXG$^#-0#D@X0/5_\>3D:-QQHW*%6S_Z-KJZ!)7K ,E38=1?AIGZ54;2\OGX2[FA-(7:1L.RHTNT"R8) -"-,:SAJ MGN?J)*G$%I72:$9J<'0E3#%5+46.DHES>XV )1!-=P>K\062,M#D3/3=#Z!Z M\0']<"1V!RYWB8)BN;3]IKS ^LD5/G0R')+.'0V01+R]=<@#M >PBGA$BAYH MZR"DSGRD'H1+)/7QB# ZP@+I"1#]-\+E;"#1UAA>#7IQ.1Q)''0X'H>#$2%R M0C]&DXL]B*3M#0B=5V3.#%I=B+TFK=>=_8]^ FN-8N@L1QNCZ<:'+L?:4T \ M=07$K6F$^Z3@- &;BC6CW*+$UUF]\J_%SMX2 OM,*VH5#3(16RSSC+#(*4KY MRP'_:_NY@.AF%[M8QULXN&!P><7_.IWT!E@8@TC3T1C_%V!: ]+I7^'WI*Q5 MUY\, RTYX9?12-OL/C;@[(*+BR'_G WJQ?DF<(71BD<@>O&,\.?7:=_Z_8-6 MU;MK[OJ\HR$5?G8$-!N;2P&J*PHD<6[::^)Z/I@#EQ@J,LY(0+D"G!;#RC MGY=@(-3!HLV/OB?%UP 8906U+33W$RE.SN6)61K96\*VRLQ5,&" !.QF=S6* MTO,F\$ 6Y7(9DX'QF=,R*95@?L9]@SP+4W/1W/YI+C&Y2E_WG=BH$ ];7QG5 M#KO)Z>A;;SI)K7=)]S8V6QC#Q=R"A"$9);66S5P*U6K0&_!IZ3B$(-$88GAR M&7_!Z#,P_8HR$''&^UU6I"OH*9CRQ=/7M\^ON3=C4<]54 !FQTART+J%@52Y1-W4ZZPG,N:Z%< MOAM88O@"+SVBG27XLKG+UG!%E8TYAK8A'), 7!"RM@,J!^%7K0CGGSU/EFCJT9:AK +JS.>CADH*RD91M1_1[M98UUMB MC\G=I[3NAQ>YPTB:@-PZ.6BX;1VN6B&'OT=^-U\0UI1$Y;(]$WF MJXQ..E*QNKER@FT&G,=B6M/HF]8H5JV?PY%H+61L@7/B7540$"8Q #I1B23^1#>FL8HJS4J3(;#W@@BA&N.X%U,S M9/8KD%BT%'=7GKG.@OO#*+<]V[N@)OQ,C7U R/"NFSBAIH/)/((C.";T)'17 MC8 +.I5]]A>N*!R&4]S#I*)QC4!C-. M^7VM(,E$P2V?< 6XN6)MNT]8EYSAGBM>F[TC@(8EIXT9.N%?#P,!R_Z1:I#%.,;+Q]RIEM].*,MPM%>ZWML9[N7GQ# %:+@4W54=9 MMESZT'2*3L0K+!'W6)4\-+N[USJ"47H0HJ,?^J7H*M3.YY$RTZ3A4W5AHF18YI' M0E359Q36U%8L>8FZ+$@W93,@&@U/)*M2>_P%WO^)_/O$G(L2=&U87'<%-P+K MT\!R]D3#>4:7,>DJ9$V71+IL1BO.T-<-V "/>5NB4*<:S6-H3^NB4!)+QN2 MG@>D:,+L8ENRI&HR_9JC(RAM&S?D!&W0\ME=K5@N[%1S:%Y;VJUMZF'L MO3GJ1$3WY## Q3EI3C_KTG!,3YOGX9B3 KRJOJ5PYA4\0-&QVJ(BHL9*]8:- MU*U/.WA.BOK9'0\D-(L2WPFW\[./1UO A@):5>A+S70UH'4$B :\9% 5]>, M0#N,3%TKD,AN*J0""YLNH5:U'43-U>G6LB6Q(W1(B"]A4T,7@1?03',!CV9= MA4 GJ=;K2S$'WVA!,YP&P\& %(VM?J-8FK6FL#R,C9XS;?44'E&CW*FX9;C& M->?:O0L$"($7;.B^>$Q-*3 #8TKLP+!6@'36;N/+$5D.A>H 3OH6&?8FV\94 MTVZNDR%HIJ)H-);F&KK];'QIZQ2MT!56[38TVP$F1I=9$5B':!_\PMAQD38R M",V,U+GMJ,Y-O^PRNE_(3.#E8B(W++5 1(3V;D[+X72O)3(O/.E_+]'NP4#.7%< :?78JQ^6PTY$S@ MY%)HZ:/\W4;96JQ0S29)<89FY:@?[E3MX>I MWX)SB6NT;O0]:C()9E-2J8^F$Q)'"7R3U"Z+4L+>+GQT8YF.0 *:Q+9_4]G1 M.?"0DMFB1Z\T:Y(N$8NX.PJB# ?UZM9 YSW\M\ZU-MUB?J\$[@55ONT=L)=4 MAEX/F^;##]W;?G/WMK[+_R:+U7Z=#">W/M@ZE]X#['[KG&X[X$YU'P3"ND ,YN@0B;L$2='2(H,H[$W;7%I[KHX5Q7Q3%H-<+\HGP3@J_?$!?'?:2 M'7ZM1.R;*_I^HW0>%,@1,+4H,W%/[@1VE%AZX$5JP16]&,[/ _0/S$=G\!$. M66$S/'+)\1LB5.HUD9&9M^! C[Z&R_=%N+56433*ELX%QL#Z(*@M)^O=FDU+ M+2> :!+U12TJLB.9D[R;7%HJ%UT/%RK%PE77>H6#<\AK74T^A&ORD7=75/B- M7L_%K\H>0+UHBR-@'UFV%X*5-$T&6,QR328#/'GP%9AB7?=)"9/1AS"98 M,KKS379R.!W)T60*:UP YG2E!!:P3H;R,AA,9_(B&%Y-8$PP&X[%D:^Z&H(% M.9I>X>R3Z5?B;78XVJ83K(R9!9/+*X,VKEGK11OAZP*\L).+*;5[O+K:CS) MZPAK9N#!*XNRBV "=M]5,!U>H$4Q&H[D>!)<#$;'XNP"IAD-+@'\Z>5%ZTVK MW^[%4/+DO>ZQGB]T\/KG1XZ'#YT./2% MT+_UZYUZ2Y5OZ1)72Q'?+-8JJKAE_8'=TA]:??_N6WUWO;K8!1[>ZR[6+[K? MRLP5D0\=OW=W_/XMG:G[N=5= ^E[8?K#;:1O>QNI[PA>-RXG=9QCWZ/_G]YK MVD',U[7EG[GEO: MM94W>VAO\-#>X/?1WF#OW(^WA^MZ!U_=VWZD[Q C>?0OOW_7VW'&52H=X M_G[IT3N_].C(BJF' J;=!4S[Z@GZ#\LROGWLH(J&A[SS0][Y(>_\D'?^/>2= MS=M//7?GS,L;U$3FR7.*(&$T V3%[3JK"EBKI9'>+:Y/'ET&K8O MZR_.;312#VK+W^VY94/-LD]59-SPWKU< P+>Y:LP-2C^&S9*E=0HM5U4Z#7P MU=+X7WVU;K_HM]K5R12A4[P/C8J(=D)^1?LG7\NP(]'GAH"54I M1I-,#J 70'>."=O1T=D<=>H=E?E9=5KI]_]3MTC5_O- MZG$RJ(5'=RJ]'L5X7:VL\IP:O/70IJV^"J0)0=YP(VTJ+K,[<7=K*(O5> -W MH&\B(,+Z$'.8EG7'?,.ZH0_^KSNU9^:5O#K\:U*%:!JU*-SD)1<['JJ_L<#T M@/0BHH?3S]R6?Y=JQ\'5[VR69&FG>%J=X;S#^+_WNX@.X\U"LT?2Z7JOV%N1K]_XODC;>.!TID=?4 MM6$77OVG%M[LYG617E*C^2@P_1".3U^$HIG?6L_\ "E#9B-^1)NU]'T)?GK M4>S?DJ!!R]:$4:B:/)QX;.]V:^- KWE'YUSQ]'.^;?5U+1]^0!Y15]CU*I!6!L M!U0[SHM7^<:GV:S+\#CPZ$/]BO**ENEP:'5%R]?95U[Q[:C_D.J+XY'WU,:$ M]1707NSNSF&W-#VG!WHF[(]ZVCR>C0CO$[IBF=O%4 M9WA_N'9\22!H!6$A>M,-48#.5M$E$#MSORV874[:]ZV/!WH_I"T!T)WF_FU@ MO/P:9+6RZ;\5%6WJ_%8.1E^,IMVN MS'N\L79OVL D'?L@Z&-W5K;O*-],:OE5$TZ6[YLF9K'#3-%29U1Z*.+LMH!.T-5;U18[! Q7NV5?.=5<^T\GQW=F@X1'K^XVX1' M!Z1[E]YC@[0;+F&K-M-\J,O PDBJUZRH=VB[#=%!./BJK/N>L//AM0+MY/VN M@//79_J;(UI9?FS7R!4!K43_WN*[O7C>F2#K*=1H%W5\!5P=Y7]?D45HM4?R MI]N9,CN@3*E?8M0*DUJ,T>G$'5=8U+_TC:FC\6QE M;#OA7%/ML"O7BRG#G] M]=.+7Y*,L9&M(_T2W3TG/??<6>04-WK+X*$"T*CC3#0)KK2NWP=!DU7 27,A M:Q F4DC%B3:N*H.F5D#RQA[B+)B'X3+@A JCQ#RYV]D M#@E^/'O]K97Z^A7RZ^S-;!8^GE\?XFA+_F-;$# MZDM+'?0UI'$AQ53* GO Y"8*VE,%X91M/3RW0":95$B;'AIM MD46:)Q^.O&?;V_-P*J1RN7T&_[ONMQ\$!L\*I(SM]=H":5P3K4&)6^.XS0[\ M*81Z>[6MC<)2D6TT]PWP6]UBDJRERD&-:2(\0&G,H+!R%"TKNVI9!S:HM>3& MR"DII2!.PW"B-PQM!HP]V+OWM=CC[@KD]]A/$F)D50RFJ;HWIZ\6.LF[;)Y[ MES8\BA?5="/UQ]:4(YQO[P[<*RAHY_RN& 48=E+7;/N!T5)P\,7\-F%T9,(T M)D,>5$E%GPR?O2J9 4!AM &E:;:+?%>D7D&GA^O4%<=JGK] S?^ZSR4(4(3M MBC9W_Y2[_)\5+][]O63WKW(H^+2Z^MP2[;![ 2(O3U_DXNJ9-0;]S-D9;'MC M;431NJ5,4]&KK6B>@]=CWQ4)OK-/&K8W7*;I9N@U69OWVAZ_.9M#05JF[VV) M+IC@R?YLA4?+<==JI$CP9'^!G+;\RB6<'H7I#U!+ P04 " !;@6Y-'!U> MB]L# ?'0 #P 'AL+W=OWML^U\^'> MV-N%,;?L5Z.TFV1K[SVLVH/'*TMB&>SRUJZ';6."U6P/X1@V+ MT6@\;+C4V<[H>3AG'"G=PPQ>3;)0QWGKS M22H/=LH]?+:FW4B]FF1YQI;2.C\/;7ZF[ %]Z?D.U@O1:^BYXMKCJR3;#S"!]Y))Q=22?\PR;IC!1F^Q3!Z MC2X.N]]M$$_LOX31+)=2P-2(M@'MMW&TH$+KVJWEQF5,\P8FV:X*X[IF%]HC M#9OI[:.P;G@7;'I6;]_+8\2>8)D]D7C!SNH\@*>#/#>Z!NV@9GCDC)(U&L$61&0U0$A>Y$\(B"/TD*><2<= M,TMV9<%AU:Y&-XI.:[/Q$>28@!PGAFR=U. <^[8!N[T<@1T38,=IP:;2"9Q' MI6[QCWT1[AT!]RXMW'S-+:R-JL&Z5^SB9XN38D3VGB![GY;L&NX 0\:N09B5 MED]=3@C3ZKC3Y2-JNAZEQ9SA<-"KT"@[=0X-%H.1'DDLDDNC5X,;L V;PJ(7 M+DH<>6)SS+0P#; ;_@MZD:(\D2<71=-('RJYKH>==Z-U!5K(/B3EB3RQ**Y# M(4X@5]QBVG)CN79<_#V1Y)0D\L26F+<+!S_;D&!=W(5@QF"4&/+$9O@D-:8E MDJLXVV.+!S:'53\1R"E-Y(D]05JVEPKDE##RQ,;8HS/V&I<$JC]>*'ODA]1' M+YH%I8_B?^MC%\*_>N1%/'(EDGPI0DS>['6,23FF2.P8<@[J=T?* M,D5BR[R01+,!SC]U-X!XC$FIIDBLFGUST(#-\>EUC$F)IT@LGOV8741C3$H\ MQ6$6*(B)@VMC8DQ*/,4!EBI1YXPQ*?$4!Q5/&>^-4.(I$XN'QJQB3,H^96+[ MT)A',29EH3*QA6C,<8Q)[H@EMM#S;&/ HK(8D[)0F=A"+V'^<9#J85(6*A-; MZ*_,".73-@VW#R&'O^Q-2"5EH3*QA9XE<)8+[*G34X3DNA=-RD)E8@O%.P/] M_[O+F&),RD)E8@O1^>8@QJ0L5":WT+[M@BZV\>8W9:$JL86>[1GL'>D59:$J ML87H[#UV>D59J$IL(1HS=GI%6:CJ+#3 M]GG:5F4LMG4<' _[,LZS(J7ZV;FX+,(ACT]5'KU=AK=J^74(9;I2\;<@<]>#M#](Z4'6'V3T(-\?Y.E!H_Z@$3UH MW!\TI@=-^H,F]*!I?]"4'C3K#YK1@V0(9!SRDQ#6?*T%<"U\KP6 +7RQ!9 M M?+,%H"U\M06P+7RW!< M?+D%T"U\NP7@+7R]%>BM?+T5Z*T/>-9&#]M\O17H MK7R]%>BM?+T5Z*U\O17HK7R]%>BM?+T5Z*U\O17HK7R]#>AM?+T-Z&U\O0WH M;0\X*T&')7R]#>AM?+T-Z&U\O0WH;7R]#>AM?+T-Z&U\O0WH;7R]/=#;\_7V M0&_/U]L#O3U?;P_T]@\XZ^[H'8N\":N/U&S+3;QWR<7PFS4=N&,Z[7!E&ULS9G?;L(@%(=?Q?1VL0AT[D_4 MFVVWF\GV JP]M8UM(8!.WWZTZI*9+G%1D]]-*1PXYX.2[Z:3CZTA-]C45>.F M4>&]>63,I075RL7:4!,BN;:U\J%K%\RH=*D6Q,1H-&:I;CPU?NC;'-%L\DRY M6E5^\+0;;U-/(V5,5:;*E[IAZR8[2CK<)XPM5=T<5Y3&W80)T>!E$[*X,#:- M0M1%[(0*QPO;?ECWMB9KRXS^A:;SO$PIT^FJ#DMB9RRIS!5$OJYB5RA+V;NW M9;/8\\Z5]:^J#HG9IF*_)L37X_#;BOH!NL@E*_MP+:BO5!?8/?E9!0^W(=66 MAL:&J/5ES_8"TCQ$'6LG7G*+U%Z=C+*3BH?4U_NP7]HNN_>^ _\).M8UYYWZ MY3@$"(<$X4A .&Y!.,8@''<@'/<@' \@''R$ H)B5(ZB5([B5(XB58YB58ZB M58[B58XB5HYB5H%B5H%B5H%B5H%B5H%B5H%B5H%B5H%B5H%B5H%B5HEB5HEB M5HEB5HEB5HEB5HEB5HEB5HEB5HEB5HEBU@3%K F*61,4LR97-&O7QK4JF[]( M/K5>'NJS[@_6[!M02P$"% ,4 " !;@6Y-'R// \ 3 @ "P M @ $ 7W)E;',O+G)E;'-02P$"% ,4 " !;@6Y-)^B'#H( M "Q $ @ 'I 9&]C4')O<',O87!P+GAM;%!+ 0(4 M Q0 ( %N!;DTBH5RP[@ "L" 1 " 9D! !D;V-0 M&UL4$L! A0#% @ M6X%N38SOAF]^ @ W0@ !@ ( !]P@ 'AL+W=OY&Q+ ! M #2 P & @ &]&0 >&PO=V]R:W-H965T&UL4$L! A0#% @ 6X%N3:,(STZP 0 T@, !@ ( ! MHQL 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M6X%N37J.W'FT 0 T@, !D ( !7R$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 6X%N359ROV2T 0 T@, !D M ( !X2P 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ 6X%N31_["C3% 0 -P0 !D ( !K3( 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 6X%N M3;^][J2V 0 T@, !D ( !JC@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 6X%N3?Y'5X^$ @ ZPD M !D ( !&PO=V]R:W-H965T&UL4$L! A0#% @ 6X%N3:-6Z),7 @ ]04 !D M ( !+48 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 6X%N38\HML<5 P %@T !D ( !"TX 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 6X%N37X% M8AMR @ ,PD !D ( !1%< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 6X%N33]Q+L)4 @ 8P@ !D M ( !.5X 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ 6X%N30.F1=?X 0 .P4 !D ( ! M,68 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 6X%N39?1M1#? P NA$ !D ( !&PO&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"% ,4 " !;@6Y-S"W63[(! #)&@ $P M@ $TI@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 - T !X. 7J " ! end XML 56 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 112 162 1 false 40 0 false 9 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.sunlinkhealth.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 107 - Disclosure - Basis of Presentation and Adoption of Recently Issued Accounting Standards Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Basis of Presentation and Adoption of Recently Issued Accounting Standards Notes 6 false false R7.htm 108 - Disclosure - Business Operations Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Business Operations Notes 7 false false R8.htm 109 - Disclosure - Discontinued Operations Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Discontinued Operations Notes 8 false false R9.htm 110 - Disclosure - Shareholders' Equity Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Shareholders' Equity Notes 9 false false R10.htm 111 - Disclosure - Revenue Recognition and Accounts Receivables Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRevenueAndAccountsReceivableTextBlock Revenue Recognition and Accounts Receivables Notes 10 false false R11.htm 112 - Disclosure - Intangible Assets Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock Intangible Assets Notes 11 false false R12.htm 113 - Disclosure - Long-Term Debt Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock Long-Term Debt Notes 12 false false R13.htm 114 - Disclosure - Income Taxes Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes Notes 13 false false R14.htm 115 - Disclosure - Commitments and Contingencies Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies Notes 14 false false R15.htm 116 - Disclosure - Related Party Transactions Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions Notes 15 false false R16.htm 117 - Disclosure - Subsequent Events Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events Notes 16 false false R17.htm 118 - Disclosure - Financial Information by Segment Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Financial Information by Segment Notes 17 false false R18.htm 119 - Disclosure - Basis of Presentation and Adoption of Recently Issued Accounting Standards (Policies) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies Basis of Presentation and Adoption of Recently Issued Accounting Standards (Policies) Policies http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock 18 false false R19.htm 120 - Disclosure - Discontinued Operations (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlockTables Discontinued Operations (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock 19 false false R20.htm 121 - Disclosure - Revenue Recognition and Accounts Receivables (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRevenueAndAccountsReceivableTextBlockTables Revenue Recognition and Accounts Receivables (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRevenueAndAccountsReceivableTextBlock 20 false false R21.htm 122 - Disclosure - Intangible Assets (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables Intangible Assets (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock 21 false false R22.htm 123 - Disclosure - Long-Term Debt (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlockTables Long-Term Debt (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock 22 false false R23.htm 124 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables Commitments and Contingencies (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock 23 false false R24.htm 125 - Disclosure - Financial Information by Segment (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Financial Information by Segment (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock 24 false false R25.htm 126 - Disclosure - Business Operations - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureBusinessOperationsAdditionalInformation Business Operations - Additional Information (Detail) Details 25 false false R26.htm 127 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperations Discontinued Operations - Schedule of Discontinued Operations (Detail) Details 26 false false R27.htm 128 - Disclosure - Discontinued Operations - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureDiscontinuedOperationsAdditionalInformation Discontinued Operations - Additional Information (Detail) Details 27 false false R28.htm 129 - Disclosure - Discontinued Operations - Components of Pension Expense (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureDiscontinuedOperationsComponentsOfPensionExpense Discontinued Operations - Components of Pension Expense (Detail) Details 28 false false R29.htm 130 - Disclosure - Shareholders' Equity - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureShareholdersEquityAdditionalInformation Shareholders' Equity - Additional Information (Detail) Details 29 false false R30.htm 131 - Disclosure - Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivablesSummaryOfRevenues Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) Details 30 false false R31.htm 132 - Disclosure - Revenue Recognition and Accounts Receivables - Summary of Revenue by Payor (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivablesSummaryOfRevenueByPayor Revenue Recognition and Accounts Receivables - Summary of Revenue by Payor (Detail) Details 31 false false R32.htm 133 - Disclosure - Revenue Recognition and Accounts Receivables - Summary Information for Receivable (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivablesSummaryInformationForReceivable Revenue Recognition and Accounts Receivables - Summary Information for Receivable (Detail) Details 32 false false R33.htm 134 - Disclosure - Revenue Recognition and Accounts Receivables - Summary of Allowance for Concession Adjustments (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivablesSummaryOfAllowanceForConcessionAdjustments Revenue Recognition and Accounts Receivables - Summary of Allowance for Concession Adjustments (Detail) Details 33 false false R34.htm 135 - Disclosure - Intangible Assets - Intangible Assets (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureIntangibleAssetsIntangibleAssets Intangible Assets - Intangible Assets (Detail) Details 34 false false R35.htm 136 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation Intangible Assets - Additional Information (Detail) Details 35 false false R36.htm 137 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtSummaryOfLongTermDebt Long-Term Debt - Summary of Long-Term Debt (Detail) Details 36 false false R37.htm 138 - Disclosure - Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtTraceRDALoanAndTraceWorkingCapitalLoanAdditionalInformation Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) Details http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlockTables 37 false false R38.htm 139 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) Details 38 false false R39.htm 140 - Disclosure - Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfContractualObligationsCommitmentsAndContingencies Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) Details 39 false false R40.htm 141 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation Related Party Transactions - Additional Information (Detail) Details 40 false false R41.htm 142 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation Subsequent Events - Additional Information (Detail) Details 41 false false R42.htm 143 - Disclosure - Financial Information by Segment - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureFinancialInformationBySegmentAdditionalInformation Financial Information by Segment - Additional Information (Detail) Details 42 false false R43.htm 144 - Disclosure - Financial Information by Segment - Segment Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureFinancialInformationBySegmentSegmentInformation Financial Information by Segment - Segment Information (Detail) Details 43 false false All Reports Book All Reports ssy-20180930.xml ssy-20180930.xsd ssy-20180930_cal.xml ssy-20180930_def.xml ssy-20180930_lab.xml ssy-20180930_pre.xml http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://xbrl.sec.gov/stpr/2018-01-31 true true ZIP 61 0001193125-18-326712-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-18-326712-xbrl.zip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�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�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�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�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